TherapeuticsMD, Inc. - 10-Q


 


Exhibit 10.2


 








CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.







Execution Version





CREDIT AND SECURITY AGREEMENT


dated as of May 1, 2018


by and among


THERAPEUTICSMD, INC.,


ITS SUBSIDIARIES FROM TIME TO TIME
PARTY HERETO,


each as Borrower, and collectively
as Borrowers,


and


MIDCAP FINANCIAL TRUST,


as Agent and as a Lender,


and


THE ADDITIONAL LENDERS


FROM TIME TO TIME PARTY HERETO








 



    	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    




Table
of Contents


	 	 	Page
	ARTICLE 1 - DEFINITIONS	1
	Section 1.1	Certain Defined Terms	1
	Section 1.2	Accounting Terms and Determinations	29
	Section 1.3	Other Definitional and Interpretive Provisions	30
	Section 1.4	Settlement and Funding Mechanics	30
	Section 1.5	Time is of the Essence	30
	Section 1.6	Time of Day	30
	ARTICLE 2 - LOANS	30
	Section 2.1	Loans	30
	Section 2.2	Interest, Interest Calculations and Certain Fees	34
	Section 2.3	Notes	36
	Section 2.4	Reserved	36
	Section 2.5	Reserved	36
	Section 2.6	General Provisions Regarding Payment; Loan Account	36
	Section 2.7	Maximum Interest	36
	Section 2.8	Taxes; Capital Adequacy; Mitigation Obligations	37
	Section 2.9	Appointment of Borrower Representative	41
	Section 2.10	Joint and Several Liability; Rights of Contribution; Subordination and Subrogation	42
	Section 2.11	Termination; Restriction on Termination	44
	ARTICLE 3 - REPRESENTATIONS AND WARRANTIES	45
	Section 3.1	Existence and Power	45
	Section 3.2	Organization and Governmental Authorization; No Contravention	45
	Section 3.3	Binding Effect	45
	Section 3.4	Capitalization	45
	Section 3.5	Financial Information	46
	Section 3.6	Litigation	46
	Section 3.7	Ownership of Property	46
	Section 3.8	No Default	46
	Section 3.9	Labor Matters	46
	Section 3.10	Regulated Entities	47
	Section 3.11	Margin Regulations	47
	Section 3.12	Compliance With Laws; Anti-Terrorism Laws	47
	Section 3.13	Taxes	47
	Section 3.14	Compliance with ERISA	48
	Section 3.15	Brokers	48
	Section 3.16	Reserved	48
	Section 3.17	Material Contracts	49
	Section 3.18	Compliance with Environmental Requirements; No Hazardous Materials	49
	Section 3.19	Intellectual Property and License Agreements	49
	Section 3.20	Solvency	49
	Section 3.21	Full Disclosure	50



 






    	 	i	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


	Section 3.22	Subsidiaries	50
	Section 3.23	Regulatory Matters	50
	ARTICLE 4 - AFFIRMATIVE COVENANTS	51
	Section 4.1	Financial Statements and Other Reports	51
	Section 4.2	Payment and Performance of Obligations	55
	Section 4.3	Maintenance of Existence	55
	Section 4.4	Maintenance of Property; Insurance	55
	Section 4.5	Compliance with Laws and Material Contracts	56
	Section 4.6	Inspection of Property, Books and Records	57
	Section 4.7	Use of Proceeds	57
	Section 4.8	Reserved	57
	Section 4.9	Reserved	57
	Section 4.10	Hazardous Materials; Remediation.	57
	Section 4.11	Further Assurances	58
	Section 4.12	Reserved	59
	Section 4.13	Power of Attorney	59
	Section 4.14	Intellectual Property and Licensing.	59
	Section 4.15	Regulatory Covenants	60
	ARTICLE 5 - NEGATIVE COVENANTS	61
	Section 5.1	Debt; Contingent Obligations	61
	Section 5.2	Liens	61
	Section 5.3	Distributions	61
	Section 5.4	Restrictive Agreements	61
	Section 5.5	Payments and Modifications of Subordinated Debt	61
	Section 5.6	Consolidations, Mergers and Sales of Assets; Change in Control	62
	Section 5.7	Purchase of Assets, Investments	62
	Section 5.8	Transactions with Affiliates	63
	Section 5.9	Modification of Organizational Documents	63
	Section 5.10	Modification of Certain Agreements	63
	Section 5.11	Conduct of Business	63
	Section 5.12	Excluded Foreign Subsidiaries.	64
	Section 5.13	Limitation on Sale and Leaseback Transactions	64
	Section 5.14	Deposit Accounts and Securities Accounts; Payroll and Benefits Accounts	64
	Section 5.15	Compliance with Anti-Terrorism Laws	64
	Section 5.16	Change in Accounting	65
	Section 5.17	Investment Company Act	65
	ARTICLE 6 - FINANCIAL COVENANTS	65
	Section 6.1	Minimum Net Revenue	65
	Section 6.2	Minimum Liquidity	66
	Section 6.3	Evidence of Compliance	66
	ARTICLE 7 - CONDITIONS	66
	Section 7.1	Conditions to Closing	66
	Section 7.2	Conditions to Each Loan	67



 


 



    	 	ii	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    




 


	Section 7.3	Searches	67
	Section 7.4	Post-Closing Requirements	68
	ARTICLE 8 – RESERVED	68
	ARTICLE 9 - SECURITY AGREEMENT	68
	Section 9.1	Generally	68
	Section 9.2	Representations and Warranties and Covenants Relating to Collateral	68
	ARTICLE 10 - EVENTS OF DEFAULT	72
	Section 10.1	Events of Default	72
	Section 10.2	Acceleration and Suspension or Termination of Term Loan Commitment	75
	Section 10.3	UCC Remedies	75
	Section 10.4	Reserved	77
	Section 10.5	Default Rate of Interest	77
	Section 10.6	Setoff Rights	77
	Section 10.7	Application of Proceeds	77
	Section 10.8	Waivers	78
	Section 10.9	Injunctive Relief	80
	Section 10.10	Marshalling; Payments Set Aside	80
	ARTICLE 11 - AGENT	80
	Section 11.1	Appointment and Authorization	80
	Section 11.2	Agent and Affiliates	80
	Section 11.3	Action by Agent	81
	Section 11.4	Consultation with Experts	81
	Section 11.5	Liability of Agent	81
	Section 11.6	Indemnification	81
	Section 11.7	Right to Request and Act on Instructions	82
	Section 11.8	Credit Decision	82
	Section 11.9	Collateral Matters	82
	Section 11.10	Agency for Perfection	82
	Section 11.11	Notice of Default	83
	Section 11.12	Assignment by Agent; Resignation of Agent; Successor Agent	83
	Section 11.13	Payment and Sharing of Payment	84
	Section 11.14	Right to Perform, Preserve and Protect	85
	Section 11.15	Additional Titled Agents	85
	Section 11.16	Amendments and Waivers	85
	Section 11.17	Assignments and Participations	86
	Section 11.18	Funding and Settlement Provisions Applicable When Non-Funding Lenders Exist	89
	ARTICLE 12 - MISCELLANEOUS	89
	Section 12.1	Survival	89
	Section 12.2	No Waivers	90
	Section 12.3	Notices.	90
	Section 12.4	Severability	91
	Section 12.5	Headings	91



 






    	 	iii	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    




 


	Section 12.6	Confidentiality	91
	Section 12.7	Waiver of Consequential and Other Damages	92
	Section 12.8	GOVERNING LAW; SUBMISSION TO JURISDICTION	92
	Section 12.9	WAIVER OF JURY TRIAL	92
	Section 12.10	Publication; Advertisement	93
	Section 12.11	Counterparts; Integration	93
	Section 12.12	No Strict Construction	93
	Section 12.13	Lender Approvals	93
	Section 12.14	Expenses; Indemnity	94
	Section 12.15	Reserved	95
	Section 12.16	Reinstatement	95
	Section 12.17	Successors and Assigns	95
	Section 12.18	USA PATRIOT Act Notification	96
	Section 12.19	Acknowledgement and Consent to Bail-In of EEA Financial Institutions	96


 











    	 	iv	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


CREDIT
AND SECURITY AGREEMENT


This CREDIT AND
SECURITY AGREEMENT (as the same may be amended, supplemented, restated or otherwise modified from time to time, the “Agreement”)
is dated as of May 1, 2018 by and among therapeuticsmd,
INC., a Nevada corporation (“TherapeuticsMD”), each of its direct and indirect Subsidiaries set forth
on the signature pages hereto and any additional borrower that may hereafter be added to this Agreement (individually as a “Borrower”,
and collectively with any entities that become party hereto as Borrower and each of their successors and permitted assigns, the
“Borrowers”), MIDCAP FINANCIAL TRUST, a Delaware statutory trust, individually as a Lender, and as Agent,
and the financial institutions or other entities from time to time parties hereto, each as a Lender.


RECITALS


Borrowers have requested
that Lenders make available to Borrowers the financing facilities as described herein. Lenders are willing to extend such credit
to Borrowers under the terms and conditions herein set forth.


AGREEMENT


NOW, THEREFORE,
in consideration of the premises and the agreements, provisions and covenants herein contained, Borrowers, Lenders and Agent agree
as follows:


Article 1
- DEFINITIONS


Section 1.1           Certain
Defined Terms. The following terms have the following meanings:


“Acceleration
Event” means the occurrence of an Event of Default (a) in respect of which Agent has declared all or any portion
of the Obligations to be immediately due and payable pursuant to Section 10.2 and/or (b) pursuant to either Section 10.1(e)
and/or Section 10.1(f).


“Account
Debtor” means “account debtor”, as defined in Article 9 of the UCC, and any other obligor in respect
of an Account.


“Accounts”
means, collectively, (a) any right to payment of a monetary obligation, whether or not earned by performance, (b) without
duplication, any “account” (as defined in the UCC), any accounts receivable (whether in the form of payments for services
rendered or goods sold, rents, license fees or otherwise), any “health-care-insurance receivables” (as defined in the
UCC), any “payment intangibles” (as defined in the UCC) and all other rights to payment and/or reimbursement of every
kind and description, whether or not earned by performance, (c) all accounts, “general intangibles” (as defined
in the UCC), Intellectual Property, rights, remedies, Guarantees, “supporting obligations” (as defined in the UCC),
“letter-of-credit rights” (as defined in the UCC) and security interests in respect of the foregoing, all rights of
enforcement and collection, all books and records evidencing or related to the foregoing, and all rights under the Financing Documents
in respect of the foregoing, (d) all information and data compiled or derived by any Borrower or to which any Borrower is
entitled in respect of or related to the foregoing, and (e) all proceeds of any of the foregoing.






    	 	 	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


“Additional
Titled Agents” has the meaning set forth in Section 11.15.


“Acquisition”
means any transaction or series of related transactions for the purpose of or resulting, directly or indirectly, in (a) the
acquisition of all or substantially all of the assets of a Person, or of any business, business line or product line, division
or other unit operation of any Person, (b) the acquisition of in excess of fifty percent (50%) of the Equity Interests of
any Person or otherwise causing any Person to become a Subsidiary of a Borrower, (c) a merger or consolidation or any other
combination with another Person (other than a Credit Party permitted under Section 5.6(a)), or (d) the acquisition (including through
licensing that requires an upfront payment) of any material Product from any other Person.


“Affiliate”
means, with respect to any Person, (a) any Person that directly or indirectly controls such Person, (b) any Person which
is controlled by or is under common control with such controlling Person, and (c) each of such Person’s (other than,
with respect to any Lender, any Lender’s) executive officers or directors (or Persons functioning in substantially similar
roles) and the spouses, parents, descendants and siblings of such executive officers, directors or other Persons. As used in this
definition, the term “control” of a Person means the possession, directly or indirectly, of the power to vote more
than (i) in the case of Agent or any Lender, ten percent (10%) or (ii) in the case of any Credit Party or Subsidiary thereof, thirty
percent (30%), of any class of voting securities of such Person or to direct or cause the direction of the management or policies
of a Person, whether through the ownership of voting securities, by contract or otherwise.


“Agent”
means MCF, in its capacity as administrative agent for itself and for Lenders hereunder, as such capacity is established in, and
subject to the provisions of, Article 11, and the successors and assigns of MCF in such capacity.


“Anti-Terrorism
Laws” means any Laws relating to terrorism or money laundering, including, without limitation, Executive Order No. 13224
(effective September 24, 2001), the USA PATRIOT Act, the Laws comprising or implementing the Bank Secrecy Act, and the Laws
administered by OFAC.


“Applicable
Margin” means seven and three quarters percent (7.75%).


“Approved
Fund” means any (a) investment company, fund, trust, securitization vehicle or conduit that is (or will be) engaged
in making, purchasing, holding or otherwise investing in commercial loans and similar extensions of credit in the ordinary course
of business, or (b) any Person (other than a natural person) which temporarily warehouses loans for any Lender or any entity
described in the preceding clause (a) and that, with respect to each of the preceding clauses (a) and (b), is administered
or managed by (i) a Lender, (ii) an Affiliate of a Lender, or (iii) a Person (other than a natural person) or an
Affiliate of a Person (other than a natural person) that administers or manages a Lender.


“Asset Disposition”
means any sale, lease, license, transfer, assignment or other consensual disposition by any Credit Party or
any Subsidiary thereof of any asset.


“Assignment
Agreement” means an assignment agreement in form and substance acceptable to Agent.






    	 	2	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


“Bankruptcy
Code” means Title 11 of the United States Code entitled “Bankruptcy”, as the same may be amended, modified
or supplemented from time to time, and any successor statute thereto.


“Base LIBOR
Rate” means, for each Interest Period, the rate per annum, determined by Agent in accordance with its customary procedures,
and utilizing such electronic or other quotation sources as it considers appropriate (rounded upwards, if necessary, to the next
1/100%), to be the rate at which Dollar deposits (for delivery on the first day of such Interest Period) in the amount of $1,000,000
are offered to major banks in the London interbank market on or about 11:00 a.m. (London time) two (2) Business Days
prior to the commencement of such Interest Period, for a term comparable to such Interest Period, which determination shall be
conclusive in the absence of manifest error; provided, however, if timely, adequate and reasonable means do not exist
for ascertaining such rate and the circumstances giving rise to the Agent’s inability to ascertain LIBOR are unlikely to
be temporary as determined in Agent’s reasonable discretion, then Agent may, upon prior written notice to Borrower Representative,
choose, in consultation with Borrower, a reasonably comparable index or source together with corresponding adjustments to “Applicable
Margin” or scale factor or floor to such index that Agent, in its reasonable discretion, has determined is necessary to preserve
the current all-in yield (including interest rate margins, any interest rate floors, original issue discount and upfront fees,
but without regard to future fluctuations of such alternative index, it being acknowledged and agreed that neither Agent nor any
Lender shall have any liability whatsoever from such future fluctuations) to use as the basis for Base LIBOR Rate.


“Base Rate”
means a per annum rate of interest equal to the greater of (a) one and one half percent (1.50%) per annum and (b) the rate of interest
announced, from time to time, within Wells Fargo Bank, National Association (“Wells Fargo”) at its principal
office in San Francisco as its “prime rate,” with the understanding that the “prime rate” is one of Wells
Fargo’s base rates (not necessarily the lowest of such rates) and serves as the basis upon which effective rates of interest
are calculated for those loans making reference thereto and is evidenced by the recording thereof after its announcement in such
internal publications as Wells Fargo may designate; provided, however, that Agent may, upon prior written notice
to Borrower, choose a reasonably comparable index or source used by Agent in its other credit facilities for similarly situated
borrowers to use as the basis for the Base Rate.


“Bail-In
Action” means the exercise of any Write-Down and Conversion Powers by the applicable EEA Resolution Authority in respect
of any liability of an EEA Financial Institution.


“Bail-In
Legislation” means, with respect to any EEA Member Country implementing Article 55 of Directive 2014/59/EU of the European
Parliament and of the Council of the European Union, the implementing law for such EEA Member Country from time to time which is
described in the EU Bail-In Legislation Schedule.


“Blocked
Person” means any Person: (a) listed in the annex to, or is otherwise subject to the provisions of, Executive Order
No. 13224, (b) owned or controlled by, or acting for or on behalf of, any Person that is listed in the annex to, or is
otherwise subject to the provisions of, Executive Order No. 13224, (c) with which any Lender is prohibited from dealing
or otherwise engaging in any transaction by any Anti-Terrorism Law, (d) that commits, threatens or conspires to commit or
supports “terrorism” as defined in Executive Order No. 13224, or (e) that is named a “specially designated
national” or “blocked person” on the most current list published by OFAC or other similar list or is named as
a “listed person” or “listed entity” on other lists made under any Anti-Terrorism Law.


“Borrower”
and “Borrowers” has the meaning set forth in the introductory paragraph hereto.






    	 	3	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


“Borrower
Representative” means TherapeuticsMD, in its capacity as Borrower Representative pursuant to the provisions of Section 2.9,
or any successor Borrower Representative selected by Borrowers and approved by Agent.


“Borrower
Unrestricted Cash” means unrestricted cash and Cash Equivalents of the Borrowers that (a) are subject to Agent’s
first priority perfected lien and held in the name of a Borrower in a Deposit Account or Securities Account that is subject to
a Deposit Account Control Agreement or Securities Account Control Agreement, as applicable, in favor of Agent at a bank or financial
institution located in the United States, (b) is not subject to any Lien (other than a Lien in favor of Agent or Permitted Liens),
and (c) are not funds for the payment of a drawn or committed but unpaid draft, ACH or EFT transaction.


“Business
Day” means any day except a Saturday, Sunday or other day on which either the Nasdaq Stock Market is closed, or on which
commercial banks in Washington, DC and New York City are authorized by law to close.


“Capital
Lease” of any Person means any lease of any property by such Person as lessee which would, in accordance with GAAP, be
required to be accounted for as a capital lease on the balance sheet of such Person.


“Cash Equivalents”
means any Investment in (a) securities issued or directly and fully guaranteed or insured by the US or any agency or instrumentality
thereof (provided that the full faith and credit of the US is pledged in support thereof) having maturities of not more
than one (1) year from the date of acquisition by such Person, (b) Dollar-denominated time deposits and certificates of deposit
with a duration of not more than one (1) year issued or accepted by any commercial bank having, or which is the principal banking
subsidiary of a bank holding company organized under the laws of the United States, any State thereof or, the District of Columbia
having capital, surplus and undivided profits aggregating in excess of $500,000,000, (c) repurchase obligations with a term
of not more than ninety (90) days for underlying securities of the types described in subsection (a) above entered into with any
bank meeting the qualifications specified in subsection (b) above, (d) commercial paper issued by any issuer rated at least
A-1 by Standard & Poor’s Corporation or at least P-1 by Moody’s Investors Service, Inc., and in each case maturing
not more than one (1) year after the date of acquisition by such Person or (e) money market or mutual fund which invests only
in the foregoing types of Investments, has portfolio assets in excess of $500,000,000, complies with the criteria set forth in
Securities and Exchange Commission Rule 2a-7 under the Investment Company Act, and has the highest rating obtainable from either
Standard & Poor’s Corporation or Moody’s Investors Service, Inc.


“CERCLA”
means the Comprehensive Environmental Response, Compensation and Liability Act of 1980, 42 U.S.C.A. § 9601 et seq.,
as the same may be amended from time to time.


“Change
in Control” means (a) the acquisition of ownership, directly or indirectly, beneficially or of record, by any person
or group (within the meaning of the Securities Exchange Act of 1934 and the rules of the SEC thereunder as in effect on the date
hereof) of Equity Interests representing more than fifty percent (50%) of the aggregate ordinary voting power represented by the
issued and outstanding Equity Interests of TherapeuticsMD or (b) occupation of a majority of the seats (other than vacant seats)
on the board of directors of the TherapeuticsMD by persons who were neither (i) nominated by the board of directors of the
TherapeuticsMD nor (ii) appointed by the directors so nominated.


“Closing
Date” means the date of this Agreement.






    	 	4	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


“Code”
means the Internal Revenue Code of 1986, as amended from time to time,
any successor statutes thereto, and applicable U.S. Department of Treasury regulations issued pursuant thereto in temporary or
final form.


“Collateral”
means all property, now existing or hereafter acquired, mortgaged or pledged to, or purported to be subjected to a Lien in favor
of, Agent, for the benefit of Agent and Lenders, pursuant to this Agreement and the Security Documents, including, without limitation,
all of the property described in Schedule 9.1 hereto; provided that, the Collateral shall not, at any time,
include any “Excluded Property”.


“Commitment
Annex” means Annex A to this Agreement.


“Competitor”
means, at any time of determination, any Person engaged in the same or substantially the same business as the Borrower and the
other Credit Parties and such business accounts for ten percent (10%) or more of the revenue or net income of such Person at the
time of such determination.


“Compliance
Certificate” means a certificate, duly executed by a Responsible Officer of Borrower Representative, appropriately completed
and substantially in the form of Exhibit A hereto.


“Consolidated
Subsidiary” means, at any date, any Subsidiary the accounts of which would be consolidated with those of “parent”
Borrower (or any other Person, as the context may require hereunder) in its consolidated financial statements if such statements
were prepared as of such date.


“Contingent
Obligation” means, with respect to any Person, any direct or indirect liability of such Person: (a) with respect
to any Debt of another Person (a “Third Party Obligation”) if the purpose or intent of such Person incurring
such liability, or the effect thereof, is to provide assurance to the obligee of such Third Party Obligation that such Third Party
Obligation will be paid or discharged, or that any agreement relating thereto will be complied with, or that any holder of such
Third Party Obligation will be protected, in whole or in part, against loss with respect thereto; (b) with respect to any
undrawn portion of any letter of credit issued for the account of such Person or as to which such Person is otherwise liable for
the reimbursement of any drawing; (c) under any Swap Contract, to the extent not yet due and payable; (d) to make take-or-pay
or similar payments if required regardless of nonperformance by any other party or parties to an agreement; or (e) for any
obligations of another Person pursuant to any Guarantee or pursuant to any agreement to purchase, repurchase or otherwise acquire
any obligation or any property constituting security therefor, to provide funds for the payment or discharge of such obligation
or to preserve the solvency, financial condition or level of income of another Person. The amount of any Contingent Obligation
shall be equal to the amount of the obligation so Guaranteed or otherwise supported or, if not a fixed and determinable amount,
the maximum amount so Guaranteed or otherwise supported.


“Controlled
Group” means all members of a group of corporations and all members of a group of trades or businesses (whether or not
incorporated) under common control which, together with the Credit Parties, are treated as a single employer under Section 414(b),
(c), (m) or (o) of the Code or Section 4001(b) of ERISA and, solely for purposes of Section 412 and 436 of the Code,
Section 414(m) or (o) of the Code.


“Correction”
means repair, modification, adjustment, relabeling, destruction or inspection (including patient monitoring) of a Product without
its physical removal to some other location.


“Credit
Exposure” means, at any time, any portion of the Term Loan Commitments and/or any other Obligations that remains outstanding;
provided, however, that no Credit Exposure shall be deemed to exist solely due to the existence of contingent indemnification
liability, absent the assertion of a claim, or the known existence of a claim reasonably likely to be asserted, with respect thereto.






    	 	5	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


“Credit
Party” means each Borrower and each Guarantor; and “Credit Parties” means all such Persons, collectively.


“DEA”
means the Drug Enforcement Administration of the United States of America, any comparable state or local Governmental Authority,
any comparable Governmental Authority in any non-United States jurisdiction, and any successor agency of any of the foregoing.


“Debt”
of a Person means at any date, without duplication, (a) all obligations of such Person for borrowed money, (b) all obligations
of such Person evidenced by bonds, debentures, notes or other similar instruments, (c) all obligations of such Person to pay
the deferred purchase price of property or services, except trade accounts payable arising in the Ordinary Course of Business and
not more than 60 days past due unless subject to a Permitted Contest, (d) all Capital Leases of such Person, (e) all
non-contingent obligations of such Person to reimburse any bank or other Person in respect of amounts paid under a letter of credit,
banker’s acceptance or similar instrument, (f) all equity securities of such Person subject to repurchase or redemption
other than at the sole option of such Person, (g) all obligations secured by a Lien on any asset of such Person, whether or
not such obligation is otherwise an obligation of such Person, (h) “earnouts”, purchase price adjustments, profit
sharing arrangements, deferred purchase money amounts and similar payment obligations or continuing obligations of any nature of
such Person arising out of purchase and sale contracts, (i) all Debt of others Guaranteed by such Person, and (j) off-balance
sheet liabilities and/or Pension Plan or Multiemployer Pension Plan liabilities of such Person. Without duplication of any of the
foregoing, Debt of Borrowers shall include any and all Loans.


“Default”
means any condition or event which with the giving of notice or lapse of time or both would, unless cured or waived, become an
Event of Default.


“Defaulted
Lender” means, so long as such failure shall remain in existence and uncured, any Lender which shall have failed to make
any Loan or other credit accommodation, disbursement, settlement or reimbursement required pursuant to the terms of any Financing
Document.


“Defined
Period” means for any given calendar month or date of determination, the twelve (12) month period ending on the last
day of such calendar month or if such date of determination is not the last day of a calendar month, the twelve (12) month period
immediately preceding any such date of determination.


“Deposit
Account” means a “deposit account” (as defined in Article 9 of the UCC), an investment account, or other
account in which funds are held or invested for credit to or for the benefit of any Borrower.


“Deposit
Account Control Agreement” means an agreement, in form and substance reasonably satisfactory to Agent, among Agent, any
Borrower and each financial institution in which such Borrower maintains a Deposit Account, which agreement provides that (a) such
financial institution shall comply with instructions originated by Agent directing disposition of the funds in such Deposit Account
without further consent by the applicable Borrower, and (b) such financial institution shall agree that it shall have no Lien
on, or right of setoff or recoupment against, such Deposit Account or the contents thereof, other than in respect of usual and
customary service fees and returned items, and containing such other terms and conditions as Agent may reasonably require.






    	 	6	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


“Disqualified
Stock” means, with respect to any Person, any Equity Interest in such Person that, within less than 91 days after the
Termination Date, either by its terms (or by the terms of any security or other equity interests into which it is convertible or
for which it is exchangeable) or upon the happening of any event or condition, (a) matures or is mandatorily redeemable (other
than solely for Permitted Debt or other equity interests in such Person or of TherapeuticsMD that do not constitute Disqualified
Stock and cash in lieu of fractional shares of such equity interests), pursuant to a sinking fund obligation or otherwise, (b) is
redeemable at the option of the holder thereof, in whole or in part (other than solely for Permitted Debt or other Equity Interests
in such Person or of TherapeuticsMD that do not constitute Disqualified Stock and cash in lieu of fractional shares of such equity
interests), (c) provides for the scheduled payments of dividends or distributions in cash, or (d) is or becomes convertible
into or exchangeable for Debt (other than Permitted Debt) or any other Equity Interests that would constitute Disqualified Stock.


“Distribution”
means as to any Person (a) any dividend or other distribution (whether in cash, securities or other property) on any Equity
Interest in such Person (except those payable solely in its Equity Interests of the same class or in common Equity Interests),
(b) any payment by such Person on account of (i) the purchase, redemption, retirement, defeasance, surrender, cancellation,
termination or acquisition of any Equity Interests in such Person or any claim respecting the purchase or sale of any Equity Interest
in such Person, or (ii) any option, warrant or other right to acquire any Equity Interests in such Person, (c)  any lease
or rental payments to an Affiliate or Subsidiary of a Borrower, or (d) repayments of or debt service on loans or other indebtedness
held by an Affiliate of any Subsidiary of a Borrower unless permitted under and made pursuant to a Subordination Agreement applicable
to such loans or other indebtedness.


“Dollars”
or “$” means the lawful currency of the United States of America.


“Drug Application”
means a New Drug Application (NDA) or an Abbreviated New Drug Application (ANDA) for any Product, as appropriate, as those terms
are defined in section 505 of the FDCA.


“EEA
Financial Institution” means (a) any credit institution or investment firm established in any EEA Member Country which
is subject to the supervision of an EEA Resolution Authority, (b) any entity established in an EEA Member Country which is a parent
of an institution described in clause (a) of this definition, or (c) any financial institution established in an EEA Member Country
which is a subsidiary of an institution described in clauses (a) or (b) of this definition and is subject to consolidated supervision
with its parent.


“EEA
Member Country” means any of the member states of the European Union, Iceland, Liechtenstein, and Norway.


“EEA
Resolution Authority” means any public administrative authority or any person entrusted with public administrative authority
of any EEA Member Country (including any delegee) having responsibility for the resolution of any EEA Financial Institution.


“Eligible
Assignee” means (a) a Lender, (b) an Affiliate of a Lender, (c) an Approved Fund, and (d) any other Person (other than
a natural person) approved by (1) Agent, and (2) the Borrower Representative, but only if and to the extent that: (A) no Event
of Default has occurred and is continuing and (B) such proposed assignment would result in the then-existing Lenders, their Affiliates
and Approved Funds holding less than fifty one percent (51%) of the Term Loans and outstanding Term Loan Commitment Amounts;  provided,
however, that notwithstanding the foregoing, (x) so long as no Event of Default has occurred and is continuing, “Eligible
Assignee” shall not include (i) any Borrower or any of a Borrower’s Subsidiaries, or (ii) any Competitor, and (y)
no proposed assignee intending to assume any unfunded portion of the Term Loan Commitment shall be an Eligible Assignee unless
such proposed assignee either already holds a portion of such Term Loan Commitment, or has been approved as an Eligible Assignee
by Agent. Notwithstanding the foregoing, Borrowers shall be deemed to have approved any prospective assignee for purposes of clause
(d)(2) above unless Agent shall have received Borrowers’ objection thereto in writing within five (5) Business Days after
Borrowers’ receipt of notice of such proposed assignment.






    	 	7	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


“Equity
Interests” means any and all shares, interests, participations or other equivalents (however designated) of equity interests
of a corporation, membership interests in a limited liability company, partnership interests in a partnership, and any and all
similar ownership interests in any Person, and any and all warrants, rights or options to purchase any of the foregoing.


“Environmental
Laws” means any present and future federal, state and local laws, statutes, ordinances, rules, regulations, standards,
policies and other governmental directives or requirements, as well as common law, pertaining to the environment, natural resources,
pollution, health (including any environmental clean-up statutes and all regulations adopted by any local, state, federal or other
Governmental Authority, and any statute, ordinance, code, order, decree, law rule or regulation all of which pertain to or impose
liability or standards of conduct concerning medical waste or medical products, equipment or supplies), safety or clean-up that
apply to any Borrower and relate to Hazardous Materials, including, without limitation, the Comprehensive Environmental Response,
Compensation and Liability Act of 1980 (42 U.S.C. § 9601 et seq.), the Resource Conservation and Recovery Act of 1976
(42 U.S.C. § 6901 et seq.), the Federal Water Pollution Control Act (33 U.S.C. § 1251 et seq.), the Hazardous
Materials Transportation Act (49 U.S.C. § 5101 et seq.), the Clean Air Act (42 U.S.C. § 7401 et seq.),
the Federal Insecticide, Fungicide and Rodenticide Act (7 U.S.C. § 136 et seq.), the Emergency Planning and Community
Right-to-Know Act (42 U.S.C. § 11001 et seq.), the Occupational Safety and Health Act (29 U.S.C. § 651 et seq.),
the Residential Lead-Based Paint Hazard Reduction Act (42 U.S.C. § 4851 et seq.), any analogous state or local laws,
any amendments thereto, and the regulations promulgated pursuant to said laws, together with all amendments from time to time to
any of the foregoing and judicial interpretations thereof.


“ERISA”
means the Employee Retirement Income Security Act of 1974, as the same may be amended, modified or supplemented from time to time,
and any successor statute thereto, and any and all rules or regulations promulgated from time to time thereunder.


“ERISA Plan”
means any “employee benefit plan”, as such term is defined in Section 3(3) of ERISA (other than a Multiemployer
Pension Plan), which any Credit Party or any Subsidiary maintains, sponsors or contributes to, or, in the case of an employee benefit
plan which is subject to Section 412 of the Code or Title IV of ERISA (other than a Multiemployer Pension Plan), to which
any Credit Party or any Subsidiary has any liability, including on account of any member of the Controlled Group, including any
liability by reason of having been a substantial employer within the meaning of Section 4063 of ERISA, or by reason of being
deemed to be a contributing sponsor under Section 4069 of ERISA.


“EU
Bail-In Legislation Schedule” means the EU Bail-In Legislation Schedule published by the Loan Market Association (or
any successor person), as in effect from time to time.


“Event of
Default” has the meaning set forth in Section 10.1.


“Excluded
Accounts” means Deposit Accounts of a Credit Party or any Subsidiary (a) into which there is deposited no funds
other than those intended solely to cover wages and payroll for employees of a Credit Party for a period of service no longer than
two weeks at any time (and related contributions to be made on behalf of such employees to health and benefit plans) plus balances
for outstanding checks for wages and payroll from prior periods; (b) constituting employee withholding accounts and contain
only funds deducted from pay otherwise due to employees for services rendered to be applied toward the tax obligations of such
employees; (c) owned by Excluded Foreign Subsidiaries and maintained outside of the United States; and (d) other than the
accounts set forth in the preceding clauses (a)-(c), accounts of Credit Parties in which there is not maintained at any point
in time funds on deposit greater than $500,000 in the aggregate for all such accounts.






    	 	8	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


“Excluded
Foreign Subsidiary” means each direct and indirect Subsidiary of a Borrower (i)(a) that is a “controlled foreign
corporation” as defined in Section 957 of the Code, (b) that is a direct or indirect Subsidiary of a “controlled foreign
corporation” as defined in Section 957 of the Code, or (c) substantially all of the assets of which are equity or debt interests
in one or more “controlled foreign corporations” as defined in Section 957 of the Code, and in each case, either (x)
the pledge of all of the capital stock of such Subsidiary as Collateral or (y) the guaranteeing by such Subsidiary of the Obligations,
could, in the good faith judgment of Borrowers, reasonably be expected to result in material adverse tax consequences to the Credit
Parties; and (ii) designated as an Excluded Foreign Subsidiary by Borrowers or Agent, provided, that after giving effect
to such designation, the aggregate gross revenues attributable to all Excluded Foreign Subsidiary in the aggregate for the most
recently ended fiscal year of Borrowers does not exceed ten percent (10%) of the aggregate consolidated gross revenues for Borrowers
and their Consolidated Subsidiaries for such fiscal year.


“Excluded Property”
means:


(a)            
any lease, license, contract, permit, letter of credit, instrument, or agreement to which
a Credit Party is a party or any of its rights or interests thereunder if and to the extent that the grant of a security interest
thereon shall constitute or result in (i) the abandonment, invalidation or unenforceability of any right, title or interest of
any Credit Party therein or (ii) result in a breach or termination pursuant to the terms of, or a default under, any such lease,
license, contract, permit, agreement or other property right; 


(b)            
governmental licenses, state or local franchises, charters and authorizations and any other
property and assets to the extent that Agent may not validly possess a security interest therein under applicable Law (including,
without limitation, rules and regulations of any Governmental Authority or agency) or the pledge or creation of a security interest
in which would require governmental consent, approval, license or authorization; 


(c)            
any “intent-to-use” trademark or service mark application for which an amendment
to allege use or statement of use has not been filed under 15 U.S.C. § 1051(c) or 15 U.S.C. § 1051(d), respectively,
or if filed, has not been deemed in conformance with 15 U.S.C. § 1051(a) or examined and accepted, respectively by the United
States Patent and Trademark Office; 


(d)            
more than 65% the voting capital stock of any Excluded Foreign Subsidiary; provided
that immediately upon any amendment of the Code that would allow the pledge of a greater percentage of such voting stock without
material adverse tax consequences to such Borrower, “Collateral” shall automatically and without further action required
by, and without notice to, any Person include such greater percentage of voting stock of such Excluded Foreign Subsidiary from
that time forward;






    	 	9	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


provided
that (x) any such limitation described in the foregoing clauses (a) and (b) on the security interests granted hereunder
shall apply only to the extent that any such prohibition could not be rendered ineffective pursuant to the UCC or any other applicable
Law (including Sections 9-406, 9-407 and 9-408 of the UCC) or principles of equity, (y) in the event of the termination
or elimination of any such prohibition or the requirement for any consent contained in such contract, agreement, permit, lease
or license or in any applicable Law, to the extent sufficient to permit any such item to become Collateral hereunder, or upon the
granting of any such consent, or waiving or terminating any requirement for such consent, a security interest in such contract,
agreement, permit, lease, license, franchise, authorization or asset shall be automatically and simultaneously granted hereunder
and shall be included as Collateral hereunder, and (z) all rights to payment of money due or to become due pursuant to, and
all rights to the proceeds from the sale of, any such Excluded Property shall be and at all times remain subject to the security
interests created by this Agreement (unless such proceeds would independently constitute Excluded Property).


“Excluded
Taxes” means any of the following Taxes imposed on or with respect to Agent, any Lender or any other recipient of any
payment to be made by or on behalf of any obligation of Credit Parties hereunder or the Obligations or required to be withheld
or deducted from a payment to Agent, such Lender or such recipient (including any interest and penalties thereon): (a) Taxes to
the extent imposed on or measured by Agent’s, any Lender’s or such recipient’s net income (however denominated),
branch profits Taxes, and franchise Taxes and similar Taxes, in each case, (i) imposed by the jurisdiction (or any political subdivision
thereof) under which Agent, such Lender or such recipient is organized, has its principal office or conducts business with respect
to entering into any of the Financing Documents or taking any action thereunder or (ii) that are Other Connection Taxes; (b) in
the case of a Lender, United States withholding Taxes imposed on amounts payable to or for the account of such Lender with respect
to an applicable interest in the Loans pursuant to a Law in effect on the date on which (i) such Lender becomes a party to this
Agreement other than as a result of an assignment requested by a Credit Party under the terms hereof or (ii) such Lender changes
its lending office for funding its Loan, except in each case to the extent that, pursuant to Section 2.8, amounts with respect
to such Taxes were payable either to such Lender’s assignor immediately before such Lender acquired the applicable interest
in a Loan or Term Loan Commitment or to such Lender immediately before it changed its lending office; (c) Taxes attributable to
any Agent’s, Lender’s or other recipient’s failure to comply with Section 2.8(c); and (d) any U.S. federal withholding
taxes imposed under FATCA.


“FATCA”
means Sections 1471 through 1474 of the Code as of the date of this Agreement (or any amended or successor version that is substantively
comparable and not materially more onerous to comply with), any current or future U.S. Treasury regulations or official interpretations
thereof and any agreement entered into pursuant to the implementation of Section 1471(b)(1) of the Code, and any intergovernmental
agreement between the United States Internal Revenue Service, the U.S. Government and any governmental or taxation authority under
any other jurisdiction which agreement’s principal purposes deals with the implementation of such sections of the Code.


“FDA”
means the Food and Drug Administration of the United States of America and any successor agency of any of the foregoing.


“FDCA”
means the Federal Food, Drug and Cosmetic Act, as amended, 21 U.S.C. Section 301 et seq., and all regulations promulgated
thereunder.


“Federal
Funds Rate” means, for any day, the rate of interest per annum (rounded upwards, if necessary, to the nearest whole multiple
of 1/100 of 1%) equal to the weighted average of the rates on overnight Federal funds transactions with members of the Federal
Reserve System, as published by the Federal Reserve Bank of New York on the Business Day next succeeding such day, provided,
however, that (a) if such day is not a Business Day, the Federal Funds Rate for such day shall be such rate on such transactions
on the next preceding Business Day, and (b) if no such rate is so published on such next preceding Business Day, the Federal
Funds Rate for such day shall be the average rate quoted to Agent on such day on such transactions as determined by Agent.






    	 	10	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


“Fee Letter”
means each agreement between Agent and Borrower relating to fees payable to Agent, in connection with this Agreement.


“Financing
Documents” means this Agreement, any Notes, the Security Documents, each Fee Letter, each subordination or intercreditor
agreement pursuant to which any Debt and/or any Liens securing such Debt is subordinated to all or any portion of the Obligations
and all other documents, instruments and agreements related to the Obligations and heretofore executed, executed concurrently herewith
or executed at any time and from time to time hereafter, as any or all of the same may be amended, supplemented, restated or otherwise
modified from time to time.


“Foreign
Lender” has the meaning set forth in Section 2.8(c)(i).


“GAAP”
means generally accepted accounting principles set forth from time to time in the opinions and pronouncements of the Accounting
Principles Board and the American Institute of Certified Public Accountants and statements and pronouncements of the Financial
Accounting Standards Board (or agencies with similar functions of comparable stature and authority within the United States accounting
profession), which are applicable to the circumstances as of the date of determination.


“General
Intangible” means any “general intangible” as defined in Article 9 of the UCC, and any personal property,
including things in action, other than accounts, chattel paper, commercial tort claims, deposit accounts, documents, goods, instruments,
investment property, letter-of-credit rights, letters of credit, money, and oil, gas or other minerals before extraction, but including
payment intangibles and software.


“Good Manufacturing
Practices” means current good manufacturing practices, including as set forth in 21 C.F.R. Parts 210 and 211, and analogous
requirements and standards set forth by a Governmental Authority in any applicable non-United States jurisdiction.


“Governmental
Authority” means any nation or government, any state, local or other political subdivision thereof, and any agency, department
or Person exercising executive, legislative, judicial, regulatory or administrative functions of any of the foregoing, whether
domestic or foreign.


“Guarantee”
by any Person means any obligation, contingent or otherwise, of such Person directly or indirectly guaranteeing any Debt or other
obligation of any other Person and, without limiting the generality of the foregoing, any obligation, direct or indirect, contingent
or otherwise, of such Person (a) to purchase or pay (or advance or supply funds for the purchase or payment of) such Debt
or other obligation (whether arising by virtue of partnership arrangements, by agreement to keep-well, to purchase assets, goods,
securities or services, to take-or-pay, or to maintain financial statement conditions or otherwise), or (b) entered into for
the purpose of assuring in any other manner the obligee of such Debt or other obligation of the payment thereof or to protect such
obligee against loss in respect thereof (in whole or in part), provided, however, that the term Guarantee shall not
include endorsements for collection or deposit in the Ordinary Course of Business. The term “Guarantee” used
as a verb has a corresponding meaning.






    	 	11	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


“Guarantor”
means any Credit Party that has executed or delivered, or shall in the future execute or deliver, any Guarantee of any portion
of the Obligations in accordance with Section 4.11(d) or as otherwise approved by Agent.


“Hazardous
Materials” means petroleum and petroleum products and compounds containing them, including gasoline, diesel fuel and
oil; explosives, flammable materials; radioactive materials; polychlorinated biphenyls and compounds containing them; lead and
lead-based paint; asbestos or asbestos-containing materials; underground or above-ground storage tanks, whether empty or containing
any substance; any substance the presence of which is prohibited by any Environmental Laws; toxic mold, any substance that requires
special handling; and any other material or substance now or in the future defined as a “hazardous substance,” “hazardous
material,” “hazardous waste,” “toxic substance,” “toxic pollutant,” “contaminant,”
“pollutant” or other words of similar import within the meaning of any Environmental Law, including: (a) any “hazardous
substance” defined as such in (or for purposes of) CERCLA, or any so-called “superfund” or “super lien”
Law, including the judicial interpretation thereof; (b) any “pollutant or contaminant” as defined in 42 U.S.C.A.
§ 9601(33); (c) any material now defined as “hazardous waste” pursuant to 40 C.F.R. Part 260; (d) any
petroleum or petroleum by-products, including crude oil or any fraction thereof; (e) natural gas, natural gas liquids, liquefied
natural gas, or synthetic gas usable for fuel; (f) any “hazardous chemical” as defined pursuant to 29 C.F.R. Part
1910; (g) any toxic or harmful substances, wastes, materials, pollutants or contaminants (including, without limitation, asbestos,
polychlorinated biphenyls (“PCB’s”), flammable explosives, radioactive materials, infectious substances,
materials containing lead-based paint or raw materials which include hazardous constituents); and (h) any other toxic substance
or contaminant that is subject to any Environmental Laws or other past or present requirement of any Governmental Authority.


“Hazardous
Materials Contamination” means contamination (whether now existing or hereafter occurring) of the improvements, buildings,
facilities, personalty, soil, groundwater, air or other elements on or of the relevant property by Hazardous Materials, or any
derivatives thereof, or on or of any other property as a result of Hazardous Materials, or any derivatives thereof, generated on,
emanating from or disposed of in connection with the relevant property.


“Healthcare
Laws” means all applicable Laws relating to the procurement, development, provision, clinical and non-clinical testing,
evaluation or investigation, product approval or clearance, manufacture, production, analysis, distribution, dispensing, importation,
exportation, use, handling, quality, reimbursement, reporting, sale, marketing, labeling, advertising, or promotion of any drug,
biologic, medical device, dietary supplement or other product (including, without limitation, any ingredient or component of, or
accessory to, the foregoing products) subject to regulation under the FDCA, the Public Health Service Act (42 U.S.C. §§
201 et seq.), or the Controlled Substances Act (21 U.S.C. §§ 801 et seq.); including but not limited to
all applicable Laws concerning fraud and abuse, including the Federal Anti-Kickback Statute (42 U.S.C. § 1320a- 7b(b)), the
federal Physician Self-Referral Law (42 U.S.C. § 1395nn), and the federal Civil Monetary Penalties Law (42 U.S.C. § 1320a-7a);
and the federal False Claims Act (31 U.S.C. §§ 3729 et seq.); all applicable Laws governing health benefits programs
sponsored by a Governmental Authority, including Medicare and Medicaid ; the Federal Trade Commission Act (15 U.S.C. §§
41 et seq.) and other applicable consumer protection Laws; all applicable Laws governing the collection, dissemination,
use, privacy, transfer, security, and confidentiality of medical records and personal information; any analogous state, local or
foreign Laws; all Laws pursuant to which Permits are issued; all regulations and legally binding guidance or rules promulgated
thereunder; and in each case, as the same may be amended from time to time.


“HHS”
has the meaning set forth in Section 4.1(i)(v).






    	 	12	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


“Indemnified
Taxes” means (a) Taxes, other than Excluded Taxes, imposed on or with respect to any payment made by or on account of
any obligation of Borrowers or any other Credit Party under any Financing Documents and (b) to the extent not otherwise described
in (a), Other Taxes.


“Instrument”
means “instrument”, as defined in Article 9 of the UCC.


“Intellectual
Property” means all copyright rights, copyright applications, copyright registrations and like protections in each work
of authorship and derivative work, whether published or unpublished, any patents, patent applications and like protections, including
improvements, divisions, continuations, renewals, reissues, extensions, and continuations-in-part of the same, trademarks, trade
names, service marks, mask works, rights of use of any name, domain names, or any other similar rights, any applications therefor,
whether registered or not, know-how, operating manuals, trade secret rights, clinical and non-clinical data, rights to unpatented
inventions, and any claims for damage by way of any past, present, or future infringement of any of the foregoing.


“Interest
Period” means any period commencing on the first day of a calendar month and ending on the last day of such calendar
month.


“Inventory”
means “inventory” as defined in Article 9 of the UCC.


“Investment”
means, with respect to any Person, directly or indirectly, (a) to purchase or acquire any stock or stock equivalents, or any obligations
or other securities of, or any interest in, any Person, including the establishment or creation of a Subsidiary, (b) to make or
commit to make any Acquisition or (c) make or purchase any advance, loan, extension of credit or capital contribution to, or any
other investment in, any Person. The amount of any Investment
shall be the original cost of such Investment plus the cost of all additions thereto, without any adjustments for increases or
decreases in value, or write-ups, write-downs or write-offs with respect thereto. 


“Investment
Company Act” means the Investment Company Act of 1940, as amended.


“IRS”
has the meaning set forth in Section 2.8(c)(i).


“Laws”
means any and all federal, state, provincial, territorial, local and foreign statutes, laws, judicial or administrative decisions,
regulations, ordinances, rules, judgments, orders, decrees, codes, injunctions, governmental agreements and governmental restrictions
enacted, issued or promulgated by, or entered into with, a Governmental Authority, whether now or hereafter in effect, which are
applicable to any Credit Party in any particular circumstance. “Laws” includes, without limitation, Healthcare
Laws and Environmental Laws.


“Lender”
means each of (a) MCF, in its capacity as a lender hereunder, (b) each other Person party hereto in its capacity as a
lender hereunder, (c) each other Person that becomes a party hereto as Lender pursuant to Section 11.17, and (d) the
respective successors of all of the foregoing, and “Lenders” means all of the foregoing.


“LIBOR Rate”
means, for each Loan, a per annum rate of interest equal to the greater of (a) one and one-half percent (1.50%) and (b) the
rate determined by Agent (rounded upwards, if necessary, to the next 1/100th%) by dividing (i) the Base LIBOR Rate
for the Interest Period, by (ii) the sum of one minus the daily average during such Interest Period of the aggregate
maximum reserve requirement (expressed as a decimal) then imposed under Regulation D of the Board of Governors of the Federal Reserve
System (or any successor thereto) for “Eurocurrency Liabilities” (as defined therein).






    	 	13	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


“Lien”
means, with respect to any asset, any mortgage, lien, pledge, charge, security interest or encumbrance of any kind, in respect
of such asset. For the purposes of this Agreement and the other Financing Documents, any Borrower or any Subsidiary shall be deemed
to own subject to a Lien any asset which it has acquired or holds subject to the interest of a vendor or lessor under any conditional
sale agreement, Capital Lease or other title retention agreement relating to such asset.


“Litigation”
means any action, suit or proceeding before any court, mediator, arbitrator or Governmental Authority.


“Loan Account”
has the meaning set forth in Section 2.6(b).


“Loan(s)”
means the Term Loan and each and every advance under the Term Loan. All references herein to the “making” of a Loan
or words of similar import mean, with respect to the Term Loan, the making of any advance in respect of a Term Loan.


“Market
Withdrawal” means a Person’s Removal or Correction of a distributed product which involves a minor violation that
would not be subject to legal action by the FDA (or any applicable and comparable state or local Governmental Authority, any applicable
and comparable Governmental Authority in any applicable non-United States jurisdiction), or which involves no violation, such as
routine stock rotation practices or routine equipment adjustments and repairs.


“Material
Adverse Effect” means with respect to any event, act, condition or occurrence of whatever nature (including any adverse
determination in any litigation, arbitration, or governmental investigation or proceeding), whether singly or in conjunction with
any other event or events, act or acts, condition or conditions, occurrence or occurrences, whether or not related, a material
adverse change in, or a material adverse effect upon, any of (a) the condition (financial or otherwise), operations, business,
or properties of the Credit Parties (taken as a whole), (b) the rights and remedies of Agent or Lenders under any Financing
Document, or the ability of any Credit Party to perform any of its obligations under any Financing Document to which it is a party,
(c) the legality, validity or enforceability of any Financing Document, (d) the existence, perfection or priority of
any security interest granted in any Financing Document (other than solely as a result of any action or inaction of Agent or Lenders
provided that such action or inaction is not caused by a Credit Party’s failure to comply with the terms of the Financing
Documents), or (e) the prospect of repayment of any material portion of the Obligations.


“Material
Contracts” means (a) the Operative Documents, (b) the agreements listed on Schedule 3.17, and (c) each agreement
or contract to which a Credit Party or its Subsidiaries is a party the termination of which could reasonably be expected to result
in a Material Adverse Effect.


“Material
Intangible Assets” means all of (a) Borrower’s Intellectual Property and (b) license or sublicense agreements or
other agreements with respect to rights in Intellectual Property, in each case that are material to the condition (financial or
other), business or operations of Borrower, as reasonably determined by Agent.


“Maturity
Date” means May 1, 2023.


“Maximum
Lawful Rate” has the meaning set forth in Section 2.7.






    	 	14	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


“MCF”
means MidCap Financial Trust, a Delaware statutory trust, and its successors and assigns.


“Medicaid”
means, collectively, the healthcare assistance program established by Title XIX of the Social Security Act (42 U.S.C. §§ 1396
et seq.) and any statutes succeeding thereto, all state statutes and plans for medical assistance enacted in connection
with such program, and all laws, rules, regulations, manuals, orders, guidelines or requirements (whether or not having the force
of Law) pertaining to such program, in each case as the same may be amended, supplemented or otherwise modified from time to time.


“Medicare”
means, collectively, the health insurance program for the aged and disabled established by Title XVIII of the Social Security Act
(42 U.S.C. §§ 1395 et seq.) and any statutes succeeding thereto, and all laws, rules, regulations, manuals,
orders or guidelines (whether or not having the force of Law) pertaining to such program, in each case as the same may be amended,
supplemented or otherwise modified from time to time.


“Monthly
Cash Burn Amount” means, with respect to Credit Parties, an amount equal to Credit Parties’ change in cash and
Cash Equivalents, without giving effect to any increase resulting from contributions or proceeds of financings, for either (a)
the immediately preceding six (6) month period as determined as of the last day of the month immediately preceding the proposed
consummation of any applicable Permitted Acquisition and based upon the financial statements delivered to Agent in accordance with
this Agreement for such period or (b) the immediately succeeding six (6) month period based upon the Transaction Projections, using
whichever calculation as between clause (a) and clause (b) demonstrates a higher burn rate (or, in other words, more cash used),
in either case, divided by six (6).


“Multiemployer
Pension Plan” means a multiemployer plan, as defined in Section 4001(a)(3) of ERISA, to which any Credit Party or
any Subsidiary has any liability, including on account of any member of the Controlled Group.


“Net
Revenue” means, for any period, (a) the consolidated gross revenues of Borrowers and their Subsidiaries generated solely
through the commercial sale of Products by Borrowers and their Subsidiaries during such period, less, without duplication, (b)(i)
trade, quantity and cash discounts allowed by Borrowers, (ii) discounts, refunds, rebates, charge backs, retroactive price adjustments
and any other allowances which effectively reduce net selling price, (iii) product returns and allowances, (iv) allowances for
shipping or other distribution expenses, (iv) set-offs and counterclaims, and (v) any other similar and customary deductions used
by Borrower in determining net revenues, all, in respect of (a) and (b), as determined in accordance with GAAP and in the Ordinary
Course of Business.


“Notes”
has the meaning set forth in Section 2.3.


“Notice
of Borrowing” means a notice of a Responsible Officer of Borrower Representative, appropriately completed and substantially
in the form of Exhibit B hereto.


“Obligations”
means all obligations, liabilities and indebtedness (monetary (including, without limitation, the payment of interest and other
amounts arising after the commencement of any case with respect to any Credit Party under the Bankruptcy Code or any similar statute
which would accrue and become due but for the commencement of such case, whether or not such amounts are allowed or allowable in
whole or in part in such case) or otherwise) of each Credit Party under this Agreement or any other Financing Document, in each
case howsoever created, arising or evidenced, whether direct or indirect, absolute or contingent, now or hereafter existing, or
due or to become due.






    	 	15	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


“OFAC”
means the U.S. Department of Treasury Office of Foreign Assets Control.


“OFAC Lists”
means, collectively, the Specially Designated Nationals and Blocked Persons List maintained by OFAC pursuant to Executive Order
No. 13224, 66 Fed. Reg. 49079 (Sept. 25, 2001) and/or any other list of terrorists or other restricted Persons maintained
pursuant to any of the rules and regulations of OFAC or pursuant to any other applicable Executive Orders.


“Operative
Documents” means the Financing Documents and Subordinated Debt Documents.


“Ordinary
Course of Business” means, in respect of any transaction involving any Credit Party, the ordinary course of business
of such Credit Party, as conducted by such Credit Party in accordance with past practices.


“Organizational
Documents” means, with respect to any Person other than a natural person, the documents by which such Person was organized
(such as a certificate of incorporation, certificate of limited partnership or articles of organization, and including, without
limitation, any certificates of designation for preferred stock or other forms of preferred equity) and which relate to the internal
governance of such Person (such as by-laws, a partnership agreement or an operating agreement, joint venture agreement, limited
liability company agreement or members agreement), including any and all shareholder agreements or voting agreements relating to
the capital stock or other Equity Interests of such Person.


“Other
Connection Taxes” means taxes imposed as a result of a present or former connection between Agent or any Lender and the
jurisdiction imposing such tax (other than connections arising from Agent or such Lender having executed, delivered, become a party
to, performed its obligations under, received payments under, engaged in any other transaction pursuant to or enforced any Financing
Document, or sold or assigned an interest in any Loans or any Financing Document).


“Other
Taxes” means all present or future stamp, court or documentary, intangible, recording, filing or similar taxes that arise
from any payment made under, from the execution, delivery, performance, enforcement or registration of, from the receipt or perfection
of a security interest under, or otherwise with respect to, any Financing Document, except any such taxes that are Other Connection
Taxes imposed with respect to an assignment (other than an assignment made pursuant to Section 2.8(i)).


“Participant
Register” has the meaning set forth in Section 11.17(a)(iii).


“Payment
Account” means the account specified on the signature pages hereof into which all payments by or on behalf of each Borrower
to Agent under the Financing Documents shall be made, or such other account as Agent shall from time to time specify by notice
to Borrower Representative.


“Payment
Notification” means a written notification substantially in the form of Exhibit C hereto.


“PBGC”
means the Pension Benefit Guaranty Corporation and any Person succeeding to any or all of its functions under ERISA.


“Pension
Plan” means any ERISA Plan that is subject to Section 412 of the Code or Title IV of ERISA, which for the avoidance
of doubt shall not include a Multiemployer Pension Plan.






    	 	16	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


“Permit”
means all licenses, certificates, accreditations, product clearances or approvals, provider numbers or provider authorizations,
supplier numbers, marketing authorizations, drug or device authorizations and approvals, other authorizations, franchises, qualifications,
accreditations, registrations, permits, consents and approvals of a Credit Party issued or required under Laws applicable to the
business of Borrowers or any of their Subsidiaries or necessary in the testing, development, manufacturing, importing, exporting,
possession, ownership, warehousing, marketing, promoting, sale, labeling, furnishing, distribution or delivery of goods or services
under Laws applicable to the business of Borrower or any of its Subsidiaries. Without limiting the generality of the foregoing,
“Permit” includes any Regulatory Required Permit.


“Permitted
Acquisition” means any Acquisition by a Borrower, in each case, to the extent that each of the following conditions shall
have been satisfied:


		(a)	the Borrower Representative shall have delivered to Agent at least
ten (10) Business Days (or such shorter period as may be agreed by Agent) prior to the closing of the proposed Acquisition: (i)
a description of the proposed Acquisition; and (ii) copies of the current versions of the respective agreements, documents or instruments
pursuant to which such Acquisition is to be consummated (and as soon as available, final drafts thereof), any schedules to such
agreements, documents or instruments and all other material ancillary agreements, instruments and documents to be executed or delivered
in connection therewith; 



		(b)	the Credit Parties (including any new Subsidiary to the extent required
by Section 4.11) shall execute and deliver the agreements, instruments and other documents to the extent required by the terms
of this Agreement, including, without limitation, Section 4.11 hereof, including such agreements, instruments and other documents
necessary to ensure that Agent receives a first priority perfected Lien in all entities and assets acquired in connection with
the proposed Acquisition to the extent required by this Agreement;



		(c)	if the Acquisition is an equity purchase, the target and its Subsidiaries
must have as its jurisdiction of formation a state within the United States and if the Acquisition is an asset purchase or a merger,
not less than 85% of the fair market value of all of the assets so acquired shall be located within the United States (or, in the
case of any Intellectual Property so acquired, registered or otherwise located in the United States);



		(d)	at the time of such Acquisition and after giving effect thereto,
no Default or Event of Default has occurred and is continuing;



		(e)	the assets acquired in such Acquisition are for use in the same lines
of business as the Credit Parties are currently engaged or a line of business reasonably related thereto;



		(f)	such Acquisition shall not be hostile and, if applicable, shall have
been approved by the board of directors (or other similar body) and/or the stockholders or other equity holders of any Person being
acquired in such Acquisition;



		(g)	all transactions in connection with such Acquisition shall be consummated
in accordance with applicable Law;



		(h)	no Debt or Liens are assumed or created (other than Permitted Liens
and Permitted Debt) in connection with such Acquisition;







    	 	17	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


 


		(i)	Agent shall have received a certificate of a Responsible Officer
of the Borrower Representative demonstrating, on a pro forma basis after giving effect to the consummation of such Acquisition,
that Credit Parties are in compliance with the financial covenants set forth in Article 6 hereof; 



		(j)	the sum of all cash amounts paid or payable in connection with all
Permitted Acquisitions (including all Debt, liabilities and Contingent Obligations (in each case to the extent otherwise permitted
hereunder) incurred or assumed and the maximum amount of any earn-out or comparable payment obligation in connection therewith,
regardless of when due or payable and whether or not reflected on a consolidated balance sheet of Borrowers) shall not exceed $10,000,000
in the aggregate for any calendar year or $50,000,000 in the aggregate during the term of this Agreement; provided that
the foregoing shall not prohibit or limit any Equity Interests of TherapeuticsMD (other than Disqualified Stock) issued by a Borrower
as consideration; and



		(k)	Agent has received, prior to the consummation of such proposed Acquisition,
updated financial projections, in form and substance reasonably satisfactory to Agent, for the immediately succeeding twelve (12)
months following the proposed consummation of the Acquisition beginning with the month during which the Acquisition is to be consummated
(the “Transaction Projections”) and such other evidence as Agent may reasonably request demonstrating that Credit
Parties have, immediately before and immediately after giving effect to the consummation of such Acquisition, an aggregate amount
of Borrower Unrestricted Cash equal to or greater than the sum of the (i) positive value of the product of (x) twelve (12) multiplied
by (y) the Monthly Cash Burn Amount, as determined as of the last day of the month immediately preceding such Acquisition and
(ii) $50,000,000.



“Permitted
Asset Dispositions” means the following Asset Dispositions:


		(a)	dispositions of Inventory in the Ordinary Course of Business and
not pursuant to any bulk sale; 



		(b)	dispositions of furniture, fixtures and equipment in the Ordinary
Course of Business that is obsolete, worn out, damaged, replaced, is no longer used or useful, unmerchantable or unsaleable, in
each case, in the Ordinary Course of Business;



		(c)	so long as no Default or Event of Default exists or would result
from such Asset Disposition (i) Asset Dispositions among the Borrowers, and (ii) Asset Dispositions among Excluded Foreign Subsidiaries;



		(d)	Permitted Licenses; provided that at the time such Permitted
License is entered into, no Default or Event of Default exists or would result from such Asset Disposition; 



		(e)	the abandonment in
the Ordinary Course of Business of
Intellectual Property (other than Material Intangible Assets) that is no longer used or useful to Borrowers or their Subsidiaries;



		(f)	sales, forgiveness or discounting, on a non-recourse basis and in
the Ordinary Course of Business, of past due Accounts in connection
with the collection or compromise thereof or the settlement of delinquent Accounts or in connection with the bankruptcy or reorganization
of suppliers or customers in accordance with the applicable terms of this Agreement; and







    	 	18	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


 


		(g)	other dispositions approved by Agent from time to time in its sole
discretion. 



“Permitted
Contest” means a contest maintained in good faith by appropriate proceedings promptly instituted and diligently conducted
and with respect to which such reserve or other appropriate provision, if any, as shall be required in conformity with GAAP shall
have been made; provided that compliance with the obligation that is the subject of such contest is effectively stayed during such
challenge.


“Permitted
Contingent Obligations” means


		(a)	Contingent Obligations arising in respect of the Debt under the Financing
Documents; 



		(b)	Contingent Obligations resulting from endorsements for collection
or deposit in the Ordinary Course of Business; 



		(c)	Contingent Obligations outstanding on the date of this Agreement
and set forth on Schedule 5.1 including extension and renewals thereof which (i) do not increase the amount of
such Contingent Obligations (other than an interest rate increase to then prevailing market levels), (ii) do not impose materially
more restrictive or adverse terms on the Credit Parties as compared to the terms of the Contingent Obligations being renewed or
extended, (iii) are not secured by any assets other than the assets securing the Contingent Obligations being extended or
renewed, or (iv) do not have obligors who are different from the obligors of the Contingent Obligations being extended or
renewed; 



		(d)	Contingent Obligations incurred in the Ordinary Course of Business
with respect to surety and appeal bonds, performance bonds and other similar obligations not to exceed $1,000,000 in the aggregate
at any time outstanding; 



		(e)	Contingent Obligations arising under indemnification obligations
contained in commercial agreements entered in the ordinary course of business, including those with title insurers to cause such
title insurers to issue to Agent mortgagee title insurance policies; 



		(f)	Contingent Obligations arising with respect to customary indemnification
obligations in favor of purchasers in connection with dispositions of personal property assets permitted under Section 5.6;




		(g)	Contingent Obligations arising with respect to customary indemnification
obligations, adjustment of purchase price, or similar obligations of any Credit Party, to the extent such Contingent Obligations
arise in connection with a Permitted Acquisition;



		(h)	so long as there exists no Event of Default both immediately before
and immediately after giving effect to any such transaction, Contingent Obligations existing or arising under any Swap Contract,
provided, however, that such obligations are (or were) entered into by Borrower or an Affiliate in the Ordinary Course of
Business for the purpose of directly mitigating risks associated with liabilities, commitments, investments, assets, or property
held or reasonably anticipated by such Person and not for purposes of speculation; and 



		(i)	other Contingent Obligations not to exceed $500,000 in the aggregate
at any time outstanding. 







    	 	19	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


“Permitted
Debt” means:


		(a)	Borrowers’ and its Subsidiaries’ Debt to Agent and each
Lender under this Agreement and the other Financing Documents;



		(b)	Debt incurred as a result of endorsing negotiable instruments received
in the Ordinary Course of Business; 



		(c)	purchase money Debt or Capital Lease obligations not to exceed $1,000,000
in the aggregate at any time (whether in the form of a loan or a lease) used solely to acquire equipment used in the Ordinary Course
of Business and secured only by such equipment and accessions thereto and proceeds thereof; 



		(d)	Debt existing on the date of this Agreement and described on Schedule 5.1
and any refinancing, extensions or renewals thereof, provided that the refinanced, extended, or renewed Debt shall not (i) have
an aggregate outstanding principal amount in excess of the aggregate principal amount of the Debt being refinanced, extended or
renewed, and any accrued interest, reasonable fees and reasonable out-of-pocket costs related thereto, (ii) impose materially
more restrictive or adverse terms on any Credit Party or any Subsidiary as compared to the terms of the Debt being refinanced,
extended or renewed (other than an interest rate increase to then prevailing market levels), (iii) be secured by any assets
other than the assets securing the Debt being refinanced, extended or renewed, or (iv) have additional obligors from the obligors
of the Debt being refinanced, extended or renewed; 



		(e)	so long as there exists no Event of Default both immediately before
and immediately after giving effect to any such transaction, Debt existing or arising under any Swap Contract, provided, however,
that such obligations are (or were) entered into by Borrower or an Affiliate in the Ordinary Course of Business for the purpose
of directly mitigating risks associated with liabilities, commitments, investments, assets, or property held or reasonably anticipated
by such Person and not for purposes of speculation; 



		(f)	Debt in the form of insurance premiums not to exceed $1,000,000 in
the aggregate at any time outstanding owed to any Person providing property, casualty, liability, or other insurance to Borrowers,
financed through the applicable insurance company so long as the amount of such Debt is not
in excess of the amount of the unpaid cost of, and shall be incurred only to defer the cost of, such insurance for the policy year
in which such Debt is incurred and such Debt is outstanding only during such policy year;



		(g)	Subordinated Debt; 



		(h)	unsecured Debt in respect of (i) credit cards, credit card processing
services, debit cards, stored value cards, purchase cards (including so-called “procurement cards” or “P-cards”)
or other similar cash management services, in each case, incurred in the Ordinary Course of Business and to the extent such Debt
is unsecured and does not exceed $2,500,000 in the aggregate at any time outstanding, and (ii) netting services or overdraft
protections and similar arrangements in connection with Deposit Accounts, in each case solely to the extent incurred in the Ordinary
Course of Business; 







    	 	20	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


 


		(i)	Debt in respect of performance, surety or appeal bonds, workers’
compensation claims, self-insurance obligations and bankers acceptances issued for the account of any Credit Party or any Subsidiary,
in each case, provided in the Ordinary Course of Business, and not to exceed $1,000,000 in the aggregate at any time outstanding,
but excluding (in each case) Debt incurred through the borrowing of money;



		(j)	without duplication, any Debt of any Borrower or any Subsidiary that
constitutes a Permitted Contingent Obligation; 



		(k)	Debt consisting of unsecured intercompany loans and advances incurred
by (i) any Borrower or Guarantor owing to any other Borrower or Guarantor, (ii) any Excluded Foreign Subsidiary owing to any other
Excluded Foreign Subsidiary, (iii) any Borrower or Guarantor owing to any Excluded Foreign Subsidiary, or (iv) any Excluded Foreign
Subsidiary owing to any Borrower or any Guarantor so long as such Debt constitutes a Permitted Investment of the applicable Credit
Party pursuant to clause (l) of the definition of Permitted Investments; provided, however, that upon the request
of Agent at any time, any such Debt shall be evidenced by promissory notes having terms reasonably satisfactory to Agent, the sole
originally executed counterparts of which shall be pledged and delivered to Agent, for the benefit of Agent and Lenders, as security
for the Obligations; and 



		(l)	unsecured Debt not to exceed $1,000,000 in the aggregate at any time
outstanding. 



“Permitted
Distributions” means the following Distributions: (a) dividends by any Borrower or Subsidiary of any Borrower or
Guarantor to any Borrower or Guarantor; (b) dividends payable solely in common stock; and (c) repurchases of stock of
former employees, directors or consultants pursuant to stock purchase agreements so long as an Event of Default does not exist
at the time of such repurchase and would not exist after giving effect to such repurchase, provided, however, that such
repurchase does not exceed $500,000 in the aggregate per fiscal year.


“Permitted
Investments” means:


		(a)	Investments shown on Schedule 5.7 and existing on the
Closing Date; 



		(b)	Investments in cash and Cash Equivalents; 



		(c)	Investments consisting of the endorsement of negotiable instruments
for deposit or collection or similar transactions in the Ordinary Course of Business; 



		(d)	Investments consisting of (i) travel advances and employee relocation
loans and other employee loans and advances in the Ordinary Course of Business, and (ii) loans to employees, officers or directors
relating to the purchase of equity securities of Borrowers or their Subsidiaries pursuant to employee stock purchase plans or agreements
approved by Borrowers’ Board of Directors (or other governing body), but the aggregate of all such loans outstanding may
not exceed $1,000,000 at any time; 



		(e)	Investments (including debt obligations) received in connection with
the bankruptcy or reorganization of customers or suppliers and in settlement of delinquent obligations of, and other disputes with,
customers or suppliers arising in the Ordinary Course of Business; 







    	 	21	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


 


		(f)	Investments consisting of notes receivable of, or prepaid royalties
and other credit extensions, to customers and suppliers who are not Affiliates, in the Ordinary Course of Business, provided,
however, that this subpart (f) shall not apply to Investments of Borrowers in any Subsidiary; 



		(g)	Deposit Accounts established in accordance with Section 5.14
and Investments in negotiable instruments deposited or to be deposited for collection in the Ordinary Course of Business; 



		(h)	Investments by any Borrower in any Subsidiary now owned or hereafter
created by such Borrower, which Subsidiary is a Borrower or has provided a Guarantee of the Obligations of the Borrowers which
Guarantee is secured by a Lien granted by such Subsidiary to Agent in all or substantially all of its property of the type described
in Schedule 9.1 hereto and otherwise made in compliance with Section 4.11(d); 



		(i)	deposits required to be made to a landlord in the Ordinary Course
of Business to secure or support obligations of any Credit Party or any Subsidiary under a lease of real property;



		(j)	accounts receivable created, acquired or made and trade credit extended
in the Ordinary Course of Business and payable in accordance with customary trade terms;



		(k)	Investments constituting Permitted Acquisitions; 



		(l)	Investments of cash and Cash Equivalents in an Excluded Foreign Subsidiary
but solely to the extent that the aggregate amount of such Investments with respect to all Excluded Foreign Subsidiaries does not,
at any time, exceed $250,000 in the aggregate in any twelve (12) month period; provided that in no event shall the aggregate
amount of Investments made in any Excluded Foreign Subsidiary exceed the amount necessary to fund the current operating expenses
of such Excluded Foreign Subsidiary (taking into account their revenue from other sources); 



		(m)	Investments by any Excluded Foreign Subsidiary in a Credit Party
or any other Excluded Foreign Subsidiary; and 



		(n)	so long as no Event of Default exists at the time of such Investment
or after giving effect to such Investment, other Investments of cash and Cash Equivalents in an amount not exceeding $1,000,000
in the aggregate. 



“Permitted
License” means (a) any non-exclusive license of patent rights of Borrower or its Subsidiaries so long as all such Permitted
Licenses are granted to third parties in the Ordinary Course of Business, do not result in a legal transfer of title to the licensed
property, and have been granted in exchange for fair consideration, and (b) any exclusive license of patent rights of Borrower
or its Subsidiaries so long as such Permitted Licenses are granted to third parties in the Ordinary Course of Business, do not
result in a legal transfer of title to the licensed property, are exclusive solely as to discrete geographical areas outside of
the United States, and have been granted in exchange for fair consideration.






    	 	22	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


“Permitted
Liens” means:


		(a)	deposits or pledges of cash to secure obligations under workmen’s
compensation, social security or similar laws, or under unemployment insurance (but excluding Liens arising under ERISA or, with
respect to any Pension Plan or Multiemployer Pension Plan, the Code) pertaining to a Borrower’s or its Subsidiary’s
employees, if any; 



		(b)	deposits or pledges of cash to secure bids, tenders, contracts (other
than contracts for the payment of money or the deferred purchase price of property or services), leases, statutory obligations,
surety and appeal bonds and other obligations of like nature arising in the Ordinary Course of Business; 



		(c)	carrier’s, warehousemen’s, mechanic’s, workmen’s,
materialmen’s or other like Liens on Collateral, other than any Material Intangible Assets, arising in the Ordinary Course
of Business with respect to obligations which are not overdue, or which are being contested pursuant to a Permitted Contest; 



		(d)	Liens for taxes, assessments or other governmental charges not at
the time delinquent or the subject of a Permitted Contest; 



		(e)	attachments, appeal bonds, judgments and other similar Liens arising
in connection with court proceedings not constituting an Event of Default under Section 10.1(h); provided, that the execution
or other enforcement of such Liens is effectively stayed and the claims secured thereby are the subject of a Permitted Contest;




		(f)	with respect to real estate, easements, rights of way, restrictions,
minor defects or irregularities of title, none of which, individually or in the aggregate, materially interfere with the benefits
of the security intended to be provided by the Security Documents, materially affect the value or marketability of the Collateral,
impair the use or operation of the Collateral for the use currently being made thereof or impair Borrowers’ ability to pay
the Obligations in a timely manner or impair the use of the Collateral or the ordinary conduct of the business of the Borrowers
taken as a whole or any Subsidiary and which, in the case of any real estate that is part of the Collateral, are set forth as exceptions
to or subordinate matters in the title insurance policy accepted by Agent insuring the lien of the Security Documents; 



		(g)	Liens and encumbrances in favor of Agent under the Financing Documents;




		(h)	Liens existing on the date hereof and set forth on Schedule 5.2
and any renewals or extensions of such Liens; provided that (i) the Debt secured by such Liens is permitted under clause
(d) of the definition Permitted Debt and (ii) any such renewal or extension does not encumber any additional assets or properties
of any Credit Party; 



		(i)	any Lien on any equipment securing Debt permitted under subpart (c) of
the definition of Permitted Debt, provided, however, that such Lien attaches concurrently with or within twenty (20)
days after the acquisition thereof; 



		(j)	purported Liens evidenced by the filing
of precautionary UCC financing statements relating solely to operating leases or consignments of personal property entered into
the Ordinary Course of Business; 







    	 	23	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


 


		(k)	Liens granted in the Ordinary Course of
Business on the unearned portion of insurance premiums securing the financing of insurance premiums to the extent the financing
is permitted clause (f) of the definition of Permitted Debt;



		(l)	Liens that are rights of set-off, bankers’ liens or similar
non-consensual Liens relating to deposit or securities accounts in favor of banks, other depositary institutions and securities
intermediaries arising in the Ordinary Course of Business; 



		(m)	Liens in favor of customs and revenue authorities arising as a matter
of Law to secure payment of customs duties in connection with the importation of goods in the Ordinary Course of Business; 



		(n)	To the extent constituting a Lien, the granting of a Permitted License;
and



		(o)	Liens solely on any cash earnest money deposits made by a Borrower
or Subsidiary thereof in connection with any letter of intent or purchase agreement with respect to a Permitted Acquisition or
other Investment expressly permitted under this Agreement.



“Permitted
Modifications” means (a) such amendments or other modifications to a Borrower’s or Subsidiary’s Organizational
Documents as are required under this Agreement or by applicable Law and fully disclosed to Agent within thirty (30) days after
such amendments or modifications have become effective, and (b) such amendments or modifications to a Borrower’s or
Subsidiary’s Organizational Documents (other than those involving a change in the name of a Borrower or Subsidiary or involving
a reorganization of a Borrower or Subsidiary under the laws of a different jurisdiction) that would not adversely affect the rights
and interests of Agent or Lenders and fully disclosed to Agent within thirty (30) days after such amendments or modifications
have become effective.


“Person”
means any natural person, corporation, limited liability company, professional association, limited partnership, general partnership,
joint stock company, joint venture, association, company, trust, bank, trust company, land trust, business trust or other organization,
whether or not a legal entity, and any Governmental Authority.


“Prepayment
Fee” has the meaning set forth in Section 2.2.


“Products”
means, from time to time, any products currently manufactured, marketed, promoted, sold, distributed, developed or being developed,
or tested or being tested by or on behalf of any Borrower or any of its Subsidiaries, including without limitation, those products
set forth on Schedule 4.15 (as updated from time to time in accordance with the terms of this Agreement); provided, that,
for the avoidance of doubt, any new Product not disclosed on Schedule 4.15 shall still constitute a “Product”
as herein defined.


“Pro Rata
Share” means (a) with respect to a Lender’s obligation to make advances in respect of a Term Loan and such
Lender’s right to receive payments of principal and interest with respect to the Term Loans, the Term Loan Commitment Percentage
of such Lender in respect of such Term Loan, and (b) for all other purposes (including, without limitation, the indemnification
obligations arising under Section 11.6) with respect to any Lender, the percentage obtained by dividing (i) the
Term Loan Commitment Amount of such Lender (or, in the event the Term Loan Commitment shall have been terminated, such Lender’s
then outstanding principal advances of such Lender under the Term Loan), by (ii) the sum of the Term Loan Commitment
(or, in the event the Term Loan Commitment shall have been terminated, the then outstanding principal advances of such Lenders
under the Term Loan) of all Lenders.






    	 	24	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


“Recall”
means a Person’s Removal or Correction of a marketed product that the FDA considers to be in violation of the FDCA and other
Laws it administers and against which the FDA would initiate legal action.


“Registered
Intellectual Property” means any patent, registered trademark or servicemark, registered copyright, registered mask work,
or any pending application for any of the foregoing.


“Regulatory
Reporting Event” has the meaning set forth in Section 4.1(i).


“Regulatory
Required Permit” means any and all Permits issued by the FDA, DEA or any other applicable Governmental Authority, including
without limitation approved Drug Applications, necessary for the development, testing, manufacture, import, export, possession,
ownership, holding, marketing, promotion, sale, labeling, or distribution, as applicable, of any Product by or on behalf of any
applicable Borrower(s) and its Subsidiaries as such activities are being conducted with respect to such Product at such time, including
but not limited to any drug listings and drug establishment registrations under 21 U.S.C. Section 360, registrations issued by
DEA under 21 U.S.C. Section 823 (if applicable to any Product), and those issued by state Governmental Authorities for the conduct
of Borrower’s or any Subsidiary’s business.


“Removal”
means the physical removal of a product from its point of use to some other location for repair, modification, adjustment, relabeling,
destruction, or inspection.


“Required
Lenders” means, at any time, Lenders holding unfunded Term Loan Commitments (which have not been terminated or expired)
and outstanding Term Loans representing more than fifty one percent (51%) of the sum of the total unfunded Term Loan Commitments
(which have not been terminated or expired) and outstanding Term Loans as of such date.


“Responsible
Officer” means any of the Chief Executive Officer, Chief Financial Officer or any other officer of the applicable Borrower
acceptable to Agent.


“SEC”
means the United States Securities and Exchange Commission.


“Securities
Account” means a “securities account” (as defined in Article 9 of the UCC), an investment account, or
other account in which investment property or securities are held or invested for credit to or for the benefit of any Borrower.


“Securities
Account Control Agreement” means an agreement, in form and substance reasonably satisfactory to Agent, among Agent, any
applicable Borrower and each securities intermediary in which such Borrower maintains a Securities Account pursuant to which Agent
shall obtain “control” (as defined in Article 9 of the UCC) over such Securities Account.


“Security
Document” means this Agreement and any other agreement, document or instrument executed concurrently herewith or at any
time hereafter pursuant to which one or more Credit Parties or any other Person either (a) Guarantees payment or performance
of all or any portion of the Obligations, and/or (b) provides, as security for all or any portion of the Obligations, a Lien
on any of its assets in favor of Agent for its own benefit and the benefit of the Lenders, as any or all of the same may be amended,
supplemented, restated or otherwise modified from time to time.






    	 	25	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


“Solvent”
means, with respect to any Person, that such Person (a) owns and will own assets the fair saleable value of which are (i) greater
than the total amount of its debts and liabilities (including subordinated and Contingent Obligations), and (ii) greater than
the amount that will be required to pay the probable liabilities of its then existing debts as they become absolute and matured
considering all financing alternatives and potential asset sales reasonably available to it; (b) has capital that is not unreasonably
small in relation to its business as presently conducted or after giving effect to any contemplated transaction; and (c) does
not intend to incur and does not believe that it will incur debts beyond its ability to pay such debts as they become due.


“Stated
Rate” has the meaning set forth in Section 2.7.


“Subordinated
Debt” means any Debt of Borrowers incurred pursuant to the terms of the Subordinated Debt Documents and with the prior
written consent of Agent, all of which documents must be in form and substance reasonably acceptable to Agent. As of the Closing
Date, there is no Subordinated Debt.


“Subordinated
Debt Documents” means any documents evidencing and/or securing Debt governed by a Subordination Agreement, all of which
documents must be in form and substance reasonably acceptable to Agent. As of the Closing Date, there are no Subordinated Debt
Documents.


“Subordination
Agreement” means any agreement between Agent and another creditor of Borrowers, as the same may be amended, supplemented,
restated or otherwise modified from time to time in accordance with the terms thereof, pursuant to which the Debt owing from any
Borrower(s) and/or the Liens securing such Debt granted by any Borrower(s) to such creditor are subordinated in any way to the
Obligations and the Liens created under the Security Documents, the terms and provisions of such Subordination Agreements to have
been agreed to by and be acceptable to Agent in the exercise of its sole discretion.


“Subsidiary”
means, with respect to any Person, (a) any corporation (or
any foreign equivalent thereof) of which an aggregate of more than fifty percent (50%) of the outstanding capital stock
having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the
time, capital stock of any other class or classes of such corporation shall have or might have voting power by reason of the happening
of any contingency) is at the time, directly or indirectly, owned legally or beneficially by such Person or one or more Subsidiaries
of such Person, or with respect to which any such Person has the right to vote or designate the vote of more than fifty percent
(50%) of such capital stock whether by proxy, agreement, operation of law or otherwise, and (b) any partnership or limited
liability company (or any foreign equivalent thereof) in which such Person and/or
one or more Subsidiaries of such Person shall have an interest (whether in the form of voting or participation in profits or capital
contribution) of more than fifty percent (50%) or of which any such Person is a general partner or may exercise the powers of a
general partner. Unless the context otherwise requires, each reference to a Subsidiary shall be a reference to a Subsidiary of
a Borrower.


“Swap Contract”
means any “swap agreement”, as defined in Section 101 of the Bankruptcy Code, that is obtained by Borrower to
provide protection against fluctuations in interest or currency exchange rates, but only if Agent provides its prior written consent
to the entry into such “swap agreement”.


“Taxes”
means all present or future taxes, levies, imposts, duties,
deductions, withholdings (including backup withholding), assessments, fees or other charges imposed by any Governmental Authority,
including any interest, additions to tax or penalties applicable thereto.






    	 	26	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


“Termination
Date” means the earlier to occur of (a) the Maturity Date, (b) any date on which Agent accelerates the maturity
of the Loans pursuant to Section 10.2, (c) if the Term Loan Tranche 1 Funding Date has not occurred by the Term Loan Tranche
1 Commitment Termination Date, the Term Loan Tranche 1 Commitment Termination Date or (d) the termination date stated in any notice
of termination of this Agreement provided by Borrowers in accordance with Section 2.11.


“Term Loan”
means, collectively, Term Loan Tranche 1, Term Loan Tranche 2 and Term Loan Tranche 3.


“Term Loan
Commitment Amount” means, with respect to each Lender, the sum of such Lender’s Term Loan Tranche 1 Commitment
Amount, Term Loan Tranche 2 Commitment Amount and Term Loan Tranche 3 Commitment Amount.


“Term Loan
Commitment Percentage” means, as to any Lender
with respect to each of such Lender’s Term Loan Commitments, (a) on the Closing
Date with respect to each tranche of the Term Loan,
the applicable percentage set forth opposite such Lender’s name on the Commitment Annex under the column “Term Loan
Tranche 1 Commitment Percentage,”
“Term Loan Tranche 2 Commitment Percentage,” and “Term Loan Tranche 3 Commitment Percentage”, (if such
Lender’s name is not so set forth thereon, then, on the Closing Date, such percentage for such Lender shall be deemed to
be zero), and (b) on any date following the Closing Date, as
applicable to each tranche of Term Loan, the percentage equal to (i)
the Term Loan Tranche 1 Commitment of such Lender on
such date divided by the aggregate Term Loan Tranche 1 Commitments on such date, (ii) the Term Loan Tranche 2 Commitment
of such Lender on such date divided by the aggregate Term Loan Tranche 2 Commitments on such date or (iii) the Term Loan
Tranche 3 Commitment of such Lender on such date divided by the aggregate Term Loan Tranche 3 Commitments on such date.


“Term Loan
Commitments” means the Term Loan Tranche 1 Commitments, Term Loan Tranche 2 Commitments and the Term Loan Tranche 3 Commitments.
For the avoidance of doubt, the aggregate Term Loan Commitments of all Lenders on the Closing Date shall be $200,000,000.


“Term Loan
Tranche 1” has the meaning set forth in Section 2.1(a)(i)(A)


“Term Loan
Tranche 1 Activation Date” means the date, if any, prior to July 31, 2018, on which the Agent receives documentation
and information evidencing, to Agent’s reasonable satisfaction, that the FDA has approved Borrowers’ Drug Application
for the testing, manufacturing, marketing and commercial sale in the United States of TX-004HR, in both 4 microgram and 10 microgram
doses, for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.


“Term Loan
Tranche 1 Commitment Amount” means, with respect to
each Lender, the amount set forth opposite such Lender’s name on Annex A
hereto under the caption “Term Loan Tranche 1 Commitment Amount”,
as amended from time to time to reflect any permitted and effective assignments and as such amount may be
reduced or terminated pursuant to this Agreement. 


“Term Loan
Tranche 1 Commitment Termination Date” means the earlier of (a) the date that is fifteen (15) Business Days following
the Term Loan Tranche 1 Activation Date and (b) July 31, 2018.


“Term Loan
Tranche 1 Commitments” means the sum of each Lender’s Term Loan Tranche 1 Commitment Amount. For the avoidance
of doubt, the aggregate Term Loan Tranche 1 Commitments of all Lenders on the Closing Date shall be $75,000,000.






    	 	27	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


“Term Loan
Tranche 1 Funding Date” has the meaning set forth in Section 2.1(a)(i)(A).


“Term Loan
Tranche 2” has the meaning set forth in Section 2.1(a)(i)(B).


“Term Loan
Tranche 2 Activation Date” means the date, if any, after the Term Loan Tranche 1 Funding Date and prior to the Term Loan
Tranche 2 Commitment Termination Date, on which the Agent receives documentation and information evidencing, to Agent’s reasonable
satisfaction, both that (a) the FDA has approved Borrowers’ Drug Application for the testing, manufacturing, marketing and
commercial sale in the United States of TX-001HR for the treatment of moderate to severe vasomotor symptoms associated with menopause
in women with a uterus, and (b) Borrower has, in the ordinary course of business, consummated its first commercial sale in the
United States of TX-001HR for the treatment of moderate to severe vasomotor symptoms associated with menopause in women with a
uterus (the “TX-001HR First Commercial Sale”).


“Term Loan
Tranche 2 Commitment Amount” means, with respect to each Lender, the amount set forth opposite such Lender’s name
on Annex A hereto under the caption “Term Loan Tranche 2 Commitment Amount”, as amended from time to time to reflect
any permitted and effective assignments and as such amount may be reduced or terminated pursuant to this Agreement.


“Term Loan
Tranche 2 Commitment Termination Date” means (a) if the Term Loan Tranche 1 Funding Date has not occurred by the Term
Loan Tranche 1 Commitment Termination Date, the Term Loan Tranche 1 Commitment Termination Date or (b) otherwise, May 31, 2019.


“Term Loan
Tranche 2 Commitments” means the sum of each Lender’s Term Loan Tranche 2 Commitment Amount. For the avoidance
of doubt, the aggregate Term Loan Tranche 2 Commitments of all Lenders on the Closing Date shall be $75,000,000.


“Term Loan
Tranche 2 Funding Date” has the meaning set forth in Section 2.1(a)(i)(B).


“Term Loan
Tranche 3” has the meaning set forth in Section 2.1(a)(i)(C).


“Term Loan
Tranche 3 Activation Date” means the date, if any, following the Term Loan Tranche 2 Funding Date but prior to the Term
Loan Tranche 3 Commitment Termination Date on which Agent receives a Compliance Certificate and such other documentation and information
as Agent may reasonably request evidencing, to Agent’s reasonable satisfaction, that Borrowers’ consolidated Net Revenue
attributable solely to the commercial sale of TX-001HR and TX-004HR for the twelve (12) month period ending on the last day of
the month immediately preceding such proposed Term Loan Tranche 3 Funding Date is greater than or equal to $75,000,000.


“Term Loan
Tranche 3 Commitment Amount” means, with respect to each Lender, the amount set forth opposite such Lender’s name
on Annex A hereto under the caption “Term Loan Tranche 3 Commitment Amount”, as amended from time to time to reflect
any permitted and effective assignments and as such amount may be reduced or terminated pursuant to this Agreement.


“Term Loan
Tranche 3 Commitment Termination Date” means the earliest to occur of the following: (a) if the Term Loan Tranche 1 Funding
Date has not occurred by the Term Loan Tranche 1 Commitment Termination Date, the Term Loan Tranche 1 Commitment Termination Date;
(b) if the Term Loan Tranche 2 Funding Date has not occurred by the Term Loan Tranche 2 Commitment Termination Date, the Term Loan
Tranche 2 Commitment Termination Date; and (c) otherwise, December 31, 2019.






    	 	28	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


“Term Loan
Tranche 3 Commitments” means the sum of each Lender’s Term Loan Tranche 3 Commitment Amount. For the avoidance
of doubt, the aggregate Term Loan Tranche 3 Commitments of all Lenders on the Closing Date shall be $50,000,000.


“Term Loan
Tranche 3 Funding Date” has the meaning set forth in Section 2.1(a)(i)(C).


“TRICARE”
means the program administered pursuant to 10 U.S.C. §§ 1071 et seq., Sections 1320a-7 and 1320a-7a
of Title 42 of the United States Code and the regulations promulgated pursuant to such statutes.


“UCC”
means the Uniform Commercial Code of the State of New York or of any other state the laws of which are required to be applied in
connection with the perfection of security interests in any Collateral.


“United
States” means the United States of America.


“U.S.
Tax Compliance Certificate” has the meaning set forth in Section 2.8(c)(i).


“Withholding
Agent” means any Borrower or Agent.


“Write-Down
and Conversion Powers” means, with respect to any EEA Resolution Authority, the write-down and conversion powers of such
EEA Resolution Authority from time to time under the Bail-In Legislation for the applicable EEA Member Country, which write-down
and conversion powers are described in the EU Bail-In Legislation Schedule.


Section 1.2           Accounting
Terms and Determinations. Unless otherwise specified herein, all accounting terms used herein
shall be interpreted, all accounting determinations hereunder (including, without limitation, determinations made pursuant to the
exhibits hereto) shall be made, and all financial statements required to be delivered hereunder shall be prepared on a consolidated
basis in accordance with GAAP applied on a basis consistent with the most recent audited consolidated financial statements of each
Borrower and its Consolidated Subsidiaries delivered to Agent and each of the Lenders on or prior to the Closing Date. If at any
time any change in GAAP would affect the computation of any financial ratio or financial requirement set forth in any Financing
Document, and either Borrowers or the Required Lenders shall so request, Agent, the Lenders and Borrowers shall negotiate in good
faith to amend such ratio or requirement to preserve the original intent thereof in light of such change in GAAP (subject to the
approval of the Required Lenders); provided, however, that until so amended, (a) such ratio or requirement shall
continue to be computed in accordance with GAAP prior to such change therein and (b) Borrowers shall provide to Agent and
the Lenders financial statements and other documents required under this Agreement which include a reconciliation between calculations
of such ratio or requirement made before and after giving effect to such change in GAAP. Notwithstanding any other provision contained
herein, all terms of an accounting or financial nature used herein shall be construed, and all computations of amounts and ratios
referred to herein shall be made, without giving effect to any election under Statement of Financial Accounting Standards 159 (or
any other Financial Accounting Standard having a similar result or effect) to value any Debt or other liabilities of any Credit
Party or any Subsidiary of any Credit Party at “fair value”, as defined therein.






    	 	29	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


Section 1.3          Other
Definitional and Interpretive Provisions. References in this Agreement to “Articles”,
“Sections”, “Annexes”, “Exhibits”, or “Schedules” shall be to Articles, Sections,
Annexes, Exhibits or Schedules of or to this Agreement unless otherwise specifically provided. Any term defined herein may be used
in the singular or plural. “Include”, “includes” and “including” shall be deemed to be followed
by “without limitation”. Except as otherwise specified or limited herein, references to any Person include the successors
and assigns of such Person. References “from” or “through” any date mean, unless otherwise specified, “from
and including” or “through and including”, respectively. Unless otherwise specified herein, the settlement of
all payments and fundings hereunder between or among the parties hereto shall be made in lawful money of the United States and
in immediately available funds. References to any statute or act shall include all related current regulations and all amendments
and any successor statutes, acts and regulations. All amounts used for purposes of financial calculations required to be made herein
shall be without duplication. References to any statute or act, without additional reference, shall be deemed to refer to federal
statutes and acts of the United States. References to any agreement, instrument or document shall include all schedules, exhibits,
annexes and other attachments thereto. References to capitalized terms that are not defined herein, but are defined in the UCC,
shall have the meanings given them in the UCC. All references herein to times of day shall be references to daylight or standard
time, as applicable.


Section
1.4              
Settlement and Funding Mechanics. Unless otherwise specified herein, the settlement
of all payments and fundings hereunder between or among the parties hereto shall be made in lawful money of the United States and
in immediately available funds.


Section
1.5              
Time is of the Essence. Time is of the essence in Borrower’s and each other Credit
Party’s performance under this Agreement and all other Financing Documents.


Section
1.6                Time of Day. Unless otherwise specified, all references herein to times of day shall
be references to Eastern time (daylight savings or standard, as applicable).


Article 2
- LOANS


Section
2.1              
Loans.


(a)               
Term Loans. 


(i)                
Term Loan Amounts.


(A)             
On the terms and subject to the conditions set forth herein and in the other Financing Documents,
each Lender with a Term Loan Tranche 1 Commitment severally hereby agrees to make to Borrowers a term loan on a Business Day occurring
on or after the Term Loan Tranche 1 Activation Date (the “Term Loan Tranche 1 Funding Date”) in an original
aggregate principal amount equal to the Term Loan Tranche 1 Commitment (the “Term Loan Tranche 1”). Each such
Lender’s obligation to fund the Term Loan Tranche 1 shall be limited to such Lender’s Term Loan Tranche 1 Commitment
Percentage, and no Lender shall have any obligation to fund any portion of any Term Loan required to be funded by any other Lender,
but not so funded. Unless previously terminated, upon the Term Loan Tranche 1 Commitment Termination Date, the Term Loan Tranche
1 Commitment shall thereupon automatically be terminated and the Term Loan Tranche 1 Commitment Amount of each Lender as of such
date shall be reduced by such Lender’s Pro Rata Share of such total reduction in the Term Loan Commitments.






    	 	30	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    




(B)             
On the terms and subject to the conditions set forth herein and in the other Financing Documents,
each Lender with a Term Loan Tranche 2 Commitment severally hereby agrees to make to Borrowers a term loan on a Business Day occurring
on or after the Term Loan Tranche 2 Activation Date and prior to the Term Loan Tranche 2 Commitment Termination Date (the “Term
Loan Tranche 2 Funding Date”) in an original aggregate principal amount equal to (but not less than) the Term Loan Tranche
2 Commitment (the “Term Loan Tranche 2”). Each such Lender’s obligation to fund the Term Loan Tranche
2 shall be limited to such Lender’s Term Loan Tranche 2 Commitment Percentage, and no Lender shall have any obligation to
fund any portion of any Term Loan required to be funded by any other Lender, but not so funded. Unless previously terminated, upon
the Term Loan Tranche 2 Commitment Termination Date, the Term Loan Tranche 2 Commitment shall thereupon automatically be terminated
and the Term Loan Tranche 2 Commitment Amount of each Lender as of such date shall be reduced by such Lender’s Pro Rata Share
of such total reduction in the Term Loan Commitments.


(C)             
On the terms and subject to the conditions set forth herein and in the other Financing Documents,
each Lender with a Term Loan Tranche 3 Commitment severally hereby agrees to make to Borrowers a term loan on a Business Day occurring
on or after the Term Loan Tranche 3 Activation Date and prior to the Term Loan Tranche 3 Commitment Termination Date (the “Term
Loan Tranche 3 Funding Date”) in an original aggregate principal amount equal to the Term Loan Tranche 3 Commitment (the
“Term Loan Tranche 3”). Each such Lender’s obligation to fund the Term Loan Tranche 3 shall be limited
to such Lender’s Term Loan Tranche 3 Commitment Percentage, and no Lender shall have any obligation to fund any portion of
any Term Loan required to be funded by any other Lender, but not so funded. Unless previously terminated, upon the Term Loan Tranche
3 Commitment Termination Date, the Term Loan Tranche 3 Commitment shall thereupon automatically be terminated and the Term Loan
Tranche 3 Commitment Amount of each Lender as of such date shall be reduced by such Lender’s Pro Rata Share of such total
reduction in the Term Loan Commitments. 


(ii)              
No Borrower shall have any right to reborrow any portion of the Term Loan that is repaid or
prepaid from time to time. Each of the Term Loan Tranche 1, Term Loan Tranche 2 and the Term Loan Tranche 3 may be funded in one
advance in an aggregate amount not to exceed the Term Loan Tranche 1 Commitment Amount, Term Loan Tranche 2 Commitment Amount and
the Term Loan Tranche 3 Commitment Amount, as applicable. Borrowers shall deliver to Agent a Notice of Borrowing with respect to
each proposed Term Loan advance, such Notice of Borrowing to be delivered, (i) in the case of a Term Loan Tranche 1 borrowing,
no later than 12:00 P.M. (Eastern time) five (5) Business Day (or such shorter period as may be agreed by Agent and the Lenders)
prior to such proposed borrowing or (ii) in the case of a Term Loan Tranche 2 or Term Loan Tranche 3 borrowing, no later than noon
(Eastern time) ten (10) Business Days (or such shorter period as may be agreed by Agent and the Lenders) prior to such proposed
borrowing. 


(iii)            
Scheduled Repayments; Mandatory Prepayments; Optional Prepayments. 


(A)             
There shall become due and payable, and Borrowers shall repay the Term Loan through, scheduled
payments as set forth on Schedule 2.1 attached hereto. Notwithstanding the payment schedule set forth above, the outstanding
principal amount of the Term Loan shall become immediately due and payable in full on the Termination Date.






    	 	31	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    




(B)             
There shall become due and payable and Borrowers shall prepay the Term Loan in the following
amounts and at the following times: 


(i)                
Unless Agent shall otherwise consent in writing, on the date on which any Credit Party (or
Agent as loss payee or assignee) receives any casualty proceeds in excess of $500,000 with respect to assets upon which Agent maintained
a Lien, an amount equal to one hundred percent (100%) of such proceeds (net of out-of-pocket expenses and repayment of secured
debt permitted under clause (c) of the definition of Permitted Debt and encumbering the property that suffered such casualty),
or such lesser portion of such proceeds as Agent shall elect to apply to the Obligations; 


(ii)             
an amount equal to any interest that is deemed to be in excess of the Maximum Lawful Rate
(as defined below) and is required to be applied to the reduction of the principal balance of the Loans by any Lender as provided
for in Section 2.7; and 


(iii)           
unless Agent shall otherwise consent in writing, upon receipt by any Credit Party of the proceeds
of any Asset Disposition (excluding Permitted Asset Dispositions), an amount equal to one hundred percent (100%) of the net cash
proceeds of such asset disposition (net of out-of-pocket expenses and repayment of secured debt permitted under clause (c) of the
definition of Permitted Debt and encumbering such asset), or such lesser portion as Agent shall elect to apply to the Obligations;
provided, that no prepayment shall be required pursuant to this Section 2.1(a)(iii)(B) subpart (iii) unless and until
the aggregate net cash proceeds received during any Fiscal Year from Asset Dispositions exceeds $500,000 (in which case all net
cash proceeds in excess of such amount shall be used to make prepayments pursuant to this Section 2.1(a)(iii)(B) subpart (iii)).


Notwithstanding the
foregoing and so long as no Event of Default or Default then exists: (1) any such casualty proceeds in excess of $500,000 and less
than $2,500,000 (other than with respect to Inventory as to which there shall be no limit on the use of such proceeds pursuant
to this Section) may be used by Borrowers within one (1) year from the receipt of such proceeds to replace or repair any assets
in respect of which such proceeds were paid so long as such proceeds are deposited into a Deposit Account that is subject to a
Deposit Account Control Agreement promptly upon receipt by such Borrower; and (2) proceeds of personal property asset dispositions
that are not made in the Ordinary Course of Business (other than Collateral consisting of Intellectual Property, unless Agent shall
otherwise elect) may be used by Borrowers within one (1) year from the receipt of such proceeds to purchase new or replacement
assets of comparable value, provided, however, that such proceeds are deposited into a Deposit Account that is subject to a Deposit
Account Control Agreement promptly upon receipt by such Borrower. All sums held by Agent pending reinvestment as described in subsections
(1) and (2) above shall be deemed additional collateral for the Obligations and may be commingled with the general funds of Agent.


(C)             
Borrowers may from time to time, with at least ten (10) Business
Days’ prior delivery to Agent
of an appropriately completed Payment Notification, prepay the Term Loan in whole or in part; provided, however, that each
such prepayment shall be in an amount equal to the lesser of (x) $5,000,000 (or a higher integral multiple of $1,000,000) and (y)
the aggregate outstanding Obligations hereunder; and provided, further, that each such prepayment shall be accompanied by
any prepayment fees and other applicable fees and amounts required hereunder or any Fee Letter or other Financing Document.






    	 	32	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    




(iv)             
All Prepayments. Except as this Agreement may specifically provide otherwise, all prepayments
of the Term Loan shall be applied by Agent to the Obligations in inverse order of maturity. The monthly payments required under
Schedule 2.1 shall continue in the same amount (for so long as the Term Loan and/or (if applicable) any advance thereunder
shall remain outstanding) notwithstanding any partial prepayment, whether mandatory or optional, of the Term Loan. Notwithstanding
anything to the contrary contained in the foregoing, in the event that there have been multiple advances under the Term Loan each
of which such advances has a separate amortization schedule of principal payments under Schedule 2.1 attached hereto,
each prepayment of the Term Loan shall be applied by Agent to reduce and prepay the principal balance of the earliest-made advance
then outstanding in the inverse order of maturity of the scheduled payments with respect to such advance until such earliest-made
advance is paid in full (and to the extent the total amount of any such partial prepayment shall exceed the outstanding principal
balance of such earliest-made advance, the remainder of such prepayment shall be applied successively to the remaining advances
under the Term Loan in the direct order of the respective advance dates in the manner provided for in this sentence). 


(v)               
LIBOR Rate. 


(A)  Except
as provided in subsection (C) below, the Term Loan shall accrue interest at the LIBOR Rate plus the Applicable Margin.


(B)             
The LIBOR Rate may be adjusted by Agent with respect to any Lender on a prospective basis
to take into account any additional or increased costs to such Lender of maintaining or obtaining any eurodollar deposits or increased
costs, in each case, due to changes in applicable Law occurring subsequent to the commencement of the then applicable Interest
Period, including changes in tax laws (except changes of general applicability in corporate income tax laws) and changes in the
reserve requirements imposed by the Board of Governors of the Federal Reserve System (or any successor), which additional or increased
costs would increase the cost of such Lender funding loans bearing interest based upon the LIBOR Rate; provided, however,
that notwithstanding anything in this Agreement to the contrary, (i) the Dodd-Frank Wall Street Reform and Consumer Protection
Act and all requests, rules, guidelines or directives thereunder or issued in connection therewith and (ii) all requests, rules,
guidelines or directives promulgated by the Bank for International Settlements, the Basel Committee on Banking Supervision (or
any successor or similar authority) or the United States or foreign regulatory authorities, in each case pursuant to Basel III,
shall in each case be deemed to be a “change in applicable Law”, regardless of the date enacted, adopted or issued.
In any such event, the affected Lender shall give Borrowers and Agent notice of such a determination and adjustment and Agent promptly
shall transmit the notice to each other Lender and, upon its receipt of the notice from the affected Lender, Borrowers may, by
notice to such affected Lender (I) require such Lender to furnish to Borrowers a statement setting forth the basis for adjusting
such LIBOR Rate and the method for determining the amount of such adjustment, or (II) repay the Loans of such Lender bearing
interest based upon the LIBOR Rate with respect to which such adjustment is made.






    	 	33	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    




(C)             
In the event that any change in market conditions or any law, regulation, treaty, or directive,
or any change therein or in the interpretation of application thereof, shall at any time after the date hereof, in the reasonable
opinion of any Lender, make it unlawful or impractical for such Lender to maintain Loans bearing interest based upon the LIBOR
Rate or to continue such maintaining, or to determine or charge interest rates at the LIBOR Rate, such Lender shall give notice
of such changed circumstances to Agent and Borrowers and Agent promptly shall transmit the notice to each other Lender, (I) in
the case of the Pro Rata Share of the Term Loan held by such Lender and then outstanding, the date specified in such Lender’s
notice shall be deemed to be the last day of the Interest Period of such portion of the Term Loan, and interest upon such portion
thereafter shall accrue interest at the Base Rate plus the Applicable Margin, and (II) such portion of the Term Loan shall
continue to accrue interest at the Base Rate plus the Applicable Margin until such Lender determines that it would no longer
be unlawful or impractical to maintain such Term Loan at the LIBOR Rate.


(D)             
Anything to the contrary contained herein notwithstanding, neither Agent nor any Lender is
required actually to acquire eurodollar deposits to fund or otherwise match fund any Obligation as to which interest accrues based
on the LIBOR Rate.


Section 2.2           Interest,
Interest Calculations and Certain Fees. 


(a)               
Interest. From and following the Closing Date, except as expressly set forth in this
Agreement, Loans and the other Obligations shall bear interest at the sum of the LIBOR Rate plus the Applicable Margin.
Interest on the Loans shall be paid in arrears on the first (1st) day of each month and on the maturity of such Loans, whether
by acceleration or otherwise. Interest on all other Obligations shall be payable upon demand. 


(b)               
Fee Letter. In addition to the other fees set forth herein, the Borrowers agree to
pay Agent the fees set forth in the Fee Letter. 


(c)               
Origination Fee. Contemporaneous with Borrowers execution of this Agreement, Borrowers
shall pay Agent, for the benefit of all Lenders committed to make Term Loans on the Closing Date, a fee in an amount equal to $2,000,000.
All fees payable pursuant to this paragraph shall be deemed
fully earned when due and payable and non-refundable as of the Closing Date.


(d)               
Reserved. 


(e)                
Prepayment Fee. If any advance under the Term Loan is prepaid at any time, in whole
or in part, for any reason (whether by voluntary prepayment by Borrowers, by reason of the occurrence of an Event of Default or
the acceleration of the Term Loan, or otherwise), or if the Term Loan shall become accelerated and due and payable in full, or
if the Lenders’ funding obligations in respect of any unfunded portion of the Term Loan shall terminate prior to the Maturity
Date, Borrowers shall pay to Agent, for the benefit of all Lenders, as compensation for the costs of such Lenders making funds
available to Borrowers under this Agreement, a prepayment fee (the “Prepayment Fee”) in an amount equal to the
amount being prepaid (or required to be prepaid, if such amount is greater) multiplied by the following applicable percentage
amount: (x) four percent (4.0%) for the first year following the Term
Loan Tranche 1 Funding Date, (y) three percent (3.0%) for the second year following the Term Loan Tranche 1 Funding Date and (z)
two percent (2.0%) thereafter. The Prepayment Fee shall not apply to or be assessed upon any prepayment made by Borrowers if such
payments were required by Agent to be made pursuant to Section 2.1(a)(iii)(B) subpart (i) (relating to casualty proceeds),
or subpart (ii) (relating to payments exceeding the Maximum Lawful Rate), or repaid pursuant to Section 2.1(a)(v)(B)(II). All fees
payable pursuant to this paragraph shall be deemed fully earned as of the Closing Date (provided that such fees shall nonetheless
only become due and payable in the circumstances described in this paragraph) and non-refundable as of the applicable date of prepayment.






    	 	34	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


(f)


Reserved.


(g)


Audit
Fees. Borrowers shall pay to Agent, for its own account and not for the benefit of any other Lenders, all reasonable fees
and expenses in connection with audits and inspections of Borrowers’ books and records, audits, valuations or appraisals
of the Collateral, audits of Borrowers’ compliance with applicable Laws and such other matters as Agent shall deem appropriate,
which shall be due and payable on the first Business Day of the month following the date of issuance by Agent of a written request
for payment thereof to Borrowers. Notwithstanding the foregoing to the contrary, so long as no Event of Default has occurred and
is continuing, Borrowers shall not be responsible for the costs of more than one (1) such audit or inspection in any calendar
year.


(h)


Wire
Fees. Borrowers shall pay to Agent, for its own account and not for the account of any other Lenders, on written demand, fees
for incoming and outgoing wires made for the account of Borrowers, such fees to be based on Agent’s then current wire fee
schedule (available upon written request of the Borrowers).


(i)


Late
Charges. If payments of principal (other than a final installment of principal upon the Termination Date), interest due on
the Obligations, or any other amounts due hereunder or under the other Financing Documents are not timely made and remain overdue
for a period of five (5) days, Borrowers, without notice or demand by Agent, promptly shall pay to Agent, for its own account
and not for the benefit of any other Lenders, as additional compensation to Agent in administering the Obligations, an amount
equal to three percent (3.0%) of each delinquent payment. 


(j)


Computation
of Interest and Related Fees. All interest and fees under each Financing Document shall be calculated on the basis of a 360-day
year for the actual number of days elapsed. The date of funding of a Loan shall be included in the calculation of interest. The
date of payment of a Loan shall be excluded from the calculation of interest. If a Loan is repaid on the same day that it is made,
one (1) day’s interest shall be charged. 


(k)


Automated
Clearing House Payments. If Agent (or its designated servicer or trustee on behalf of a securitization vehicle) so elects,
monthly payments of principal, interest, fees, expenses or any other amounts due and owing from Borrower to Agent hereunder shall
be paid to Agent by Automated Clearing House debit of immediately available funds from the financial institution account designated
by Borrower Representative in the Automated Clearing House debit authorization executed by Borrowers or Borrower Representative
in connection with this Agreement, and shall be effective upon receipt. Borrowers shall execute any and all forms and documentation
necessary from time to time to effectuate such automatic debiting. In no event shall any such payments be refunded to Borrowers.






    	 	35	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


Section 2.3          Notes.
The portion of the Loans made by each Lender shall be evidenced, if so requested by such Lender, by one or more promissory
notes executed by Borrowers on a joint and several basis (each, a “Note”) in an original principal amount equal
to such Lender’s Term Loan Commitments.


Section
2.4              
Reserved.


Section
2.5              
Reserved.


Section
2.6              
General Provisions Regarding Payment; Loan Account.


(a)               
All payments to be made by each Borrower under any Financing Document, including payments
of principal and interest made hereunder and pursuant to any other Financing Document, and all fees, expenses, indemnities and
reimbursements, shall be made without set-off, recoupment or counterclaim. If any payment hereunder becomes due and payable on
a day other than a Business Day, such payment shall be extended to the next succeeding Business Day and, with respect to payments
of principal, interest thereon shall be payable at the then applicable rate during such extension (it being understood and agreed
that, solely for purposes of calculating financial covenants and computations contained herein and determining compliance therewith,
if payment is made, in full, on any such extended due date, such payment shall be deemed to have been paid on the original due
date without giving effect to any extension thereto). Any payments received in the Payment Account before 12:00 Noon (Eastern
time) on any date shall be deemed received by Agent on such date, and any payments received in the Payment Account at or after
12:00 Noon (Eastern time) on any date shall be deemed received by Agent on the next succeeding Business Day. 


(b)               
Agent shall maintain a loan account (the “Loan Account”) on its books to
record Loans and other extensions of credit made by the Lenders hereunder or under any other Financing Document, and all payments
thereon made by each Borrower. All entries in the Loan Account shall be made in accordance with Agent’s customary accounting
practices as in effect from time to time. The balance in the Loan Account, as recorded in Agent’s books and records at any
time shall be conclusive and binding evidence of the amounts due and owing to Agent by each Borrower absent manifest error; provided,
however, that any failure to so record or any error in so recording shall not limit or otherwise affect any Borrower’s
duty to pay all amounts owing hereunder or under any other Financing Document. Agent shall endeavor to provide Borrowers with a
monthly statement regarding the Loan Account (but neither Agent nor any Lender shall have any liability if Agent shall fail to
provide any such statement). Unless any Borrower notifies Agent of any objection to any such statement (specifically describing
the basis for such objection) within ninety (90) days after the date of receipt thereof, it shall be deemed final, binding and
conclusive upon Borrowers in all respects as to all matters reflected therein.


Section 2.7          Maximum
Interest. In no event shall the interest charged with respect to the Loans or any other Obligations
of any Borrower under any Financing Document exceed the maximum amount permitted under the laws of the State of New York or of
any other applicable jurisdiction. Notwithstanding anything to the contrary herein or elsewhere, if at any time the rate of interest
payable hereunder or under any Note or other Financing Document (the “Stated Rate”) would exceed the highest
rate of interest permitted under any applicable law to be charged (the “Maximum Lawful Rate”), then for so long
as the Maximum Lawful Rate would be so exceeded, the rate of interest payable shall be equal to the Maximum Lawful Rate; provided,
however, that if at any time thereafter the Stated Rate is less than the Maximum Lawful Rate, each Borrower shall, to the
extent permitted by law, continue to pay interest at the Maximum Lawful Rate until such time as the total interest received is
equal to the total interest which would have been received had the Stated Rate been (but for the operation of this provision) the
interest rate payable. Thereafter, the interest rate payable shall be the Stated Rate unless and until the Stated Rate again would
exceed the Maximum Lawful Rate, in which event this provision shall again apply. In no event shall the total interest received
by any Lender exceed the amount which it could lawfully have received had the interest been calculated for the full term hereof
at the Maximum Lawful Rate. If, notwithstanding the prior sentence, any Lender has received interest hereunder in excess of the
Maximum Lawful Rate, such excess amount shall be applied to the reduction of the principal balance of the Loans or to other amounts
(other than interest) payable hereunder, and if no such principal or other amounts are then outstanding, such excess or part thereof
remaining shall be paid to Borrowers. In computing interest payable with reference to the Maximum Lawful Rate applicable to any
Lender, such interest shall be calculated at a daily rate equal to the Maximum Lawful Rate divided by the number of days
in the year in which such calculation is made.






    	 	36	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


Section
2.8              
Taxes; Capital Adequacy; Mitigation Obligations.


(a)               
All payments of principal and interest on the Loans and all other amounts payable hereunder
shall be made free and clear of and without deduction for any present or future Taxes, except as required by applicable Law. If
any applicable law (as determined in the good faith discretion of an applicable Withholding Agent) requires the deduction or withholding
of any Tax from any such payment by a Withholding Agent, then the applicable Withholding Agent shall be entitled to make such deduction
or withholding and shall timely pay the full amount deducted or withheld to the relevant Governmental Authority in accordance with
applicable Law and if any such withholding or deduction is in respect of any Indemnified Taxes, then the Borrowers shall pay such
additional amount or amounts as is necessary to ensure that the net amount actually received by Agent and each Lender will equal
the full amount Agent and such Lender would have received had no such withholding or deduction of Indemnified Taxes been required
(including, without limitation, such withholdings and deductions applicable to additional sums payable under this Section 2.8).
After payment of any Tax by a Borrower to a Governmental Authority pursuant to this Section 2.8, such Borrower shall promptly forward
to Agent the original or a certified copy of an official receipt, a copy of the return reporting such payment, or other documentation
reasonably satisfactory to Agent evidencing such payment to such authority. Borrowers shall timely pay to the relevant Governmental
Authority in accordance with applicable Law, or at the option of Agent timely reimburse it for the payment of, any Other Taxes.


(b)               
The Borrowers shall indemnify Agent and Lenders, within ten (10) days after demand thereof,
for the full amount of any Indemnified Taxes (including Indemnified Taxes imposed or asserted on or attributable to amounts payable
under this Section 2.8) payable or paid by Agent or any Lender or required to be withheld or deducted from a payment to Agent
or any Lender and any reasonable out of pocket expenses arising therefrom or with respect thereto, whether or not such Indemnified
Taxes and Other Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority. A certificate in reasonable
detail as to the amount of such payment or liability delivered to Borrowers by a Lender (with a copy to Agent), or by Agent on
its own behalf or on behalf of a Lender, shall be conclusive absent manifest error.


(c)               
Each Agent and Lender that is entitled to an exemption from or reduction of withholding tax
with respect to payments made under any Financing Document shall deliver to Borrower Representative and Agent (in the case of deliveries
by a Lender), at the time or times prescribed by applicable Law or reasonably requested by Borrower Representative or Agent (in
the case of deliveries by a Lender), such properly completed and executed documentation reasonably requested by Borrower Representative
or Agent (in the case of deliveries by a Lender) as will permit such payments to be made without withholding or at a reduced rate
of withholding. In addition, each Agent and Lender, if reasonably requested by Borrower Representative or Agent, shall deliver
such other documentation prescribed by applicable Law or reasonably requested by Borrowers or Agent (in the case of deliveries
by a Lender) as will enable Borrowers or Agent (in the case of deliveries by a Lender) to determine whether or not such Agent or
Lender, as applicable, is subject to backup withholding or information reporting requirements. Notwithstanding anything to the
contrary in the preceding two sentences, the completion, execution and submission of such documentation (other than such documentation
set forth in Sections 2.8(c)(i), 2.8(c)(ii) and 2.8(e) below) shall not be required if in such Agent’s or Lender’s
reasonable judgment such completion, execution or submission would subject such Lender to any material unreimbursed cost or expense
or would materially prejudice the legal or commercial position of such Lender.






    	 	37	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    




(i)                
Each Agent and Lender that is not a “United States person” (as such term is defined
in Section 7701(a)(30) of the Code) for U.S. federal income tax purposes and is a party hereto on the Closing Date or purports
to become an assignee of an interest pursuant to Section 11.17(a) after the Closing Date (unless such Lender was already a
Lender hereunder immediately prior to such assignment) (each such Lender a “Foreign Lender”) shall, to the extent
permitted by Law, execute and deliver to Borrower Representative and Agent (in the case of deliveries by a Lender) (in such number
of copies as shall be requested by the recipient) on or prior to the date on which such Agent or Foreign Lender becomes a party
to this Agreement (and from time to time thereafter upon the reasonable request of the Borrower Representative or Agent) whichever
of the following is applicable: (A) in the case of an Agent or Foreign Lender claiming the benefits of an income tax treaty
to which the United States is a party, (x) with respect to payments of interest under any Financing Document, two (2) properly
completed and executed originals of United States Internal Revenue Service (“IRS”) Forms W-8BEN or W-8BEN-E
(or successor form) establishing an exemption from, or reduction of, U.S. federal withholding tax pursuant to the “interest”
article of such tax treaty and (y) with respect to any other applicable payments under any Financing Documents, two (2) properly
completed and executed originals of IRS Forms W-8BEN or W-8BEN-E (or successor form) establishing an exemption from, or reduction
of, U.S. federal withholding tax pursuant to the “business profits” or “other income” article of such tax
treaty; (B) two (2) executed originals of Form W-8ECI (or successor form); (C) in the case of an Agent or Foreign Lender
claiming the benefits of the exemption for portfolio interest under Section 881(c) of the Code, (x) a certificate substantially
in the form of Exhibit D-1 to the effect that such Agent or Foreign Lender is not a “bank” within the meaning
of Section 881(c)(3)(A) of the Code, a “10 percent shareholder” of any Borrower within the meaning of Section 881(c)(3)(B)
of the Code, or a “controlled foreign corporation” described in Section 881(c)(3)(C) of the Code (a “U.S.
Tax Compliance Certificate”) and (y) two (2) executed originals of IRS Forms W-8BEN or W-8BEN-E (or successor form);
(D) to the extent an Agent or Foreign Lender is not the beneficial owner, two (2) executed originals of IRS Form W-8IMY, accompanied
by IRS Form W-8ECI, IRS Form W-8BEN or W-8BEN-E (or successor form), a U.S. Tax Compliance Certificate substantially in the form
of Exhibit D-2 or Exhibit D-3, IRS Form W-9 (or successor form), and/or other certification documents from
each beneficial owner, as applicable; provided that if the Agent or Foreign Lender is a partnership and one or more direct
or indirect partners of such Foreign Lender are claiming the portfolio interest exemption, such Agent or Foreign Lender may provide
a U.S. Tax Compliance Certificate substantially in the form of Exhibit D-4 on behalf of each such direct and indirect
partner; or (E) other applicable forms, certificates or documents prescribed by the IRS. Each Agent and Lender agrees that
if any form or certification it previously delivered expires or becomes obsolete or inaccurate in any respect, it shall update
such form or certification or promptly notify Borrower Representative and Agent in writing of its legal inability to do so. In
addition, to the extent permitted by applicable Law, such forms shall be delivered by each Agent and Foreign Lender upon the obsolescence
or invalidity of any form previously delivered by such Foreign Lender. Each Agent and Foreign Lender shall promptly notify Borrower
Representative at any time it determines that it is no longer in a position to provide any previously delivered certificate to
Borrower Representative (or any other form of certification adopted by the U.S. taxing authorities for such purpose).






    	 	38	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    




(ii)              
Each Agent and Lender that is a “United States person” (as such term is defined
in Section 7701(a)(30) of the Code) for U.S. federal income tax purposes and is a party hereto on the Closing Date or purports
to become an assignee of an interest pursuant to Section 11.17(a) after the Closing Date (unless such Lender was already a
Lender hereunder immediately prior to such assignment) shall, to the extent permitted by Law, provide to Borrower Representative
and Agent (in the case of deliveries by a Lender) on or prior to the date on which such Agent or Lender becomes a party to this
Agreement (and from time to time thereafter upon the reasonable request of the Borrower Representative or Agent), a properly completed
and executed IRS Form W-9 or any successor form certifying as to such Agent’s or Lender’s entitlement to an exemption
from U.S. backup withholding and other applicable forms, certificates or documents prescribed by the IRS or reasonably requested
by Borrower Representative or Agent. Each such Agent and Lender shall promptly notify Borrowers at any time it determines that
any certificate previously delivered to Borrower Representative (or any other form of certification adopted by the U.S. governmental
authorities for such purposes) is no longer valid. 


(iii)            
Any Agent and Foreign Lender shall, to the extent it is legally entitled to do so, deliver
to Borrower Representative and Agent, in the case of deliveries by a Lender, (in such number of copies as shall be requested by
the recipient) on or prior to the date on which such Agent or Foreign Lender becomes a party to this Agreement (and from time to
time thereafter upon the reasonable request of the Borrower Representative or Agent), executed copies of any other form prescribed
by applicable Law as a basis for claiming exemption from or a reduction in U.S. Federal withholding Tax, duly completed, together
with such supplementary documentation as may be prescribed by applicable law to permit Borrowers or Agent to determine the withholding
or deduction required to be made.


(d)               
If any Agent or Lender determines, in its sole discretion exercised in good faith, that it
has received a refund in respect of any Taxes as to which it has been indemnified by any Borrower pursuant to this Section 2.8
(including by the payment of additional amounts pursuant to this Section 2.8), then it shall promptly pay an amount equal
to such refund to Borrowers, net of all reasonable out-of-pocket expenses of such Lender or of Agent with respect thereto, including
any Taxes; provided, however, that Borrowers, upon the written request of such Lender or Agent, agree to repay any
amount paid over to Borrowers to such Lender or to Agent (plus any related penalties, interest or other charges imposed by the
relevant Governmental Authority) in the event such Lender or Agent is required, for any reason, to disgorge or otherwise repay
such refund. Notwithstanding anything to the contrary in this Section 2.8, in no event will the indemnified party be required
to pay any amount to an indemnifying party pursuant to this Section 2.8(d) the payment of which would place the indemnified
party in a less favorable net after-Tax position than the indemnified party would have been in if the Tax subject to indemnification
and giving rise to such refund had not been deducted, withheld or otherwise imposed and the indemnification payments or additional
amounts with respect to such Tax had never been paid. This Section 2.8 shall not be construed to require any indemnified party
to make available its Tax returns (or any other information relating to its Taxes that it deems confidential) to the indemnifying
party or any other Person.






    	 	39	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


(e)               
If a payment made to an Agent or Lender under any Financing Document would be subject to U.S.
federal withholding tax imposed by FATCA if such Agent or Lender were to fail to comply with the applicable reporting requirements
of FATCA (including those contained in Section 1471(b) or 1472(b) of the Code, as applicable), such Agent or Lender shall
deliver to Borrower Representative and Agent (in the case of deliveries by a Lender) at the time or times prescribed by Law and
at such time or times reasonably requested by Borrower Representative or Agent such documentation prescribed by applicable Law
(including as prescribed by Section 1471(b)(3)(C)(i) of the Code) and such additional documentation reasonably requested by
Borrower Representative or Agent as may be necessary for Borrowers and Agent to comply with their obligations under FATCA and to
determine that such Lender has complied with such Lender’s obligations under FATCA or to determine the amount to deduct and
withhold from such payment. Solely for purposes of this clause (e), “FATCA” shall include any amendments made
to FATCA after the date of this Agreement.


(f)                
Each Lender shall severally indemnify Agent, within ten (10) days after demand therefor, for
(i) any Indemnified Taxes attributable to such Lender (but only to the extent that any Credit Party has not already indemnified
Agent for such Indemnified Taxes and without limiting the obligation of the Credit Parties to do so), (ii) any Taxes attributable
to such Lender’s failure to comply with the provisions of Section 11.17 relating to the maintenance of a Participant Register
and (iii) any Excluded Taxes attributable to such Lender, in each case, that are payable or paid by Agent in connection with any
Financing Document, and any reasonable expenses arising therefrom or with respect thereto, whether or not such Taxes were correctly
or legally imposed or asserted by the relevant Governmental Authority. A certificate as to the amount of such payment or liability
delivered to any Lender by Agent shall be conclusive absent manifest error. Each Lender hereby authorizes Agent to set off and
apply any and all amounts at any time owing to such Lender under any Financing Document or otherwise payable by Agent to such Lender
from any other source against any amount due to Agent under this paragraph (f).


(g)               
Each party’s obligations under Section 2.8(a) through (f) shall
survive the resignation or replacement of Agent or any assignment of rights by, or the replacement of, a Lender, and the repayment,
satisfaction or discharge of all Obligations hereunder.


(h)               
If any Lender shall reasonably determine that the adoption or taking effect of, or any change
in, any applicable Law regarding capital adequacy, in each instance, after the Closing Date, or any change after the Closing Date
in the interpretation, administration or application thereof by any Governmental Authority, central bank or comparable agency charged
with the interpretation, administration or application thereof, or the compliance by any Lender or any Person controlling such
Lender with any request, guideline or directive regarding capital adequacy (whether or not having the force of Law) of any such
Governmental Authority, central bank or comparable agency adopted or otherwise taking effect after the Closing Date, has or would
have the effect of reducing the rate of return on such Lender’s or such controlling Person’s capital as a consequence
of such Lender’s obligations hereunder to a level below that which such Lender or such controlling Person could have achieved
but for such adoption, taking effect, change, interpretation, administration, application or compliance (taking into consideration
such Lender’s or such controlling Person’s policies with respect to capital adequacy) then from time to time, upon
demand by such Lender (which demand shall be accompanied by a certificate setting forth the basis for such demand and a calculation
of the amount thereof in reasonable detail, a copy of which shall be furnished to Agent), Borrowers shall promptly pay to such
Lender such additional amount as will compensate such Lender or such controlling Person for such reduction, so long as such amounts
have accrued on or after the day which is two hundred seventy (270) days prior to the date on which such Lender first made demand
therefor; provided that notwithstanding anything in this Agreement to the contrary, (i) the Dodd-Frank Wall Street
Reform and Consumer Protection Act and all requests, rules, guidelines or directives thereunder or issued in connection therewith
and (ii) all requests, rules, guidelines or directives promulgated by the Bank for International Settlements, the Basel Committee
on Banking Supervision (or any successor or similar authority) or the United States or foreign regulatory authorities, in each
case pursuant to Basel III, shall in each case be deemed to be a “change in applicable Law”, regardless of the
date enacted, adopted or issued.






    	 	40	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


(i)                
If any Lender requests compensation under either Section 2.1(a)(iv) or Section 2.8(h),
or requires Borrowers to pay any additional amount to any Lender or any Governmental Authority for the account of any Lender pursuant
to Section 2.8, then, upon the written request of Borrower Representative, such Lender shall use reasonable efforts to designate
a different lending office for funding or booking its Loans hereunder or to assign its rights and obligations hereunder (subject
to the provisions of Section 11.17) to another of its offices, branches or affiliates, if, in the reasonable judgment of such
Lender, such designation or assignment (i) would eliminate or materially reduce amounts payable pursuant to any such Section,
as the case may be, in the future, (ii) would not subject such Lender to any unreimbursed cost or expense and (iii) would
not otherwise be disadvantageous to such Lender (as determined in its sole good faith discretion). Without limitation of the provisions
of Section 12.14, each Borrower hereby agrees to pay all reasonable and documented, out-of-pocket costs and expenses incurred
by any Lender in connection with any such designation or assignment.


Section
2.9              
Appointment of Borrower Representative.


(a)                
Each Borrower hereby irrevocably appoints and constitutes Borrower Representative as its agent
and attorney-in-fact to request and receive Loans in the name or on behalf of such Borrower and any other Borrowers, deliver Notices
of Borrowing, give instructions with respect to the disbursement of the proceeds of the Loans , giving and receiving all other
notices and consents hereunder or under any of the other Financing Documents and taking all other actions (including in respect
of compliance with covenants) in the name or on behalf of any Borrower or Borrowers pursuant to this Agreement and the other Financing
Documents. Agent and Lenders may disburse the Loans to such bank account of Borrower Representative or a Borrower or otherwise
make such Loans to a Borrower, in each case as Borrower Representative may designate or direct, without notice to any other Borrower.
Notwithstanding anything to the contrary contained herein, Agent may at any time and from time to time require that Loans to or
for the account of any Borrower be disbursed directly to an operating account of such Borrower.


(b)               
Borrower Representative hereby accepts the appointment by Borrowers to act as the agent and
attorney-in-fact of Borrowers pursuant to this Section 2.9. Borrower Representative shall ensure that the disbursement of any Loans
that are at any time requested by or to be remitted to or for the account of a Borrower, shall be remitted or issued to or for
the account of such Borrower. 


(c)                
Each Borrower hereby irrevocably appoints and constitutes Borrower Representative as its agent
to receive statements on account and all other notices from Agent, Lenders with respect to the Obligations or otherwise under or
in connection with this Agreement and the other Financing Documents.


(d)               
Any notice, election, representation, warranty, agreement or undertaking made or delivered
by or on behalf of any Borrower by Borrower Representative shall be deemed for all purposes to have been made or delivered by such
Borrower, as the case may be, and shall be binding upon and enforceable against such Borrower to the same extent as if made or
delivered directly by such Borrower.






    	 	41	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


(e)                
No resignation by or termination of the appointment of Borrower Representative as agent and
attorney-in-fact as aforesaid shall be effective, except after ten (10) Business Days’ prior written notice to Agent. If
the Borrower Representative resigns under this Agreement, Borrowers shall be entitled to appoint a successor Borrower Representative
(which shall be a Borrower and shall be reasonably acceptable to Agent as such successor). Upon the acceptance of its appointment
as successor Borrower Representative hereunder, such successor Borrower Representative shall succeed to all the rights, powers
and duties of the retiring Borrower Representative and the term “Borrower Representative” means such successor Borrower
Representative for all purposes of this Agreement and the other Financing Documents, and the retiring or terminated Borrower Representative’s
appointment, powers and duties as Borrower Representative shall be thereupon terminated.


Section
2.10             
Joint and Several Liability; Rights of Contribution; Subordination and Subrogation.


(a)               
Borrowers are defined collectively to include all Persons named as one of the Borrowers herein;
provided, however, that any references herein to “any Borrower”, “each Borrower” or similar references,
shall be construed as a reference to each individual Person named as one of the Borrowers herein. Each Person so named shall be
jointly and severally liable for all of the obligations of Borrowers under this Agreement. Each Borrower, individually, expressly
understands, agrees and acknowledges, that the credit facilities would not be made available on the terms herein in the absence
of the collective credit of all of the Persons named as the Borrowers herein, the joint and several liability of all such Persons,
and the cross-collateralization of the collateral of all such Persons. Accordingly, each Borrower individually acknowledges that
the benefit to each of the Persons named as one of the Borrowers as a whole constitutes reasonably equivalent value, regardless
of the amount of the credit facilities actually borrowed by, advanced to, or the amount of collateral provided by, any individual
Borrower. In addition, each entity named as one of the Borrowers herein hereby acknowledges and agrees that all of the representations,
warranties, covenants, obligations, conditions, agreements and other terms contained in this Agreement shall be applicable to and
shall be binding upon and measured and enforceable individually against each Person named as one of the Borrowers herein as well
as all such Persons when taken together. By way of illustration, but without limiting the generality of the foregoing, the terms
of Section 10.1 of this Agreement are to be applied to each individual Person named as one of the Borrowers herein (as well
as to all such Persons taken as a whole), such that the occurrence of any of the events described in Section 10.1 of this
Agreement as to any Person named as one of the Borrowers herein shall constitute an Event of Default even if such event has not
occurred as to any other Persons named as the Borrowers or as to all such Persons taken as a whole.


(b)               
Notwithstanding any provisions of this Agreement to the contrary, it is intended that the
joint and several nature of the liability of each Borrower for the Obligations and the Liens granted by Borrowers to secure the
Obligations, not constitute a Fraudulent Conveyance (as defined below). Consequently, Agent, Lenders and each Borrower agree that
if the liability of a Borrower for the Obligations, or any Liens granted by such Borrower securing the Obligations would, but for
the application of this sentence, constitute a Fraudulent Conveyance, the liability of such Borrower and the Liens securing such
liability shall be valid and enforceable only to the maximum extent that would not cause such liability or such Lien to constitute
a Fraudulent Conveyance, and the liability of such Borrower and this Agreement shall automatically be deemed to have been amended
accordingly. For purposes hereof, the term “Fraudulent Conveyance” means a fraudulent conveyance under Section 548
of Chapter 11 of Title II of the Bankruptcy Code or a fraudulent conveyance or fraudulent transfer under the applicable provisions
of any fraudulent conveyance or fraudulent transfer law or similar law of any state, nation or other governmental unit, as in effect
from time to time.






    	 	42	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


(c)               
Agent is hereby authorized, without notice or demand (except as otherwise specifically required
under this Agreement) and without affecting the liability of any Borrower hereunder, at any time and from time to time, to (i) renew,
extend or otherwise increase the time for payment of the Obligations; (ii) with the written agreement of any Borrower, change
the terms relating to the Obligations or otherwise modify, amend or change the terms of any Note or other agreement, document or
instrument now or hereafter executed by any Borrower and delivered to Agent for any Lender; (iii) accept partial payments
of the Obligations; (iv) take and hold any Collateral for the payment of the Obligations or for the payment of any guaranties
of the Obligations and exchange, enforce, waive and release any such Collateral; (v) apply any such Collateral and direct
the order or manner of sale thereof as Agent, in its sole discretion, may determine; and (vi) settle, release, compromise,
collect or otherwise liquidate the Obligations and any Collateral therefor in any manner, all guarantor and surety defenses being
hereby waived by each Borrower. Without limitations of the foregoing, with respect to the Obligations, each Borrower hereby makes
and adopts each of the agreements and waivers set forth in each Guarantee, the same being incorporated hereby by reference. Except
as specifically provided in this Agreement or any of the other Financing Documents, Agent shall have the exclusive right to determine
the time and manner of application of any payments or credits, whether received from any Borrower or any other source, and such
determination shall be binding on all Borrowers. All such payments and credits may be applied, reversed and reapplied, in whole
or in part, to any of the Obligations that Agent shall determine, in its sole discretion, without affecting the validity or enforceability
of the Obligations of the other Borrower.


(d)               
Each Borrower hereby agrees that, except as hereinafter provided, its obligations hereunder
shall be unconditional, irrespective of (i) the absence of any attempt to collect the Obligations from any obligor or other
action to enforce the same; (ii) the waiver or consent by Agent with respect to any provision of any instrument evidencing
the Obligations, or any part thereof, or any other agreement heretofore, now or hereafter executed by a Borrower and delivered
to Agent; (iii) failure by Agent to take any steps to perfect and maintain its security interest in, or to preserve its rights
to, any security or collateral for the Obligations; (iv) the institution of any proceeding under the Bankruptcy Code, or any
similar proceeding, by or against a Borrower or Agent’s election in any such proceeding of the application of Section 1111(b)(2)
of the Bankruptcy Code; (v) any borrowing or grant of a security interest by a Borrower as debtor-in-possession, under Section 364
of the Bankruptcy Code; (vi) the disallowance, under Section 502 of the Bankruptcy Code, of all or any portion of Agent’s
claim(s) for repayment of any of the Obligations; or (vii) any other circumstance other than payment in full of the Obligations
which might otherwise constitute a legal or equitable discharge or defense of a guarantor or surety.


(e)               
Borrowers hereby agree, as between themselves, that to the extent that Agent, on behalf of
Lenders, shall have received from any Borrower any Recovery Amount (as defined below), then the paying Borrower shall have a right
of contribution against each other Borrower in an amount equal to such other Borrower’s contributive share of such Recovery
Amount; provided, however, that in the event any Borrower suffers a Deficiency Amount (as defined below), then the Borrower
suffering the Deficiency Amount shall be entitled to seek and receive contribution from and against the other Borrowers in an amount
equal to the Deficiency Amount; and provided, further, that in no event shall the aggregate amounts so reimbursed by reason
of the contribution of any Borrower equal or exceed an amount that would, if paid, constitute or result in Fraudulent Conveyance.
Until all Obligations have been paid and satisfied in full, no payment made by or for the account of a Borrower including, without
limitation, (i) a payment made by such Borrower on behalf of the liabilities of any other Borrower, or (ii) a payment
made by any other Guarantor under any Guarantee, shall entitle such Borrower, by subrogation or otherwise, to any payment from
such other Borrower or from or out of such other Borrower’s property. The right of each Borrower to receive any contribution
under this Section 2.10(e) or by subrogation or otherwise from any other Borrower shall be subordinate in right of payment
to the Obligations and such Borrower shall not exercise any right or remedy against such other Borrower or any property of such
other Borrower by reason of any performance of such Borrower of its joint and several obligations hereunder, until the Obligations
have been indefeasibly paid and satisfied in full, and no Borrower shall exercise any right or remedy with respect to this Section 2.10(e)
until the Obligations have been indefeasibly paid and satisfied in full. As used in this Section 2.10(e), the term “Recovery
Amount” means the amount of proceeds received by or credited to Agent from the exercise of any remedy of the Lenders
under this Agreement or the other Financing Documents, including, without limitation, the sale of any Collateral. As used in this
Section 2.10(e), the term “Deficiency Amount” means any amount that is less than the entire amount a Borrower
is entitled to receive by way of contribution or subrogation from, but that has not been paid by, the other Borrowers in respect
of any Recovery Amount attributable to the Borrower entitled to contribution, until the Deficiency Amount has been reduced to Zero
Dollars ($0) through contributions and reimbursements made under the terms of this Section 2.10(e) or otherwise.






    	 	43	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


Section
2.11             
Termination; Restriction on Termination.


(a)               
Termination by Lenders. In addition to the rights set forth in Section 10.2, Agent
may, and at the direction of Required Lenders shall, terminate this Agreement without notice upon or after the occurrence and during
the continuance of an Event of Default.


(b)               
Termination by Borrowers. Upon at least fifteen
(15)
days’ prior written notice and pursuant to payoff documentation in form and substance reasonably satisfactory to Agent and
Lenders, Borrowers may, at its option, terminate this Agreement; provided, however, that no such termination shall be effective
until Borrowers have complied with Section 2.2 and the terms of any Fee Letter. Any notice of termination
given by Borrowers shall be irrevocable unless all Lenders otherwise agree in writing;
provided that such notice may state that it is conditioned upon the effectiveness of other credit facilities, indentures
or similar agreements or other transactions, in which case such notice may be revoked by the Borrowers (by notice to the Agent
on or prior to the specified effective date) if such condition is not satisfied and
no Lender shall have any obligation to make any Loans on or after the termination date stated in such notice. Borrowers may elect
to terminate this Agreement in its entirety only. No section of this Agreement or type of Loan available hereunder may be terminated
singly. 


(c)               
Effectiveness of Termination. All of the Obligations shall be immediately due and payable
upon the Termination Date. All undertakings, agreements, covenants, warranties and representations of Borrowers contained in the
Financing Documents shall survive any such termination and Agent shall retain its Liens in the Collateral and Agent and each Lender
shall retain all of its rights and remedies under the Financing Documents notwithstanding such termination until all Obligations
have been discharged or paid, in full, in immediately available funds, including, without limitation, all Obligations under Section 2.2
and the terms of any Fee Letter resulting from such termination. Notwithstanding the foregoing or
the payment in full of the Obligations, Agent shall not be required to terminate its Liens in the Collateral unless, with respect
to any loss or damage Agent may incur as a result of dishonored checks or other items of payment received by Agent from Borrower
or any Account Debtor and applied to the Obligations, Agent shall, at its option, have retained cash Collateral or other Collateral
for such period of time as Agent, in its reasonable discretion, may deem necessary to protect Agent and each Lender from any such
loss or damage; provided, however that such retained cash Collateral or other Collateral shall not exceed $20,000
in the aggregate at any time.






    	 	44	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


Article 3
- REPRESENTATIONS AND WARRANTIES


To induce Agent and
Lenders to enter into this Agreement and to make the Loans and other credit accommodations contemplated hereby, each Borrower hereby
represents and warrants to Agent and each Lender that:


Section 3.1           Existence
and Power. Each Credit Party (a) is an entity as specified on Schedule 3.1, (b)
is duly organized, validly existing and in good standing under the laws of the jurisdiction specified on Schedule 3.1
and no other jurisdiction, (c) has the same legal name as it appears in such Credit Party’s Organizational Documents and
an organizational identification number (if any), in each case as specified on Schedule 3.1, (d) has all powers to
own its assets and has powers and all Permits necessary or desirable in the operation of its business as presently conducted or
as proposed to be conducted, except where the failure to have such Permits could not reasonably be expected to have a Material
Adverse Effect, and (e) is qualified to do business as a foreign entity in each jurisdiction in which it is required to be so qualified,
which jurisdictions as of the Closing Date are specified on Schedule 3.1, except in
the case of this clause (e) where the failure to be so qualified could not reasonably be expected to have a Material Adverse
Effect. Except as set forth on Schedule 3.1, no Credit Party (x) has had, over the five (5) year period preceding
the Closing Date, any name other than its current name, or (y) was incorporated or organized under the laws of any jurisdiction
other than its current jurisdiction of incorporation or organization.


Section 3.2           Organization
and Governmental Authorization; No Contravention. The execution, delivery and performance by
each Credit Party of the Financing Documents to which it is a party (a) are within its powers, (b) have been duly authorized by
all necessary action pursuant to its Organizational Documents, (c) require no further action by or in respect of, or filing with,
any Governmental Authority and (d) do not violate, conflict with or cause a breach or a default under (i) any Law applicable
to any Credit Party, (ii) any of the Organizational Documents of any Credit Party, or (iii) any agreement or instrument binding
upon it, except for such violations, conflicts, breaches or defaults as could not, with respect to this clause (iii), reasonably
be expected to have a Material Adverse Effect.


Section 3.3           Binding
Effect. Each of the Financing Documents to which any Credit Party is a party constitutes a
valid and binding agreement or instrument of such Credit Party, enforceable against such Credit Party in accordance with its respective
terms, except as the enforceability thereof may be limited by bankruptcy, insolvency or other similar laws relating to the enforcement
of creditors’ rights generally and by general equitable principles. Each
Financing Document has been duly executed and delivered by each Credit Party party thereto.


Section 3.4           Capitalization.
The authorized equity securities of each of the Credit Parties as of the Closing Date are as set forth on Schedule 3.4.
All issued and outstanding equity securities of each of the Credit Parties are duly authorized and validly issued, fully paid and
nonassessable. All issued and outstanding equity securities of any Subsidiary of any Credit Party are free and clear of all Liens
other than Permitted Liens, and such equity securities were issued in compliance with all applicable Laws. The identity of the
holders of the equity securities of each of the Credit Parties (other than TherapeuticsMD) and the percentage of their fully-diluted
ownership of the equity securities of each of the Credit Parties as of the Closing Date is set forth on Schedule 3.4.
Except as set forth on Schedule 3.4, as of the Closing Date there are no preemptive or other outstanding rights, options,
warrants, conversion rights or similar agreements or understandings for the purchase or acquisition from any Credit Party of any
equity securities of any such entity.






    	 	45	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


Section 3.5           Financial
Information. All financial statements and related information delivered to Agent and pertaining
to the financial condition of any Credit Party fairly presents the financial position of such Credit Party as of such date in conformity
with GAAP (and as to unaudited financial statements, subject to normal year-end adjustments and the absence of footnote disclosures).
Since December 31, 2017, there has been no Material Adverse Effect.


Section 3.6          Litigation.
Except as set forth on Schedule 3.6 as of the Closing Date, and except as hereafter disclosed to Agent in writing,
there is no Litigation pending against, or to such Borrower’s knowledge threatened in writing, against any Credit Party or,
to such Borrower’s knowledge, any party (other than a Credit Party) to any Operative Document that would reasonably be expected
to result in a judgment against, or liability for, any Credit Party or any Subsidiary thereof in an amount in excess of $1,000,000.
There is no Litigation pending in which an adverse decision would reasonably be expected to have a Material Adverse Effect or which
in any manner draws into question the validity of any of the Financing Documents.


Section 3.7          Ownership
of Property. Each Borrower and its Subsidiaries are the lawful sole owner of, has good and
marketable title to and is in lawful possession of, or has valid leasehold interests in, all properties, accounts and other assets
(real or personal, tangible, intangible or mixed) purported or reported to be owned or leased (as the case may be) by such Person.


Section 3.8          No
Default. No Event of Default, or to such Borrower’s knowledge, Default, has occurred
and is continuing. No Credit Party is in breach or default under or with respect to any contract, agreement, lease or other instrument
to which it is a party or by which its property is bound or affected, which breach or default could reasonably be expected to have
a Material Adverse Effect.


Section 3.9           Labor
Matters. As of the Closing Date, there are no strikes or other material labor disputes pending
or, to any Borrower’s knowledge, threatened against any Credit Party. Except as could not reasonably be expected to result
in a Material Adverse Effect, (a) hours worked and payments made to the employees of each Borrower and each of its Subsidiaries
have not been in violation of the Fair Labor Standards Act or any other applicable Law dealing with such matters and (b) all
payments due from each Borrower and each of its Subsidiaries, or for which any claim may be made against any of them, on account
of wages and employee and retiree health and welfare insurance and other benefits have been paid or accrued as a liability on their
books, as the case may be. The consummation of the transactions contemplated by the Financing Documents will not give rise to a
right of termination or right of renegotiation on the part of any union under any collective bargaining agreement to which any
Borrower or any Subsidiary is a party or by which it is bound.






    	 	46	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


Section 3.10        Regulated
Entities. No Credit Party is an “investment company” or a company “controlled”
by an “investment company” or a “subsidiary” of an “investment company,” all within the meaning
of the Investment Company Act.


Section 3.11        Margin
Regulations. None of the proceeds from the Loans have been or will be used, directly or indirectly,
for the purpose of purchasing or carrying any “margin stock” (as defined in Regulation U of the Federal Reserve Board),
for the purpose of reducing or retiring any indebtedness which was originally incurred to purchase or carry any “margin stock”
or for any other purpose which might cause any of the Loans to be considered a “purpose credit” within the meaning
of Regulation T, U or X of the Federal Reserve Board.


Section
3.12              
Compliance With Laws; Anti-Terrorism Laws.


(a)               
Each Credit Party is in compliance with the requirements of all applicable Laws, except for
such Laws the noncompliance with which could not reasonably be expected to have a Material Adverse Effect.


(b)               
None of the Credit Parties and, to the knowledge of the Credit Parties, none of their Affiliates
(i) is in violation of any Anti-Terrorism Law, (ii) engages in or conspires to engage in any transaction that evades
or avoids, or has the purpose of evading or avoiding, or attempts to violate, any of the prohibitions set forth in any Anti-Terrorism
Law, (iii) is a Blocked Person, or is controlled by a Blocked Person, (iv) is acting or will act for or on behalf of a Blocked
Person, (v) is associated with, or will become associated with, a Blocked Person or (vi) is providing, or will provide, material,
financial or technical support or other services to or in support of acts of terrorism of a Blocked Person. No Credit Party nor,
to the knowledge of any Credit Party, any of its Affiliates or agents acting or benefiting in any capacity in connection with the
transactions contemplated by this Agreement, (A) conducts any business or engages in making or receiving any contribution
of funds, goods or services to or for the benefit of any Blocked Person, or (B) deals in, or otherwise engages in any transaction
relating to, any property or interest in property blocked pursuant to Executive Order No. 13224, any similar executive order
or other Anti-Terrorism Law.


Section 3.13        Taxes.
All federal and material state and local tax returns, reports and statements required to be filed by or on behalf of each
Credit Party have been filed with the appropriate Governmental Authorities in all jurisdictions in which such returns, reports
and statements are required to be filed and, except to the extent subject to a Permitted Contest, all Taxes (including real property
Taxes) and other charges shown to be due and payable in respect thereof have been timely paid prior to the date on which any fine,
penalty, interest, late charge or loss may be added thereto for nonpayment thereof. Except to the extent subject to a Permitted
Contest, all material state and local sales and use Taxes required to be paid by each Credit Party have been paid. All federal
and material state tax returns have been filed by each Credit Party for all periods for which tax returns were due with respect
to employee income tax withholding, social security and unemployment taxes, and, except to the extent subject to a Permitted Contest,
the amounts shown thereon to be due and payable have been paid in full or adequate provisions therefor have been made.






    	 	47	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


Section
3.14              
Compliance with ERISA.


(a)               
Except as would not reasonably be expected to have a Material Adverse Effect, (i) each ERISA
Plan (and the related trusts and funding agreements) complies in form and in operation with, (ii) each ERISA Plan (and the related
trusts and funding agreements) has been administered in compliance with, (iii) the terms of each ERISA Plan satisfy, the applicable
requirements of ERISA and the Code, and (iv) no Credit Party or any Subsidiary of any Credit Party has incurred liability for any
excise tax under Sections 4971 through 5000 of the Code.


(b)               
During the six (6) year period prior to the Closing Date or the making of any Loan and except
as would not reasonably be expected to have a Material Adverse Effect, (x) no steps have been taken to terminate any Pension
Plan and (y) no contribution failure has occurred with respect to any Pension Plan sufficient to give rise to a Lien under
Section 303(k) of ERISA. (i) No condition exists or event or transaction has occurred with respect to any Pension Plan which
could reasonably be expected to result in the incurrence by any Credit Party or any Subsidiary of any liability, fine or penalty
(other than, for the avoidance of doubt, accrual of benefits in the Ordinary Course of Business), (ii) no Credit Party or any Subsidiary
of any Credit Party has incurred liability to the PBGC (other than for current premiums) with respect to any Pension Plan, (iii)
all contributions (if any) have been made on a timely basis to any Multiemployer Pension Plan that are required to be made by any
Credit Party, any Subsidiary of any Credit Party, or any other member of the Controlled Group under the terms of the plan or of
any collective bargaining agreement or by applicable Law; (iv) no Credit Party, Subsidiary of any Credit Party, or to the knowledge
of the Credit Parties, any member of the Controlled Group has withdrawn or partially withdrawn from any Multiemployer Pension Plan,
incurred any withdrawal liability with respect to any such plan or received notice of any claim or demand for withdrawal liability
or partial withdrawal liability from any such plan, and no condition has occurred which, if continued, could reasonably be expected
to result in a withdrawal or partial withdrawal from any such plan, and (v) no Credit Party, Subsidiary of any Credit Party or
any member of the Controlled Group has received any notice that any Multiemployer Pension Plan is in reorganization, that increased
contributions may be required to avoid a reduction in plan benefits or the imposition of any excise tax, that any such plan is
or has been funded at a rate less than that required under Section 412 of the Code, that any such plan is or may be terminated,
or that any such plan is or may become insolvent, except, with respect to clauses (i), (ii), (iii) and (iv), as would not reasonably
be expected to have a Material Adverse Effect.


Section 3.15        Brokers.
 Except for fees payable to Agent and/or Lenders, no broker, finder or other intermediary has brought about the obtaining,
making or closing of the transactions contemplated by the Financing Documents, and no Credit Party has or will have any obligation
to any Person in respect of any finder’s or brokerage fees, commissions or other expenses in connection herewith or therewith.


Section 3.16         Reserved.







    	 	48	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


Section 3.17        Material
Contracts. Except for the Financing Documents and the other agreements set forth on Schedule 3.17,
as of the Closing Date there are no Material Contracts. The consummation of the transactions contemplated by the Financing Documents
will not give rise to a right of termination in favor of any party to any Material Contract (other than any Credit Party), except
for such Material Contracts the noncompliance with which would not reasonably be expected to have a Material Adverse Effect.


Section 3.18        Compliance
with Environmental Requirements; No Hazardous Materials. Except in each case as set forth on
Schedule 3.18 and as would not reasonably be expected to have a Material Adverse Effect:


(a)               
no notice, notification, demand, request for information, citation, summons, complaint or
order has been issued, no complaint has been filed, no penalty has been assessed and no investigation or review is pending, or
to such Borrower’s knowledge, threatened by any Governmental Authority or other Person with respect to any (i) alleged
violation by any Credit Party of any Environmental Law, (ii) alleged failure by any Credit Party to have any Permits required
in connection with the conduct of its business or to comply with the terms and conditions thereof, (iii) any generation, treatment,
storage, recycling, transportation or disposal of any Hazardous Materials, or (iv) release of Hazardous Materials; and 


(b)               
no property now owned or leased by any Credit Party and, to the knowledge of each Borrower,
no such property previously owned or leased by any Credit Party, to which any Credit Party has, directly or indirectly, transported
or arranged for the transportation of any Hazardous Materials, is listed or, to such Borrower’s knowledge, proposed for listing,
on the National Priorities List promulgated pursuant to CERCLA, or CERCLIS (as defined in CERCLA) or any similar state list or
is the subject of federal, state or local enforcement actions or, to the knowledge of such Borrower, other investigations which
may lead to claims against any Credit Party for clean-up costs, remedial work, damage to natural resources or personal injury claims,
including, without limitation, claims under CERCLA.


For purposes of this
Section 3.18, each Credit Party shall be deemed to include any business or business entity (including a corporation) that
is, in whole or in part, a predecessor of such Credit Party.


Section 3.19        Intellectual
Property and License Agreements. A list of all Registered Intellectual Property of each Credit
Party and all in-bound license or sublicense agreements, exclusive out-bound license or sublicense agreements, or other rights
of any Credit Party to use Intellectual Property (but excluding in-bound licenses of over-the-counter software that is commercially
available to the public), as of the Closing Date and, as updated pursuant to Section 4.14, is set forth on Schedule 3.19. Schedule
3.19 shall be prepared by Borrowers in the form provided by Agent and contain all information required in such form. Except for
Permitted Licenses, each Credit Party is the sole owner of its Intellectual Property free and clear of any Liens. Each patent set
forth on Schedule 3.19 is valid and enforceable and no part of the Material Intangible Assets has been judged invalid or unenforceable,
in whole or in part, and to the best of Borrowers’ knowledge, no claim has been made that any part of the Intellectual Property
violates the rights of any third party.


Section 3.20        Solvency.
Each Borrower is, and after giving effect to the Loan advance and the liabilities and obligations of each Borrower under
the Operative Documents, will be, Solvent; and each other Credit Party together with Borrower and its Subsidiaries, taken as a
whole, is Solvent.






    	 	49	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


Section 3.21         Full
Disclosure. None of the written information (financial or otherwise, but excluding any projections
and forward-looking statements, estimates, budgets and industry data of a general nature) furnished by or on behalf of any Credit
Party to Agent or any Lender in connection with the consummation of the transactions contemplated by the Financing Documents (in
each case, taken as a whole and as modified or supplemented by other information so furnished promptly after the same becomes available)
contains any untrue statement of a material fact or omits to state a material fact necessary to make the statements contained herein
or therein not misleading in light of the circumstances under which such statements were made. All financial projections and forward-looking
statements delivered to Agent and the Lenders by the Borrowers have been prepared on the basis of the assumptions stated therein
and such projections represent the Borrowers’ best estimate of the Borrowers’ future financial performance as of the
date of delivery and such assumptions are believed by the Borrowers to be fair and reasonable in light of current business conditions
at the time of delivery to Agent, provided that it being understood that such projections are subject to uncertainties and
contingencies, some of which are beyond the control of the Borrowers, and the Borrowers can give no assurance that such projections
will be attained, that actual results may differ in a material manner from such projections and any failure to meet such projections
shall not automatically be deemed to be a breach of any representation or covenant herein.


Section 3.22        Subsidiaries.
Borrowers do not own any stock, partnership interests, limited liability company interests or other equity securities or
Subsidiaries except for Permitted Investments.


Section
3.23              
Regulatory Matters.


(a)               
All of Borrower’s and its Subsidiaries’ material Products and material Regulatory
Required Permits as of the Closing Date are listed on Schedule 4.15. With respect to each such Product, (i) Borrower and
its Subsidiaries have received, and such Product is the subject of, all Regulatory Required Permits needed in connection with
the development, testing, manufacture, import, export, holding, marketing, promotion, sale, labeling, and distribution, as applicable,
of such Product as currently being conducted by or on behalf of Borrower, and have provided Agent with all notices and other information
required by Section 4.1, and (ii) such Product has been and is being developed, tested, manufactured, imported, exported, held,
marketed, promoted, or sold, labeled, or distributed, as the case may be, in material compliance with all applicable Laws, including
but not limited to Healthcare Laws, and Regulatory Required Permits.


(b)               
None of the Borrowers or any Subsidiary thereof are in violation of any Healthcare Law or
any judgment, order, writ, injunction, settlement, or agreement issued by or entered into with the FDA or any other applicable
Governmental Authority, except where any such violation could not reasonably be expected to result in a Material Adverse Effect.
None of Borrowers or any Subsidiary thereof has received (i) any unresolved inspection reports, warning letters, untitled letters
or similar documents with respect to TX-001HR, TX-004HR or any other Product material to the business of the Borrowers (taken as
a whole) from any Governmental Authority that assert material lack of compliance with any applicable Healthcare Law; or (ii) any
written notice of a regulatory enforcement action, investigation or inquiry (other than non-material routine or periodic inspections
or reviews) or any criminal, civil, injunctive, seizure or detention action against or relating to it or any Product for alleged
lack of compliance with any applicable Healthcare Law, except with respect to this clause (ii), where any such lack of compliance
could not reasonably be expected to have a Material Adverse Effect; and, to the knowledge of Borrower, there is no such regulatory
enforcement action, investigation or inquiry or criminal, civil, injunctive, seizure or detention action pending.






    	 	50	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    




(c)               
To the Borrowers’ knowledge, none of the Borrowers’ or their Subsidiaries’
officers, directors, employees, shareholders, agents or affiliates has made an untrue statement of material fact or fraudulent
statement to the FDA or failed to disclose a material fact required to be disclosed to the FDA, committed an act, made a statement,
or failed to make a statement that could reasonably be expected to provide a basis for the FDA to invoke its policy respecting
“Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities,” set forth in 56 Fed. Reg. 46191 (September
10, 1991) or for any other Governmental Authority to invoke a similar policy or Law.


(d)               
None of Borrowers or any Subsidiary thereof or, to the knowledge of Borrower, any of their
respective suppliers is employing or utilizing the services of any Person who has been debarred, disqualified, suspended or otherwise
excluded under any applicable Healthcare Law.


(e)               
There have been no Recalls, safety alerts, withdrawals, clinical holds, marketing suspensions,
or similar actions conducted, undertaken or issued by the Borrowers or any Subsidiary thereof or, to Borrowers’ knowledge,
any other Person, whether or not at the request, demand or order of any Governmental Authority, with respect to any Product.


(f)                
As of the Closing Date, no
Borrower or any Subsidiary thereof receives any payments from
Medicare, Medicaid, or TRICARE.


(g)               
As of the Closing Date, there have been no Regulatory Reporting Events.


Article 4
- AFFIRMATIVE COVENANTS


Each Borrower agrees
that, so long as any Credit Exposure exists:


Section 4.1           Financial
Statements and Other Reports. Each Borrower will deliver to Agent:


(a)               
as soon as available, but no later than forty-five (45) days after the last day of each fiscal
quarter, a company prepared consolidated (and, if any Excluded Foreign Subsidiaries then exist, consolidating) balance sheet, cash
flow and income statement (including year-to-date results) covering Borrowers’ and its Consolidated Subsidiaries’ consolidated
operations during the period, prepared under GAAP, consistently applied, setting forth in comparative form the corresponding figures
as at the end of the corresponding fiscal quarter of the previous fiscal year and the projected figures for such period based upon
the projections required hereunder, all in reasonable detail, certified by a Responsible Officer and in a form acceptable to Agent;



(b)               
[reserved];






    	 	51	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    




(c)               
as soon as available, but no later than ninety (90) days after the last day of Borrower’s
fiscal year, audited consolidated (and, if any Excluded Foreign Subsidiaries then exist, consolidating) financial statements prepared
under GAAP, consistently applied, together with an unqualified opinion on the financial statements from an independent certified
public accounting firm acceptable to Agent in its reasonable discretion, it being agreed by Agent that Grant Thornton LLP and its
successors are acceptable to Agent; 


(d)               
within five (5) days of delivery or filing thereof, copies of all statements, reports
and notices made available to Borrower’s security holders or to any holders of Subordinated Debt and copies of all reports
and other filings made by Borrower with any stock exchange on which any securities of any Borrower are traded and/or the SEC; provided
that, such delivery requirement shall be satisfied to the extent such reports and other filings are publically available on the
SEC’s EDGAR system or any successor thereto; 


(e)               
prompt written notice of an event that materially and adversely affects the value of any Material
Intangible Asset; 


(f)                
within sixty (60) days after the start of each fiscal year, projections for the forthcoming
two fiscal years, on a quarterly basis for the current year and on an annual basis for the subsequent year; 


(g)               
promptly (but in any event within ten (10) days of any request therefor) such other readily
available budgets, sales projections, operating plans and other financial information and information, reports or statements regarding
the Borrowers, their business and the Collateral as Agent may from time to time reasonably request; 


(h)               
within thirty (30) days after the last day of each month (or, in the case of the last month
in each fiscal quarter, within forty-five (45) days after the last day of such month), a duly completed Compliance Certificate
signed by a Responsible Officer setting forth calculations showing monthly cash and Cash Equivalents of Borrowers and Borrowers
and their Consolidated Subsidiaries and compliance with the financial covenants set forth in this Agreement; 


(i)                
written notice to Agent promptly, but in any event within five (5) Business Days of a Responsible
Officer of a Borrower receiving written notice or otherwise becoming aware that:


(i)                
any development, testing, manufacturing, or distribution of any Product that is material to
Borrowers’ business should cease, whether (A) temporarily and (1) outside of the ordinary course of business or (2) pursuant
to an order by a Governmental Authority, or (B) permanently; 


(ii)              
any sales of a Product which is material to Borrowers’ business should cease or such
Product should be withdrawn from the marketplace, whether temporarily or permanently; 


(iii)            
any Governmental Authority is conducting a non-routine investigation, audit, or review of
any material Regulatory Required Permit; 


(iv)             
any material Regulatory Required Permit has been suspended, revoked. withdrawn, or adversely
limited, modified, or restricted;






    	 	52	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


(v)               
any Governmental Authority, including without limitation the FDA, DEA, the Office of the Inspector
General of the Department of Health and Human Services (“HHS”) or the United States Department of Justice, has
commenced or threatened to initiate any administrative, regulatory, civil or criminal enforcement action, injunction, seizure,
investigation or non-routine inspection related to or against any Product or any Credit Party or a Subsidiary thereof, or any action
to enjoin a Credit Party or a Subsidiary thereof, or their officers, directors, employees, shareholders or their agents and Affiliates,
in such capacity, from conducting their businesses at any facility owned or used by them; 


(vi)             
receipt by Borrower or any Subsidiary thereof from the FDA of a warning letter, Form FDA-483,
untitled letter, other correspondence or notice setting forth alleged violations of any Law, including any Healthcare Law or other
laws and regulations enforced by the FDA, or any comparable correspondence or notice from any other Governmental Authority responsible
for regulating drug products and establishments with regard to any Product or the testing, development, manufacture, processing,
packing, holding, import, export, labeling, or distribution thereof;


(vii)           
any failures in the manufacturing of any Product have occurred such that the amount of such
Product successfully manufactured in accordance with applicable Laws and all specifications thereof and sales by Borrower therefor
in any month shall decrease significantly as compared to the quantities of such Product and sales otherwise planned to be generated
in such month;


(viii)         
any Borrower or any Subsidiary thereof becoming
subject to any proceeding, suit, administrative
or regulatory enforcement action, investigation or non-routine inspection by any federal,
state or local Governmental Authority or quasi-governmental body, agency, board or authority or any other administrative or investigative
body (including the Office of the Inspector General of HHS);
or


(ix)             
any Borrower or any Subsidiary thereof engaging in any Recalls, Market Withdrawals, or other
forms of product retrieval from the marketplace of any Products, except for routine stock rotation practices or routine equipment
adjustments and repairs (each of the events set forth in clauses (i)-(ix) a “Regulatory Reporting Event”). Borrower
shall, and shall cause each Credit Party, to promptly provide such further information (including copies of relevant documentation)
as Agent or any Lender shall reasonably request with respect to any Regulatory Reporting Event; 


(j)                
promptly after the request by any Lender, all documentation and other information that such
Lender reasonably requests in order to comply with its ongoing obligations under applicable “know your customer” and
anti-money laundering rules and regulations, including, without limitation, the USA PATRIOT Act; 


(k)               
promptly, but in any event within five (5) Business Days, after any Responsible Officer of
any Borrower obtains knowledge of the occurrence of any event or change (including, without limitation, any notice of any violation
of Healthcare Laws) that has resulted or could reasonably be expected to result in, either in any case or in the aggregate, a Material
Adverse Effect, a certificate of a Responsible Officer specifying the nature and period of existence of any such event or change,
or specifying the notice given or action taken by such holder or Person and the nature of such event or change, and what action
the applicable Credit Party or Subsidiary has taken, is taking or proposes to take with respect thereto;






    	 	53	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    




(l)                
promptly, but in any event within five (5) Business Days, after any Responsible Officer of
any Borrower obtains knowledge of the occurrence of a reportable event under Section 4043 of ERISA (for which a reporting
requirement is not waived) with respect to any Pension Plan;


(m)             
promptly, but in any event within five (5) Business Days, upon receipt of the same, copies
of all notices, requests and other documents received by any Credit Party or any Subsidiary under or pursuant to any Material Contract
regarding or related to any material breach or default by any party thereto or any other event that could reasonably be expected
to materially impair the value of the interests or the rights of any Credit Party or any Subsidiary under any Material Contract
or otherwise have a Material Adverse Effect;


(n)               
together with the next Compliance Certificate required to be delivered under subsection (i)
with respect to the last month of a fiscal quarter, following the request of Agent written notice of the execution of any material
amendment, consent, waiver or other modification to any Material Contract or the entry into any new Material Contract and, following
the request of Agent, a copy of any such amendment, consent, waiver, other modification or new Material Contract;


(o)               
written notice to Agent promptly, but in any event within three (3) Business Days, of a Responsible
Officer of a Borrower receiving written notice or otherwise becoming aware of:


(i)                
any legal actions pending or threatened in writing against any Borrower or any of its Subsidiaries
that could reasonably be expected to result in damages or costs to any Borrower or any of its Subsidiaries of One Million Dollars
($1,000,000) or more;


(ii)              
the institution of any proceeding (A) seeking equitable relief with respect to a Credit Party
or Subsidiary or involving an alleged liability of any Credit Party or any Subsidiary equal to or greater than $1,000,000 or any
adverse determination in any proceeding involving equitable relief or a potential liability of any Credit Party or any Subsidiary
equal to or greater than $1,000,000 or (B) which in any manner calls into question the validity or enforceability of any Financing
Document;


(iii)            
any Default or Event of Default; or


(iv)             
any strikes or other labor disputes pending or, to any Borrower’s knowledge, threatened
in writing against any Credit Party;


Borrowers represent
and warrant that Schedule 4.1(o) sets forth a complete list of all matters existing as of the Closing Date for which notice
could be required under clause (o) above. Borrower shall, and shall cause each Credit Party, to provide such further information
(including copies of such documentation) as Agent or any Lender shall reasonably request with respect to any of the events or notices
described in clauses (j) and (o) above.






    	 	54	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


Section 4.2          Payment
and Performance of Obligations. Each Borrower (a) will pay and discharge, and cause each
Subsidiary to pay and discharge, on a timely basis as and when due, all of their respective obligations and liabilities, except
for such obligations and/or liabilities (i) that may be the subject of a Permitted Contest, or (ii) the nonpayment or
nondischarge of which could not reasonably be expected to have a Material Adverse Effect or result in a Lien against any Collateral,
except for Permitted Liens, (b) will without limiting anything contained in the foregoing clause (a), except to the extent subject
to a Permitted Contest, pay all amounts due and owing in respect of Taxes (including without limitation, payroll and withholdings
tax liabilities) on a timely basis as and when due, and in any case prior to the date on which any fine, penalty, interest, late
charge or loss may be added thereto for nonpayment thereof, except as the nonpayment of such amounts is less than $250,000 in the
aggregate at any one time outstanding, (c) will maintain, and cause each Subsidiary to maintain, in accordance with GAAP,
appropriate reserves for the accrual of all of their respective obligations and liabilities, and (d) will not breach or permit
any Subsidiary to breach, or permit to exist any default under, the terms of any lease, commitment, contract, instrument or obligation
to which it is a party, or by which its properties or assets are bound, except for such breaches or defaults which could not reasonably
be expected to have a Material Adverse Effect.


Section 4.3          Maintenance
of Existence. Each Borrower will preserve, renew and keep in full force and effect, and will
cause each Subsidiary to preserve, renew and keep in full force and effect, (a) their respective existence, except in connection
with a transaction permitted under Section 5.6, (b) their respective rights, privileges and franchises necessary or desirable
in the normal conduct of business, except in connection with a transaction permitted under Section 5.6 or where the failure
to maintain such rights, privileges and franchises could not reasonably be expected to have a Material Adverse Effect, and (c) their
respective qualification to do business and good standing in each jurisdiction in which it conducts business, except where the
failure to be qualified or in good standing could not reasonably be expected to have a Material Adverse Effect.


Section
4.4              
Maintenance of Property; Insurance.


(a)               
Each Borrower will keep, and will cause each Subsidiary to keep, all property useful and necessary
in its business in good working order and condition, ordinary wear and tear excepted. If all or any part of the Collateral useful
or necessary in its business becomes damaged or destroyed, each Borrower will, and will cause each Subsidiary to, promptly and
completely repair and/or restore the affected Collateral in a good and workmanlike manner, subject to Agent agreeing to disburse
insurance proceeds or other sums to pay costs of the work of repair or reconstruction. 


(b)               
Upon completion of any Permitted Contest, Borrowers shall, and will cause each Subsidiary
to, promptly pay the amount due, if any, and deliver to Agent proof of the completion of the contest and payment of the amount
due, if any.


(c)               
Each Borrower will maintain (i) casualty insurance on all real and personal property
on an all risks basis (including the perils of flood, windstorm and quake where available at commercially reasonable cost), covering
the repair and replacement cost of all such property and business interruption coverages with extended period of indemnity (for
the period reasonably required by Agent from time to time) and indemnity for extra expense, in each case without application of
coinsurance and with agreed amount endorsements, (ii) general and professional liability insurance (including products/completed
operations liability coverage), and (iii) such other insurance coverage, in each case against loss or damage of the kinds
customarily insured against by Persons engaged in the same or similar business, of such types and in such amounts as are customarily
carried under similar circumstances by such other Persons; provided, however, that, in no event shall such insurance
be in amounts or with coverage less than, or with carriers with qualifications inferior to, any of the insurance or carriers in
existence as of the Closing Date (or required to be in existence after the Closing Date under a Financing Document). All such insurance
shall be provided by insurers having an A.M. Best policyholders rating, or otherwise reasonably acceptable to Agent.






    	 	55	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    




(d)               
On or prior to the Term Loan Tranche 1 Funding Date, and at all times thereafter, each Borrower
will cause Agent to be named as an additional insured, assignee and lender loss payee (which shall include, as applicable, identification
as mortgagee), as applicable, on each insurance policy required to be maintained pursuant to this Section 4.4 pursuant to
endorsements in form and substance reasonably acceptable to Agent. Borrowers shall deliver to Agent and the Lenders (i) on
the Closing Date, a certificate from Borrowers’ insurance broker dated no more than five (5) Business Days prior to such
date showing the amount of coverage as of such date, and that such policies will include effective waivers (whether under the terms
of any such policy or otherwise) by the insurer of all claims for insurance premiums against all loss payees and additional insureds
and all rights of subrogation against all loss payees and additional insureds, and that if all or any part of such policy is canceled,
terminated or expires, the insurer will forthwith give notice thereof to each additional insured, assignee and loss payee and that
no cancellation, reduction in amount or material change in coverage thereof shall be effective until at least thirty (30) days
after receipt by each additional insured, assignee and loss payee of written notice thereof, (ii) on an annual basis, and
upon the request of any Lender through Agent from time to time full information as to the insurance carried, (iii) within
five (5) Business Days of receipt of notice from any insurer, a copy of any notice of cancellation, nonrenewal or material change
in coverage from that existing on the date of this Agreement, (iv) forthwith, notice of any cancellation or nonrenewal of
coverage by any Borrower, and (v) at least thirty (30) days prior to expiration of any policy of insurance, evidence of renewal
of such insurance upon the terms and conditions herein required.


(e)               
In the event any Borrower fails to provide Agent with evidence of the insurance coverage required
by this Agreement, Agent may, following written notice to Borrower Representative, purchase insurance at Borrowers’ expense
to protect Agent’s interests in the Collateral. This insurance may, but need not, protect such Borrower’s interests.
The coverage purchased by Agent may not pay any claim made by such Borrower or any claim that is made against such Borrower in
connection with the Collateral. Such Borrower may later cancel any insurance purchased by Agent, but only after providing Agent
with evidence that such Borrower has obtained insurance as required by this Agreement. If Agent purchases insurance for the Collateral,
Borrowers will be responsible for the costs of that insurance to the fullest extent provided by law, including interest and other
charges imposed by Agent in connection with the placement of the insurance, until the effective date of the cancellation or expiration
of the insurance. The costs of the insurance may be added to the Obligations. The costs of the insurance may be more than the cost
of insurance such Borrower is able to obtain on its own. 


Section 4.5          Compliance
with Laws and Material Contracts. Each Borrower will comply, and cause each Subsidiary to comply,
with the requirements of all applicable Laws and Material Contracts, except to the extent that failure to so comply could not reasonably
be expected to (a) have a Material Adverse Effect, or (b) result in any Lien upon a material portion of the assets of
any such Person in favor of any Governmental Authority.






    	 	56	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


Section 4.6          Inspection
of Property, Books and Records. Each Borrower will keep, and will cause each Subsidiary to
keep, proper books of record substantially in accordance with GAAP in which full, true and correct entries shall be made of all
dealings and transactions in relation to its business and activities; and will permit, and will cause each Subsidiary to permit,
at the sole cost of the applicable Borrower or any applicable Subsidiary, representatives of Agent to visit and inspect any of
their respective properties, to examine and make abstracts or copies from any of their respective books and records, to conduct
a collateral audit and analysis of their respective operations and the Collateral, to verify the amount and age of the Accounts,
the identity and credit of the respective Account Debtors, to review the billing practices of Borrowers and to discuss their respective
affairs, finances and accounts with their respective officers, employees and independent public accountants (subject to applicable
confidentiality and legal privilege restrictions) as often as may reasonably be desired; provided, however, that so long as no
Default or Event of Default exists and is continuing, the Borrowers and their Subsidiaries shall only be required to reimburse
Agent for one such visit or inspection in any calendar year. In the absence of a Default or an Event of Default, Agent shall give
the applicable Borrower or any applicable Subsidiary commercially reasonable prior notice of such exercise. No notice shall be
required during the existence and continuance of any Default.


Section 4.7           Use
of Proceeds. Borrowers shall use the proceeds of the Term Loan solely for working capital needs
of Borrowers and their Subsidiaries and other general corporate purposes. The proceeds of the Term Loans will not be used, directly
or indirectly, for the purpose of purchasing or carrying any “margin stock” (as defined in Regulation U of the Federal
Reserve Board), for the purpose of reducing or retiring any indebtedness which was originally incurred to purchase or carry any
“margin stock” or for any other purpose which might cause any of the Term Loans to be considered a “purpose credit”
within the meaning of Regulation T, U or X of the Federal Reserve Board.


Section 4.8           Reserved.



Section
4.9               
Reserved.


Section
4.10           
Hazardous Materials; Remediation.


(a)               
If any release or disposal of Hazardous Materials shall occur or shall have occurred on any
real property or any other assets of any Borrower or any other Credit Party, such Borrower will use commercially reasonable efforts
to cause, or direct the applicable Credit Party to cause, the prompt containment and removal of such Hazardous Materials and the
remediation of such real property or other assets as is necessary to comply with all Environmental Laws and Healthcare Laws. Without
limiting the generality of the foregoing, each Borrower shall, and shall cause each other Credit Party to, comply in all material
respects with each Environmental Law and Healthcare Law requiring the performance at any real property by any Borrower or any other
Credit Party of activities in response to the release or threatened release of a Hazardous Material.


(b)               
Borrowers will provide Agent within thirty (30) days after written demand therefor with a
bond, letter of credit or similar financial assurance evidencing to the reasonable satisfaction of Agent that sufficient funds
are available to pay the cost of removing, treating and disposing of any Hazardous Materials or Hazardous Materials Contamination
and discharging any assessment which may be established on any property as a result thereof, such demand to be made, if at all,
upon Agent’s reasonable business determination that the failure to remove, treat or dispose of any Hazardous Materials or
Hazardous Materials Contamination, or the failure to discharge any such assessment could reasonably be expected to have a Material
Adverse Effect.






    	 	57	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


Section
4.11             
Further Assurances.


(a)               
Each Borrower will, and will cause each Subsidiary to, at its own cost and expense, promptly
and duly take, execute, acknowledge and deliver all such further acts, documents and assurances as may from time to time be necessary
or as Agent or the Required Lenders may from time to time reasonably request in order to carry out the intent and purposes of the
Financing Documents and the transactions contemplated thereby, including all such actions to (i) establish, create, preserve,
protect and perfect a first priority Lien (subject only to Permitted Liens) in favor of Agent for itself and for the benefit of
the Lenders on the Collateral (including Collateral acquired after the date hereof), and (ii) unless Agent shall agree otherwise
in writing, cause all Subsidiaries of Borrowers (other than Excluded Foreign Subsidiaries) to be jointly and severally obligated
with the other Borrowers under all covenants and obligations under this Agreement, including the obligation to repay the Obligations.



(b)               
Upon receipt of an affidavit of an authorized representative of Agent or a Lender as to the
loss, theft, destruction or mutilation of any Note or any other Financing Document which is not of public record, and, in the case
of any such mutilation, upon surrender and cancellation of such Note or other applicable Financing Document, Borrowers will issue,
in lieu thereof, a replacement Note or other applicable Financing Document, dated the date of such lost, stolen, destroyed or mutilated
Note or other Financing Document in the same principal amount thereof and otherwise of like tenor.


(c)               
Upon the request of Agent, Borrowers shall obtain a landlord’s agreement or mortgagee
agreement, as applicable, from the lessor of each leased property or mortgagee of owned property with respect to any business location
where Collateral with an aggregate value in excess of $1,000,000 is located, or material records relating to such Collateral and/or
software and equipment relating to such records or Collateral,
is stored or located, which agreement or letter shall be reasonably satisfactory in form and substance to Agent. Borrowers shall
timely and fully pay and perform its material obligations under all leases and other agreements with respect to each leased location
where any such amount of Collateral, or any material records related thereto, is or may be located.


(d)               
Borrower shall provide Agent with at least five (5) Business Days (or such shorter period
as Agent may accept in its sole discretion) prior written notice of its intention to create (or to the extent permitted under this
Agreement, acquire) a new Subsidiary. Promptly upon, but in any event within ten (10) Business Days following the formation (or
to the extent permitted under this Agreement, acquisition) of a new Subsidiary, Borrowers shall (i) pledge, have pledged or cause
or have caused to be pledged to Agent pursuant to a pledge agreement in form and substance reasonably satisfactory to Agent, all
of the outstanding shares of Equity Interests or other Equity Interests of such new Subsidiary (except to the extent such shares
constitute Excluded Property) owned directly or indirectly by any Borrower, along with undated stock or equivalent powers for such
certificates, executed in blank; (ii) unless Agent shall agree otherwise in writing, cause the new Subsidiary (other than
an Excluded Foreign Subsidiary) to take such other actions (including entering into or joining any Security Documents) as are necessary
or advisable in the reasonable opinion of Agent in order to grant Agent, acting on behalf of the Lenders, a first priority Lien
(subject to Permitted Liens which have priority by operation of Law) on all real and personal property of such Subsidiary in existence
as of such date and in all after acquired property, which first priority Liens are required to be granted pursuant to this Agreement;
(iii) unless Agent shall agree otherwise in writing, cause such new Subsidiary (other than an Excluded Foreign Subsidiary)
to either (at the election of Agent) become a Borrower hereunder with joint and several liability for all obligations of Borrowers
hereunder and under the other Financing Documents pursuant to a joinder agreement or other similar agreement in form and substance
reasonably satisfactory to Agent or to become a Guarantor of the obligations of Borrowers hereunder and under the other Financing
Documents pursuant to a guaranty and suretyship agreement in form and substance reasonably satisfactory to Agent; and (iv) cause
the new Subsidiary to deliver certified copies of such Subsidiary’s certificate or articles of incorporation, together with
good standing certificates, by-laws (or other operating agreement or governing documents), resolutions of the Board of Directors
or other governing body, approving and authorize the execution and delivery of the Security Documents, incumbency certificates
and to execute and/or deliver such other documents and legal opinions or to take such other actions as may be reasonably requested
by Agent, in each case, in form and substance reasonably satisfactory to Agent.






    	 	58	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


(e)               
From the date hereof and continuing through the termination of this Agreement, Borrower shall,
and shall cause each Credit Party to, make reasonably available to Agent and each Lender, at reasonably times and frequency without
expense to Agent or any Lender, each Credit Party’s officers, employees and agents and books, to the extent that Agent or
any Lender may reasonably deem them necessary to prosecute or defend any third-party suit or proceeding instituted by or against
Agent or any Lender with respect to any Collateral or relating to a Credit Party.


Section 4.12         Reserved.



Section 4.13        Power
of Attorney. Each of the authorized representatives of Agent is hereby irrevocably made, constituted
and appointed the true and lawful attorney for Borrowers (without requiring any of them to act as such) with full power of substitution
to do the following: (a) after the occurrence and during the continuance of an Event of Default, endorse the name of Borrowers
upon any and all checks, drafts, money orders, and other instruments for the payment of money that are payable to Borrowers and
constitute collections on Borrowers’ Accounts; (b) after the occurrence and during the continuance of an Event of Default,
execute in the name of Borrowers any schedules, assignments, instruments, documents, and statements that Borrowers are obligated
to give Agent under this Agreement; (c) after the occurrence and during the continuance of an Event of Default, take any action
Borrowers are required to take under this Agreement; (d) after the occurrence and during the continuance of an Event of Default,
do such other and further acts and deeds in the name of Borrowers that Agent may deem necessary or desirable to enforce any Account
or other Collateral or perfect Agent’s security interest or Lien in any Collateral; and (e) after the occurrence and
during the continuance of an Event of Default, do such other and further acts and deeds in the name of Borrowers that Agent may
deem necessary or desirable to enforce its rights with regard to any Account or other Collateral. This power of attorney shall
be irrevocable and coupled with an interest.


Section
4.14             
Intellectual Property and Licensing.


(a)                
To the extent (A) Borrower acquires and/or develops any new Registered Intellectual Property,
(B) Borrower enters into or becomes bound by any additional in-bound license or sublicense agreement, any additional out-bound
license or sublicense agreement or other material agreement with respect to rights in Intellectual Property (other than over-the-counter
software that is commercially available to the public), or (C) there occurs any other material change in Borrower’s Registered
Intellectual Property, in-bound licenses or sublicenses or exclusive out-bound licenses or sublicenses from that listed on Schedule
3.19, Borrower shall, together with the next Compliance Certificate required to be delivered pursuant to Section 4.1 with respect
to the last month of a fiscal quarter, deliver to Agent an updated Schedule 3.19 reflecting such updated information. With
respect to any updates to Schedule 3.19 involving exclusive out-bound licenses or sublicenses, such licenses shall be consistent
with the definitions of and limitations herein pertaining to Permitted Licenses.






    	 	59	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    




(b)               
If Borrower obtains any Registered Intellectual Property (other than copyrights, mask works
and related applications, which are addressed below), Borrower shall promptly (and in any event within fifteen (15) days of obtaining
same) notify Agent and execute such documents and provide such other information (including, without limitation, copies of applications)
and take such other actions as Agent shall request in its good faith business judgment to perfect and maintain a first priority
perfected security interest in favor of Agent, for the ratable benefit of Lenders, in such
Registered Intellectual Property. 


(c)                
Borrower shall own, or be licensed to use or otherwise have the right to use, all Material
Intangible Assets. Borrower shall cause all Registered Intellectual Property to be duly and properly registered, filed or issued
in the appropriate office and jurisdictions for such registrations, filings or issuances, except where the failure to do so would
not reasonably be expected to result in a Material Adverse Effect. Borrower shall at all times conduct its business without material
infringement of any Intellectual Property rights of others. Borrower shall (i) protect, defend and maintain the validity and enforceability
of its Material Intangible Assets (ii) promptly advise Agent in writing of material infringements of its Material Intangible Assets,
or of a material claim of infringement by Borrower on the Intellectual Property rights of others; and (iii) not allow any of Borrower’s
Material Intangible Assets to be abandoned, invalidated, forfeited or dedicated to the public or to become unenforceable other
than by operation of Law. Borrower shall not become a party to, nor become bound by, any material license or other agreement with
respect to which Borrower is the licensee that prohibits or otherwise restricts Borrower from granting a security interest in Borrower’s
interest in such license or agreement or other property.


Section
4.15             
Regulatory Covenants.


(a)               
Borrowers shall have, and shall ensure that it and each of its Subsidiaries has, each material
Permit and other material rights from, and have made all declarations and filings with, all applicable Governmental Authorities,
all self-regulatory authorities and all courts and other tribunals necessary to engage in the ownership, management and operation
of the business or the assets of any Borrower and Borrowers shall ensure that no Governmental Authority has taken action to limit,
suspend or revoke any such material Permit. Borrower shall ensure that all such Permits are valid and in full force and effect
and Borrowers are in material compliance with the terms and conditions of all such Permits in all material respects.


(b)               
Borrowers will, and will cause each of its Subsidiaries to, maintain in full force and effect,
and free from restrictions, probations, conditions or known conflicts which would materially impair the use or operation of Borrowers’
or such Subsidiary’s business and assets, all Permits necessary under Healthcare Laws to carry on the business of Borrowers
and its Subsidiaries as it is conducted on the Closing Date in all material respects.


(c)               
In connection with the development, testing, manufacture, import, export, holding, marketing,
promotion, sale, labeling, or distribution of any Product by or on behalf of any Borrower or any Subsidiary thereof, each Borrower
and Subsidiary shall have obtained and comply in all material respects with all material Regulatory Required Permits at all times
issued or required to be issued by any Governmental Authority, specifically including the FDA, with respect to such activities
being conducted by or behalf of Borrower or such Subsidiaries at any such time.






    	 	60	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


(d)               
Borrowers will, and will cause each of its Subsidiaries to, timely file or cause to be timely
filed (with applicable Governmental Authorities all material notifications, reports, submissions, Permit renewals and reports required
by Healthcare Laws (which reports will be materially accurate and complete in all respects and not misleading in any respect and
shall not remain open or unsettled).


(e)               
If, after the Closing Date, Borrowers or any of their Subsidiaries determine to manufacture,
sell, develop (beyond initial testing), or market any new material Product, Borrowers shall deliver prior written notice to Agent
of such determination (which shall include a brief description of such Product) and, together with delivery of the next Compliance
Certificate required to be delivered pursuant to Section 4.1 with respect to the last month of a fiscal quarter, shall provide
an updated Schedule 4.15 (and copies of such Permits as Agent may request) reflecting updates related to such determination.



(f)                
Borrower shall notify Agent at least ten (10) Business Days prior
to it or any of its Subsidiaries beginning to receive payments from
Medicare, Medicaid, or TRICARE.


(g)               
Borrower shall ensure that each Product (i)
is not adulterated or misbranded within the meaning of the FDCA or
any other applicable Laws in any material respect; (ii) is not
an article prohibited from introduction into interstate commerce under the provisions of Sections 505 of the FDCA; (iii)
has been and/or shall be developed, tested, manufactured, imported, exported,
held, marketed, advertised, promoted, sold, labeled, and distributed, as applicable, and each service has been conducted, in material
compliance with all applicable Permits and Laws;
and (iv) each Product has been and/or
shall be manufactured in accordance with Good Manufacturing Practices in
all material respects. 


Article 5
- NEGATIVE COVENANTS


Each Borrower agrees
that, so long as any Credit Exposure exists:


Section 5.1           Debt;
Contingent Obligations. No Borrower will, or will permit any Subsidiary to, directly or indirectly,
create, incur, assume, guarantee or otherwise become or remain directly or indirectly liable with respect to, any Debt, except
for Permitted Debt. No Borrower will, or will permit any Subsidiary to, directly or indirectly, create, assume, incur or suffer
to exist any Contingent Obligations, except for Permitted Contingent Obligations.


Section 5.2           Liens.
No Borrower will, or will permit any Subsidiary to, directly or indirectly, create, assume or suffer to exist any Lien on
any asset now owned or hereafter acquired by it, except for Permitted Liens.


Section 5.3          Distributions.
No Borrower will, or will permit any Subsidiary to, directly or indirectly, declare, order, pay, make or set apart any sum
for any Distribution, except for Permitted Distributions.


Section 5.4          Restrictive
Agreements. No Borrower will, or will permit any Subsidiary to, directly or indirectly (a) enter
into or assume any agreement (other than (i) the Financing Documents, (ii) any agreements for purchase money debt permitted under
clause (c) of the definition of Permitted Debt provided that such restriction relates solely to the equipment (and accessions
thereto and the proceeds thereof) being purchased or leased with such purchase money Debt, and (iii) customary provisions in leases
of real property and tangible personal property restricting the assignment thereof or the assets governed thereby) prohibiting
the creation or assumption of any Lien upon its properties or assets, whether now owned or hereafter acquired, or (b) create
or otherwise cause or suffer to exist or become effective any consensual encumbrance or restriction of any kind (except as provided
by the Financing Documents) on the ability of any Subsidiary to: (i) pay or make Distributions to any Borrower or any Subsidiary;
(ii) pay any Debt owed to any Borrower or any Subsidiary; (iii) make loans or advances to any Borrower or any Subsidiary;
or (iv) transfer any of its property or assets to any Borrower or any Subsidiary.






    	 	61	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


Section 5.5          Payments
and Modifications of Subordinated Debt. No Borrower will, or will permit any Subsidiary to,
directly or indirectly (a) declare, pay, make or set aside any amount for payment in respect of Subordinated Debt or any other
Debt that has been subordinated to any of the Obligations, except for payments made in full compliance with and expressly permitted
under the Subordination Agreement or the terms of such subordination, (b) amend or otherwise modify the terms of any Subordinated
Debt, except for amendments or modifications made in full compliance with the Subordination Agreement, (c) declare, pay, make or
set aside any amount for payment in respect of any Debt hereinafter incurred that, by its terms, or by separate agreement, is subordinated
to the Obligations, except for payments made in full compliance with and expressly permitted under the subordination provisions
applicable thereto, or (d) amend or otherwise modify the terms of any such Debt if the effect of such amendment or modification
is to (i) increase the interest rate or fees on, or change the manner or timing of payment of, such Debt, (ii) accelerate or shorten
the dates upon which payments of principal or interest are due on, or the principal amount of, such Debt, (iii) change in a manner
adverse to any Credit Party or Agent any event of default or add or make more restrictive any covenant with respect to such Debt,
(iv) change the prepayment provisions of such Debt or any of the defined terms related thereto, (v) change the subordination provisions
thereof (or the subordination terms of any guaranty thereof), or (vi) change or amend any other term if such change or amendment
would materially increase the obligations of the obligor or confer additional material rights on the holder of such Debt in a manner
adverse to Borrowers, any Subsidiaries, Agent or Lenders.


Section 5.6           Consolidations,
Mergers and Sales of Assets; Change in Control. 


(a)               
No Borrower will, or will permit any Subsidiary to, directly or indirectly consolidate or
merge or amalgamate with or into any other Person other than (i) consolidations or mergers among Borrowers where a Borrower is
a surviving entity, (ii) consolidations or mergers among a Guarantor and a Borrower so long as the Borrower is the surviving entity,
(iii) consolidations or mergers among Guarantors or (iv) consolidations or mergers among Subsidiaries that are not Credit Parties.


(b)               
No Borrower will, or will permit any Subsidiary to, directly or indirectly consummate any
Asset Dispositions other than Permitted Asset Dispositions. 


Section 5.7           Purchase
of Assets, Investments. No Borrower will, or will permit any Subsidiary to, directly or indirectly:


(a)               
acquire, make, own or hold any Investment other than Permitted Investments;






    	 	62	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    




(b)               
make or otherwise consummate any Acquisition other than a Permitted Acquisitions;


(c)               
without limiting clauses (a) or (b), acquire any assets other than in the Ordinary Course
of Business and other than Permitted Acquisitions; or


(d)                
form any joint venture or partnership entity with any other Person without the prior written
consent of Agent (which consent shall not be unreasonably withheld, conditioned or delayed).


Section 5.8          Transactions
with Affiliates. Except (a) as otherwise disclosed on Schedule 5.8, (b) for Permitted
Distributions, (c) for transactions among the Credit Parties that are permitted by the Financing Documents, (d) for (i) payments
of salaries, bonuses and fringe benefits to individuals, (ii) directors fees and awards of Equity Interests and (iii) advances
and reimbursements to employees, officers or directors, in each case, made in the Ordinary Course of Business and to the extent
not otherwise constituting “Debt” of the Borrowers or their Subsidiaries and (e) for transactions that contain terms
that are no less favorable to the applicable Borrower or any Subsidiary, as the case may be, than those which might be obtained
from a third party not an Affiliate of any Credit Party, no Borrower will, or will permit any Subsidiary to, directly or indirectly,
enter into or permit to exist any transaction (including the purchase, sale, lease or exchange of any property or the rendering
of any service) with any Affiliate of any Borrower.


Section 5.9          Modification
of Organizational Documents. No Borrower will, or will permit any Subsidiary to, directly or
indirectly, amend or otherwise modify any Organizational Documents of such Person, except for Permitted Modifications.


Section 5.10         Modification
of Certain Agreements. No Borrower will, or will permit any Subsidiary to, directly or indirectly,
amend or otherwise modify any Material Contract, which amendment or modification in any case: (a) is contrary to the terms
of this Agreement or any other Financing Document; or (b) could reasonably be expected to be materially adverse to the rights,
interests or privileges of Agent or the Lenders or their ability to enforce the same. Each Borrower shall, prior to entering into
any such amendment or other modification of any of the foregoing documents, deliver to Agent reasonably in advance of the execution
thereof, any final or execution form copy of amendments or other modifications to such documents, and such Borrower agrees not
to take, nor permit any of its Subsidiaries to take, any such action with respect to any such documents without obtaining such
approval from Agent.


Section 5.11        Conduct
of Business. No Borrower will, or will permit any Subsidiary to, directly or indirectly, engage
in any line of business other than those businesses engaged in on the Closing Date and described on Schedule 5.11 and
businesses reasonably related thereto. No Borrower will, or will permit any Subsidiary to, other than in the ordinary course of
business, change its normal billing payment and reimbursement policies and procedures with respect to its Accounts (including,
without limitation, the amount and timing of finance charges, fees and write-offs).






    	 	63	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


Section
5.12              
Excluded Foreign Subsidiaries.


(a)               
Borrower shall not permit, at any time, the total amount of cash and cash equivalents held
by (x) each Excluded Foreign Subsidiary (individually) to exceed $250,000 (or the equivalent thereof in any foreign currency) or
(y) the Excluded Foreign Subsidiaries (taken collectively) to exceed $1,000,000 (or the equivalent thereof in any foreign currency)
in the aggregate; provided, however, that nothing in this Section 5.12(a) shall require an Excluded Foreign Subsidiary to
make any Distribution that would be prohibited by applicable Law. 


(b)               
No Credit Party shall make any Asset Disposition to or Investment in any Excluded Foreign
Subsidiary other than Investments of cash and cash equivalents permitted to be made pursuant to clause (l) of the definition of
“Permitted Investment”. 


(c)               
No Borrower will, or will permit any Subsidiary, to commingle any of its assets (including
any bank accounts, cash or cash equivalents) with the assets of any Person other than a Credit Party.


Section 5.13        Limitation
on Sale and Leaseback Transactions. No Borrower will, or will permit any Subsidiary to, directly
or indirectly, enter into any arrangement with any Person whereby, in a substantially contemporaneous transaction, any Borrower
or any Subsidiaries sells or transfers all or substantially all of its right, title and interest in an asset and, in connection
therewith, acquires or leases back the right to use such asset.


Section 5.14         Deposit
Accounts and Securities Accounts; Payroll and Benefits Accounts. 


(a)               
Except for Excluded Accounts, no Credit Party shall, directly or indirectly, establish any
new Deposit Account or Securities Account without prior written notice to Agent, and unless Agent, such Borrower or such Subsidiary
and the bank, financial institution or securities intermediary at which the account is to be opened enter into a Deposit Account
Control Agreement or Securities Account Control Agreement prior to or concurrently with the establishment of such Deposit Account
or Securities Account. 


(b)               
As of the Closing Date and each date the Compliance Certificate is required to be delivered
pursuant to Section 4.1 with respect to the last month of a fiscal quarter, Borrowers represent and warrant that Schedule 5.14
lists all of the Deposit Accounts and Securities Accounts of each Borrower. On or prior to the Term Loan Tranche 1 Funding Date
and at all times thereafter, Borrowers will cause all Deposit Accounts and Securities Accounts of each Borrower (other than Excluded
Accounts) to be subject to a Deposit Account Control Agreement or a Securities Account Control Agreement, as applicable, in favor
of Agent.


Section 5.15         Compliance
with Anti-Terrorism Laws. Agent hereby notifies Borrowers that pursuant to the requirements
of Anti-Terrorism Laws, and Agent’s policies and practices, Agent is required to obtain, verify and record certain information
and documentation that identifies Borrowers and its principals, which information includes the name and address of each Borrower
and its principals and such other information that will allow Agent to identify such party in accordance with Anti-Terrorism Laws.
No Borrower will, or will permit any Subsidiary to, directly or indirectly, knowingly enter into any Material Contracts with any
Blocked Person or any Person listed on the OFAC Lists. Each Borrower shall immediately notify Agent if such Borrower has knowledge
that any Borrower, any additional Credit Party or any of their respective Affiliates or agents acting or benefiting in any capacity
in connection with the transactions contemplated by this Agreement is or becomes a Blocked Person or (a) is convicted on,
(b) pleads nolo contendere to, (c) is indicted on, or (d) is arraigned and held over on charges involving money
laundering or predicate crimes to money laundering. No Borrower will, or will permit any Subsidiary to, directly or indirectly,
(i) conduct any business or engage in any transaction or dealing with any Blocked Person, including, without limitation, the
making or receiving of any contribution of funds, goods or services to or for the benefit of any Blocked Person, (ii) deal
in, or otherwise engage in any transaction relating to, any property or interests in property blocked pursuant to Executive Order
No. 13224, any similar executive order or other Anti-Terrorism Law, or (iii) engage in or conspire to engage in any transaction
that evades or avoids, or has the purpose of evading or avoiding, or attempts to violate, any of the prohibitions set forth in
Executive Order No. 13224 or other Anti-Terrorism Law.






    	 	64	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


Section 5.16        Change
in Accounting. No Borrower shall, and no Borrower shall suffer or permit any of its Subsidiaries
to, (a) make any significant change in accounting treatment or reporting practices, except as required by GAAP or (b) change the
fiscal year or method for determining fiscal quarters of any Credit Party or of any Consolidated Subsidiary of any Credit Party.


Section
5.17            
Investment Company Act.No Borrower shall, nor shall it permit any Subsidiary to,
directly or indirectly, engage in any business, enter into any transaction, use any securities or take any other action or permit
any of its Subsidiaries to do any of the foregoing, that would cause it or any of its Subsidiaries to become subject to the registration
requirements of the Investment Company Act, by virtue of being an “investment company” or a company “controlled”
by an “investment company” not entitled to an exemption within the meaning of the Investment Company Act.


Article 6
- FINANCIAL COVENANTS


Section 6.1           Minimum
Net Revenue. 


(a)               
At all times prior to the Term Loan Tranche 2 Funding Date, Borrower shall not permit its
consolidated Net Revenue attributable solely to the commercial sale of TX-004HR for any Defined Period, commencing with the Defined
Period ending on September 30, 2018 (and as tested quarterly thereafter), to be less than the minimum amount set forth on Schedule
6.1(a) for such Defined Period. 


(b)               
At all times following the Term Loan Tranche 2 Funding Date, Borrower shall not permit its
consolidated Net Revenue attributable solely to the commercial sale of TX-004HR and TX-001HR for any Defined Period, commencing
with the Defined Period ending on September 30, 2018 (and as tested quarterly thereafter), to be less than (i) if the TX-001HR
First Commercial Sale occurs on or before March 31, 2019, the minimum amount set forth on Schedule 6.1(b) for such Defined
Period or (ii) if the TX-001HR First Commercial Sale occurs after March 31, 2019, the minimum amount set forth on Schedule 6.1(c)
for such Defined Period.






    	 	65	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    




(c)               
A breach of a financial covenant contained in this Section 6.1 shall be deemed to have occurred
as of the last day of the applicable Defined Period, regardless of when the financial statements reflecting such breach are delivered
to Agent. 


Section
6.2              
Minimum Liquidity. Borrowers will not permit Borrower Unrestricted Cash at any time
during the term of this Agreement to be less than $50,000,000.


Section 6.3          Evidence
of Compliance. Borrowers shall furnish to Agent, as required by Section 4.1, a Compliance Certificate
as evidence (x) of the monthly cash and Cash Equivalents of Borrowers and Borrowers and their Consolidated Subsidiaries, (y) of
Borrowers’ compliance with the covenants in this Article, and (z) that no Event of Default specified in this Article has
occurred. The Compliance Certificate shall include, without limitation, (a) a statement and report, in form and substance
reasonably satisfactory to Agent, detailing Borrowers’ calculations, and (b) to the extent reasonably requested by Agent,
back-up documentation (including, without limitation, bank statements, invoices, receipts and other evidence of costs incurred
during such quarter as Agent shall reasonably require) evidencing the propriety of the calculations.


Article 7
- CONDITIONS


Section 7.1          Conditions
to Closing. The obligation of each Lender to enter into this Agreement on the Closing Date
shall be subject to the receipt by Agent of each agreement, document and instrument set forth on the closing checklist attached
hereto as Exhibit E, each in form and substance reasonably satisfactory to Agent, and such other closing deliverables reasonably
requested by Agent and Lenders, and to the satisfaction of the following conditions precedent, each to the satisfaction of Agent
and Lenders in their sole discretion:


(a)               
the receipt by Agent of executed counterparts of this Agreement and
the other Financing Documents;


(b)               
the payment of all fees, expenses and other amounts due and payable under each Financing Document;



(c)               
the fact that the representations and warranties of each Credit Party contained in the Financing
Documents shall be true, correct and complete on and as of the Closing Date, except to the extent that any such representation
or warranty relates to a specific date in which case such representation or warranty shall be true and correct as of such earlier
date; and 


(d)               
since December 31, 2017, the absence of any material adverse change in any aspect of the business,
operations, properties, prospects or condition (financial or otherwise) of any Credit Party, or any event or condition which could
reasonably be expected to result in a Material Adverse Effect.


Each Lender, by delivering
its signature page to this Agreement, shall be deemed to have acknowledged receipt of, and consented to and approved, each
Financing Document, each additional Operative Document and each other document, agreement and/or instrument required to be approved
by Agent, Required Lenders or Lenders, as applicable, on the Closing Date.






    	 	66	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


Section 7.2          Conditions
to Each Loan. The obligation of the Lenders to make a Loan or an advance in respect of any
Loan, is subject to the satisfaction of the following additional conditions:


(a)               
the fact that, immediately before and after such advance or issuance, no Default or Event
of Default shall have occurred and be continuing;


(b)                
the fact that the representations and warranties of each Credit Party contained in the Financing
Documents shall be true, correct and complete in all material respects on and as of the date of such borrowing, except to the extent
that any such representation or warranty relates to a specific date in which case such representation or warranty shall be true
and correct in all material respects as of such earlier date; provided, however, in each case, such materiality qualifier shall
not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof;


(c)               
 the fact that no material adverse change in the condition (financial or otherwise), properties,
business, or operations of Borrowers or any other Credit Party shall have occurred and be continuing with respect to Borrowers
or any Credit Party since the date of this Agreement; 


(d)               
in the case of each borrowing of the Term Loan Tranche 1, Term Loan Tranche 2 or Term Loan
Tranche 3, Agent has received a duly executed Notice of Borrowing in accordance with the provisions of Section 2.1(a)(ii); 


(e)                
in the case of a borrowing of the Term Loan Tranche 1, the Term Loan Tranche 1 Activation
Date shall have occurred;


(f)                
in the case of a borrowing of the Term Loan Tranche 1, receipt by Agent of each agreement,
document and instrument set forth on Schedule 7.2 hereto, each in form and substance reasonably satisfactory to Agent, and
the satisfaction of each other condition set forth on Schedule 7.2 to the reasonable satisfaction of Agent;


(g)               
in the case of a borrowing of the Term Loan Tranche 2, (i) the Term Loan Tranche 1 Funding
Date shall have occurred and (ii) the Term Loan Tranche 2 Activation Date shall have occurred; and


(h)                
in the case of any borrowing of the Term Loan Tranche 3, (i) each of the Term Loan Tranche
1 Funding Date and the Term Loan Tranche 2 Funding Date shall have occurred and (ii) the Term Loan Tranche 3 Activation Date shall
have occurred. 


Each giving of a
Notice of Borrowing hereunder and each acceptance by any Borrower of the proceeds of any Loan made hereunder shall be deemed to
be a representation and warranty by each Borrower on the date of such notice or acceptance as to the facts specified in this Section.


Section 7.3           Searches.
Before the Closing Date, and thereafter (as and when determined by Agent in its discretion), Agent shall have the right
to perform, all at Borrowers’ expense, the searches described in clauses (a), (b), and (c) below against Borrowers and any
other Credit Party, the results of which are to be consistent with Borrowers’ representations and warranties under this Agreement
and the satisfactory results of which shall be a condition precedent to all advances of Loan proceeds: (a) UCC searches with
the Secretary of State of the jurisdiction in which the applicable Person is organized; (b) judgment, pending litigation,
federal tax lien, personal property tax lien, and corporate and partnership tax lien searches, in each jurisdiction searched under
clause (a) above; and (c) searches of applicable corporate, limited liability company, partnership and related records to
confirm the continued existence, organization and good standing of the applicable Person and the exact legal name under which such
Person is organized.






    	 	67	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


Section 7.4          Post-Closing
Requirements. Borrowers shall complete each of the post-closing obligations and/or provide
to Agent each of the documents, instruments, agreements and information listed on Schedule 7.4 attached hereto on or
before the date set forth for each such item thereon, each of which shall be completed or provided in form and substance reasonably
satisfactory to Agent.


Article 8
- REserved


Article 9
- SECURITY AGREEMENT


Section 9.1          Generally.
As security for the payment and performance of the Obligations, and without limiting any other grant of a Lien and security
interest in any Security Document, Borrowers hereby assign and grant to Agent, for the benefit of itself and Lenders a continuing
first priority Lien on and security interest in, upon, and to the personal property set forth on Schedule 9.1 attached
hereto and made a part hereof.


Section
9.2              
Representations and Warranties and Covenants Relating to Collateral.


(a)               
The security interest granted pursuant to this Agreement constitutes a valid and, to the extent
such security interest is required to be perfected by this Agreement and any other Financing Document, continuing perfected security
interest in favor of Agent in all Collateral subject, for the following Collateral, to the occurrence of the following: (i) in
the case of all Collateral in which a security interest may be perfected by filing a financing statement under the UCC, the completion
of the filings and other actions specified on Schedule 9.2(b) (which, in the case of all filings and other documents referred
to on such schedule, have been delivered to Agent in completed and duly authorized form), (ii) with respect to any Deposit Account,
the execution of Deposit Account Control Agreements, (iii) in the case of letter-of-credit rights that are not supporting obligations
of Collateral, the execution of a contractual obligation granting control to Agent over such letter-of-credit rights, (iv) in the
case of electronic chattel paper, the completion of all steps necessary to grant control to Agent over such electronic chattel
paper, (v) in the case of all certificated stock, debt instruments and investment property, the delivery thereof to Agent of such
certificated stock, debt instruments and investment property consisting of instruments and certificates, in each case properly
endorsed for transfer to Agent or in blank, (vi) in the case of all investment property not in certificated form, the execution
of control agreements with respect to such investment property and (vii) in the case of all other instruments and tangible chattel
paper that are not certificated stock, debt instructions or investment property, the delivery thereof to Agent of such instruments
and tangible chattel paper. Such security interest shall be prior to all other Liens on the Collateral except for Permitted Liens.






    	 	68	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    




(b)               
Schedule 9.2(b) sets forth (i) each chief executive office and principal
place of business of each Borrower and each of their respective Subsidiaries, and (ii) all of the addresses (including all
warehouses) at which any of the Collateral with a value in excess of $500,000 in the aggregate is located and/or books and records
of Borrowers regarding any Collateral or any of Borrower’s assets, liabilities, business operations or financial condition
are kept, which such Schedule 9.2(b) indicates in each case which Borrower(s) have Collateral and/or books located
at such address, and, in the case of any such address not owned by one or more of the Borrowers(s), indicates the nature of such
location (e.g., leased business location operated by Borrower(s), third party warehouse, consignment location, processor location,
etc.) and the name and address of the third party owning and/or operating such location.


(c)               
Without limiting the generality of Section 3.19, except as indicated on Schedule 3.19
with respect to any rights of any Borrower as a licensee under any material license of Intellectual Property owned by another Person,
and except for the filing of financing statements under the UCC, no authorization, approval or other action by, and no notice to
or filing with, any Governmental Authority or consent of any other Person is required for (i) the grant by each Borrower to
Agent of the security interests and Liens in the Collateral provided for under this Agreement and the other Security Documents
(if any), or (ii) the exercise by Agent of its rights and remedies with respect to the Collateral provided for under this
Agreement and the other Security Documents or under any applicable Law, including the UCC and neither any such grant of Liens in
favor of Agent or exercise of rights by Agent shall violate or cause a material default under any agreement between any Borrower
and any other Person relating to any such collateral, including any material license to which a Borrower is a party, whether as
licensor or licensee, with respect to any Intellectual Property, whether owned by such Borrower or any other Person.


(d)               
As of the Closing Date, except as set forth on Schedule 9.2(d), no Borrower has any
ownership interest in any Chattel Paper (as defined in Article 9 of the UCC), letter of credit rights, commercial tort claims,
Instruments, documents or investment property (other than Equity Interests in any Subsidiaries of such Borrower disclosed on Schedule 3.4)
in each case with a value in excess of $500,000 in the aggregate, and Borrowers shall give notice to Agent promptly (but in any
event not later than the delivery by Borrowers of the next Compliance Certificate required pursuant to Section 4.1 with respect
to the last month of a fiscal quarter) upon the acquisition by any Borrower of any such Chattel Paper, letter of credit rights,
commercial tort claims, Instruments, documents, investment property in each case with a value in excess of $500,000 in the aggregate.
No Person other than Agent or (if applicable) any Lender has “control” (as defined in Article 9 of the UCC) over
any Deposit Account, investment property (including Securities Accounts and commodities account), letter of credit rights or electronic
chattel paper with a value in excess of $500,000 in the aggregate in which any Borrower has any interest (except for such control
arising by operation of law in favor of any bank or securities intermediary or commodities intermediary with whom any Deposit Account,
Securities Account or commodities account of Borrowers is maintained).


(e)               
Borrowers shall not, and shall not permit any Credit Party to, take any of the following actions
or make any of the following changes unless Borrowers have given at least thirty (30) days prior written notice to Agent of Borrowers’
intention to take any such action (which such written notice shall include an updated version of any Schedule impacted by
such change) and have executed any and all documents, instruments and agreements and taken any other actions related to such notice
that Agent may reasonably request after receiving such written notice in order to protect and preserve the Liens, rights and remedies
of Agent with respect to the Collateral: (i) change the legal name or organizational identification number of any Borrower
as it appears in official filings with the Secretary of State or other applicable governing body in the jurisdiction of its organization,
(ii) change the jurisdiction of incorporation or formation of any Borrower or Credit Party or allow any Borrower or Credit
Party to designate any jurisdiction as an additional jurisdiction of incorporation for such Borrower or Credit Party, or change
the type of entity that it is, or (iii) change its chief executive office, principal place of business, or the location of
its books and records (other than electronic duplications thereof) or move any Collateral (other than Inventory in-transit) with
a value in excess of $500,000 in the aggregate to or place any such Collateral on any location that is not then listed on the Schedules
and/or establish any business location at any location that is not then listed on the Schedules.






    	 	69	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


(f)                
At any time after the occurrence and during the continuance of an Event of Default, Borrowers
shall not adjust, settle or compromise the amount or payment of any Account, or release wholly or partly any Account Debtor, or
allow any credit or discount thereon (other than adjustments, settlements, compromises, credits and discounts in the Ordinary Course
of Business) without the prior written consent of Agent. Without limiting the generality of this Agreement or any other provisions
of any of the Financing Documents relating to the rights of Agent after the occurrence and during the continuance of an Event of
Default, Agent shall have the right at any time after the occurrence and during the continuance of an Event of Default to: (i) exercise
the rights of Borrowers with respect to the obligation of any Account Debtor to make payment or otherwise render performance to
Borrowers and with respect to any property that secures the obligations of any Account Debtor or any other Person obligated on
the Collateral, and (ii) adjust, settle or compromise the amount or payment of such Accounts.


(g)               
Without limiting the generality of Sections 9.2(c) and 9.2(e):


(i)                
Borrowers shall deliver to Agent all tangible Chattel Paper and all Instruments and documents
with a value in excess of $500,000 in the aggregate owned by any Borrower and constituting part of the Collateral duly endorsed
and accompanied by duly executed instruments of transfer or assignment, all in form and substance reasonably satisfactory to Agent.
Borrowers shall provide Agent with “control” (as defined in Article 9 of the UCC) of all electronic Chattel Paper
owned by any Borrower and constituting part of the Collateral by having Agent identified as the assignee on the records pertaining
to the single authoritative copy thereof and otherwise complying with the applicable elements of control set forth in the UCC.
Borrowers also shall deliver to Agent all security agreements securing any such Chattel Paper and securing any such Instruments.
Borrowers will mark conspicuously all such Chattel Paper and all such Instruments and documents with a legend, in form and substance
reasonably satisfactory to Agent, indicating that such Chattel Paper and such instruments and documents are subject to the security
interests and Liens in favor of Agent created pursuant to this Agreement and the Security Documents. Borrowers shall comply with
all the provisions of Section 5.14 with respect to the Deposit Accounts and Securities Accounts of Borrowers.


(ii)              
Borrowers shall deliver to Agent all letters of credit with a value in excess of $500,000
in the aggregate on which any Borrower is the beneficiary and which give rise to letter of credit rights owned by such Borrower
which constitute part of the Collateral in each case duly endorsed and accompanied by duly executed instruments of transfer or
assignment, all in form and substance reasonably satisfactory to Agent. Borrowers shall take any and all actions as may be necessary
or desirable, or that Agent may request, from time to time, to cause Agent to obtain exclusive “control” (as defined
in Article 9 of the UCC) of any such letter of credit rights in a manner reasonably acceptable to Agent.


(iii)            
Borrowers shall promptly advise Agent upon any Borrower becoming aware that it has any interests
in any filed actions in connection with commercial tort claims with a value in excess of $500,000 in the aggregate that constitute
part of the Collateral, which such notice shall include descriptions of the events and circumstances giving rise to such commercial
tort claim and the dates such events and circumstances occurred, the potential defendants with respect such commercial tort claim
and any court proceedings that have been instituted with respect to such commercial tort claims, and Borrowers shall, with respect
to any such commercial tort claim, execute and deliver to Agent such documents as Agent shall reasonably request to perfect, preserve
or protect the Liens, rights and remedies of Agent with respect to any such commercial tort claim.






    	 	70	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


(iv)             
Borrowers shall, on or prior to the Term Loan Tranche 1 Funding Date, for each leased location
where (A) any Collateral is stored or located and (B) any Collateral in the possession or control of any warehouse, consignee,
bailee or any of Borrowers’ agents or processors (except any such location where neither material books and records nor Collateral
with a value in excess of $500,000 in the aggregate is stored or located), obtain a warehouse receipt, consignment agreement, landlord
waiver, mortgagee agreement or bailee waiver (as applicable), which agreement shall be satisfactory in form and substance to Agent
prior to the commencement of such lease or of such possession or control (as applicable). Borrower has notified Agent that Collateral
and books and records are currently located at the locations set forth on Schedule 9.2(b) and Borrowers shall give
notice to Agent promptly (but in any event not later than the delivery by Borrowers of the next Compliance Certificate required
pursuant to Section 4.1 with respect to the last month of a fiscal quarter) of any new business location (except any such
location where neither material books and records nor Collateral with a value in excess of $500,000 in the aggregate is stored
or located). 


(v)               
Borrowers shall cause all equipment and other tangible personal property constituting Collateral
other than Inventory to be maintained and preserved in the same condition, repair and in working order as when new or in the condition
acquired by the Borrowers, ordinary wear and tear excepted, and shall in the Ordinary Course of Business promptly make or cause
to be made all repairs, replacements and other improvements in connection therewith that are necessary or desirable to such end.
Upon request of Agent, Borrowers shall promptly deliver to Agent any and all issued certificates of title, applications for title
or similar evidence of ownership of all such tangible personal property with a value in excess of $500,000 in the aggregate and
shall, upon Agent’s request, cause Agent to be named as lienholder on any such certificate of title or other evidence of
ownership. Borrowers shall not permit any such tangible personal property to become fixtures to real estate unless such real estate
is subject to a Lien in favor of Agent.


(vi)             
Each Borrower hereby authorizes Agent to file without the signature of such Borrower one or
more UCC financing statements relating to liens on personal property relating to all or any part of the Collateral, which financing
statements may list Agent as the “secured party” and such Borrower as the “debtor” and which describe and
indicate the collateral covered thereby as all or any part of the Collateral under the Financing Documents (including an indication
of the collateral covered by any such financing statement as “all assets” of such Borrower now owned or hereafter acquired),
in such jurisdictions as Agent from time to time determines in its commercially reasonable discretion are appropriate, and to file
without the signature of such Borrower any continuations of or corrective amendments to any such financing statements, in any such
case in order for Agent to perfect, preserve or protect the Liens, rights and remedies of Agent with respect to the Collateral.
Each Borrower also ratifies its authorization for Agent to have filed in any jurisdiction any initial financing statements or amendments
thereto if filed prior to the date hereof.






    	 	71	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    




(vii)           
As of the Closing Date, no Borrower holds, and after the Closing Date Borrowers shall promptly
notify Agent in writing upon any Borrower obtaining knowledge of the creation or acquisition by any Borrower of, any Collateral
which constitutes a claim in excess of $500,000 in the aggregate against any Governmental Authority, including, without limitation,
the federal government of the United States or any instrumentality or agency thereof, the assignment of which claim is restricted
by any applicable Law, including, without limitation, the federal Assignment of Claims Act and any other comparable Law. Upon the
request of Agent, Borrowers shall take such steps as may be necessary, or that Agent may request, to comply with any such applicable
Law.


(viii)         
Borrowers shall furnish to Agent from time to time any statements and schedules further identifying
or describing the Collateral and any other material information, reports or evidence concerning the Collateral as Agent may reasonably
request from time to time. 


Article 10
- EVENTS OF DEFAULT


Section 10.1        Events
of Default. For purposes of the Financing Documents, the occurrence of any of the following
conditions and/or events, whether voluntary or involuntary, by operation of law or otherwise, shall constitute an “Event
of Default”:


(a)               
(i) any Credit Party shall fail to pay when due any principal, interest, premium or fee under
any Financing Document or any other amount payable under any Financing Document, (ii) there shall occur any default in the
performance of or compliance with any of the following sections of this Agreement: Section 4.1
(except Sections 4.1(a) (c) and (h)), Section 4.2(b), Section 4.4(c), Section 4.6,
Section 4.14 (except for Sections 4.14 (a) and (b)), Article
5, Article 6 or Section 7.4, or (iii) there shall occur any default in the performance of or compliance with any of the following
sections of this Agreement: Sections 4.1(a) (c) and (h), or Sections 4.14 (a) and (b) and such default continues for three
(3) Business Days after the earlier of (i) receipt by Borrower Representative of notice from Agent or Required Lenders of
such default, or (ii) actual knowledge of a Responsible Officer of any Borrower or any other Credit Party of such default;


(b)               
any Credit Party defaults in the performance of or compliance with any term contained in this
Agreement or in any other Financing Document (other than occurrences described in other provisions of this Section 10.1 for
which a different grace or cure period is specified or for which no grace or cure period is specified and thereby constitute immediate
Events of Default) and such default is not remedied by the Credit Party or waived by Agent within thirty (30) days after the earlier
of (i) receipt by Borrower Representative of notice from Agent or Required Lenders of such default, or (ii) actual knowledge
of a Responsible Officer of any Borrower or any other Credit Party of such default;


(c)               
any representation, warranty, certification or statement made by any Credit Party or any other
Person in any Financing Document or in any certificate, financial statement or other document delivered pursuant to any Financing
Document is incorrect in any respect (or in any material respect if such representation, warranty, certification or statement is
not by its terms already qualified as to materiality) when made (or deemed made);


(d)               
(i) failure of any Credit Party to pay when due or within any applicable grace period
any principal, interest or other amount on Debt (other than the Loans), or the occurrence of any breach, default, condition or
event with respect to any Debt (other than the Loans), if the effect of such failure or occurrence is to cause or to permit the
holder or holders of any such Debt, or to cause, Debt or other liabilities having an individual principal amount in excess of $3,000,000
or having an aggregate principal amount in excess of $3,000,000 to become or be declared due prior to its stated maturity, or (ii) the
occurrence of any breach or default under any terms or provisions of any Subordinated Debt Document or under any agreement subordinating
the Subordinated Debt to all or any portion of the Obligations or the occurrence of any event requiring the prepayment of any Subordinated
Debt;






    	 	72	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


(e)               
any Credit Party or any Subsidiary of a Borrower shall commence a voluntary case or other
proceeding seeking liquidation, reorganization or other relief with respect to itself or its debts under any bankruptcy, insolvency
or other similar law now or hereafter in effect or seeking the appointment of a trustee, receiver, liquidator, custodian or other
similar official of it or any substantial part of its property, or shall consent to any such relief or to the appointment of or
taking possession by any such official in an involuntary case or other proceeding commenced against it, or shall make a general
assignment for the benefit of creditors, or shall fail generally to pay its debts as they become due, or shall take any corporate
action to authorize any of the foregoing;


(f)                
an involuntary case or other proceeding shall be commenced against any Credit Party or any
Subsidiary of a Borrower seeking liquidation, reorganization or other relief with respect to it or its debts under any bankruptcy,
insolvency or other similar law now or hereafter in effect or seeking the appointment of a trustee, receiver, liquidator, custodian
or other similar official of it or any substantial part of its property, and such involuntary case or other proceeding shall remain
undismissed and unstayed for a period of sixty (60) days; or an order for relief shall be entered against any Credit Party or any
Subsidiary of a Borrower under applicable federal bankruptcy, insolvency or other similar law in respect of (i) bankruptcy,
liquidation, winding-up, dissolution or suspension of general operations, (ii) composition, rescheduling, reorganization,
arrangement or readjustment of, or other relief from, or stay of proceedings to enforce, some or all of the debts or obligations,
or (iii) possession, foreclosure, seizure or retention, sale or other disposition of, or other proceedings to enforce security
over, all or any substantial part of the assets of such Credit Party or Subsidiary;


(g)               
(i) institution of any steps by any Person to terminate a Pension Plan if as a result
of such termination any Credit Party or any member of the Controlled Group could be required to make a contribution to such Pension
Plan, or could incur a liability or obligation to such Pension Plan, in excess of $1,000,000, (ii) a contribution failure
occurs with respect to any Pension Plan sufficient to give rise to a Lien under Section 303(k) of ERISA or Section 430(k)
of the Code or an event occurs that could reasonably be expected to give rise to a Lien under Section 4068 of ERISA, or (iii) there
shall occur any withdrawal or partial withdrawal from a Multiemployer Pension Plan and the withdrawal liability (without unaccrued
interest) to Multiemployer Pension Plans as a result of such withdrawal (including any outstanding withdrawal liability that any
Credit Party or any member of the Controlled Group have incurred on the date of such withdrawal) exceeds $1,000,000; 


(h)               
one or more judgments or orders for the payment of money (not paid or fully covered by insurance
maintained in accordance with the requirements of this Agreement and as to which the relevant insurance company has acknowledged
coverage) aggregating in excess of $1,000,000 shall be rendered against any or all Credit Parties and either (i) enforcement
proceedings shall have been commenced by any creditor upon any such judgments or orders, or (ii) there shall be any period
of twenty (20) consecutive days during which a stay of enforcement of any such judgments or orders, by reason of a pending appeal,
bond or otherwise, shall not be in effect;


(i)                
any Lien created by any of the Security Documents shall at any time fail to constitute a valid
and perfected Lien on all of the Collateral purported to be encumbered thereby (other than solely as a result of any action or
inaction of Agent or Lenders provided that such action or inaction is not caused by a Credit Party’s failure to comply with
the terms of the Financing Documents), subject to no prior or equal Lien except Permitted Liens, or any Credit Party shall so assert;






    	 	73	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


(j)                
the institution by any Governmental Authority of criminal proceedings against any Credit Party
that could reasonably be expected to result in a fine, penalty or other liabilities in excess of $500,000;


(k)               
a default or event of default occurs under any Guarantee of any portion of the Obligations;



(l)                
[reserved];


(m)             
TherapeuticsMD’s equity securities fail to remain registered with the SEC and listed
for trading on the Nasdaq Stock Market; 


(n)               
the occurrence of any fact, event or circumstance that could reasonably be expected to result
in a Material Adverse Effect; 


(o)               
 (i) the voluntary withdrawal or institution of any action or proceeding by the FDA or similar
Governmental Authority to order the withdrawal of any material Product (including TX-001HR and TX-004HR) or Product class or category
from the market or to enjoin Borrower, its Subsidiaries or any representative of Borrower or its Subsidiaries from manufacturing,
marketing, selling or distributing any Product or Product class or category, (ii) the institution of any action or proceeding by
FDA or any other Governmental Authority to revoke, suspend, reject, withdraw, limit, or restrict any Regulatory Required Permit
held by Borrower, its Subsidiaries or any representative of Borrower or its Subsidiaries which, in each case, has or could reasonably
be expected to result in a Material Adverse Effect, (iii) the commencement of any enforcement action against Borrower, its Subsidiaries
or any representative of Borrower or its Subsidiaries (with respect to the business of Borrower or its Subsidiaries), or any of
its Products or manufacturing facilities for the Products by FDA or any other Governmental Authority which has or could reasonably
be expected to result in a Material Adverse Effect, or (iv) the occurrence of adverse events or adverse drug reactions in connection
with a Product which has or could reasonably be expected to result in a Material Adverse Effect;


(p)               
(i) any Credit Party materially defaults under or materially breaches (after any applicable
grace period contained therein) any Material Contract the termination of which could reasonably be expected to result in a Material
Adverse Effect and such default or breach is not effectively and permanently waived by the applicable counterparties to such Material
Contract within ten (10) Business Days of a Responsible Officer of Borrower becoming aware of such default or breach, or (ii) such
a Material Contract is terminated by a third party or parties party thereto prior to the expiration thereof and, in each case of
termination, a substitute agreement of substantially the same or greater value to the Credit Parties is not established promptly
(but in any event with ten (10) Business Days) thereafter by such Credit Party;


(q)               
any of the Operative Documents shall for any reason fail to constitute the valid and binding
agreement of any party thereto, or any Credit Party shall so assert, in each case, unless such Operative Document terminates pursuant
to the terms and conditions thereof without any breach or default thereunder by any Credit Party thereto; or






    	 	74	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


(r)                
the occurrence of a Change in Control.


All cure periods
provided for in this Section 10.1 shall run concurrently with any cure period provided for in any applicable Financing Documents
under which the default occurred.


Section 10.2        Acceleration
and Suspension or Termination of Term Loan Commitment. Upon the occurrence and during the continuance
of an Event of Default, Agent may, and shall if requested by Required Lenders, (a) by notice to Borrower Representative suspend
or terminate the Term Loan Commitment and the obligations of Agent and the Lenders with respect thereto, in whole or in part (and,
if in part, each Lender’s Term Loan Commitment shall be reduced in accordance with its Pro Rata Share), and/or (b) by
notice to Borrower Representative declare all or any portion of the Obligations to be, and the Obligations shall thereupon become,
immediately due and payable, with accrued interest thereon, without presentment, demand, protest or other notice of any kind, all
of which are hereby waived by each Borrower and Borrowers will pay the same; provided, however, that in the case
of the occurrence and continuance of either of the Events of Default specified in Section 10.1(e) or 10.1(f) above, without
any notice to any Borrower or any other act by Agent or the Lenders, the Term Loan Commitment and the obligations of Agent and
the Lenders with respect thereto shall thereupon immediately and automatically terminate and all of the Obligations shall become
immediately and automatically due and payable without presentment, demand, protest or other notice of any kind, all of which are
hereby waived by each Borrower and Borrowers will pay the same.


Section
10.3           
UCC Remedies.


(a)               
Upon the occurrence of and during the continuance of an Event of Default under this Agreement
or the other Financing Documents, Agent, in addition to all other rights, options, and remedies granted to Agent under this Agreement
or at law or in equity, may exercise, either directly or through one or more assignees or designees, all rights and remedies granted
to it under all Financing Documents and under the UCC in effect in the applicable jurisdiction(s) and under any other applicable
law; including, without limitation:


(i)                
the right to take possession of, send notices regarding, and collect directly the Collateral,
with or without judicial process;


(ii)              
the right to (by its own means or with judicial assistance) enter any of Borrowers’
premises and take possession of the Collateral, or to render it usable or saleable, or dispose of the Collateral on such premises
in compliance with subsection (iii) below and to take possession of Borrowers’ original books and records, to obtain access
to Borrowers’ data processing equipment, computer hardware and software relating to the Collateral and to use all of the
foregoing and the information contained therein in any manner Agent deems appropriate, without any liability for rent, storage,
utilities, or other sums, and Borrowers shall not resist or interfere with such action (if Borrowers’ books and records are
prepared or maintained by an accounting service, contractor or other third party agent, Borrowers hereby irrevocably authorize
such service, contractor or other agent, upon notice by Agent to such Person that an Event of Default has occurred and is continuing,
to deliver to Agent or its designees such books and records, and to follow Agent’s instructions with respect to further services
to be rendered);


(iii)            
the right to require Borrowers at Borrowers’ expense to assemble all or any part of
the Collateral and make it available to Agent at any place designated by Lender;






    	 	75	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


(iv)             
the right to notify postal authorities to change the address for delivery of Borrowers’
mail to an address designated by Agent and to receive, open and dispose of all mail addressed to any Borrower; and/or


(v)               
the right to enforce Borrowers’ rights against Account Debtors and other obligors, including,
without limitation, (i) the right to collect Accounts directly in Agent’s own name (as agent for Lenders) and to charge
the collection costs and expenses, including attorneys’ fees, to Borrowers, and (ii) the right, in the name of Agent
or any designee of Agent or Borrowers, to verify the validity, amount or any other matter relating to any Accounts by mail, telephone,
telegraph or otherwise, including, without limitation, verification of Borrowers’ compliance with applicable Laws. Borrowers
shall cooperate fully with Agent in an effort to facilitate and promptly conclude such verification process. Such verification
may include contacts between Agent and applicable federal, state and local regulatory authorities having jurisdiction over the
Borrowers’ affairs, all of which contacts Borrowers hereby irrevocably authorize.


(b)               
Each Borrower agrees that a notice received by it at least ten (10) days before the time of
any intended public sale, or the time after which any private sale or other disposition of the Collateral is to be made, shall
be deemed to be reasonable notice of such sale or other disposition. If permitted by applicable law, any perishable Collateral
which threatens to speedily decline in value or which is sold on a recognized market may be sold immediately by Agent without prior
notice to Borrowers. At any sale or disposition of Collateral, Agent may (to the extent permitted by applicable law) purchase all
or any part of the Collateral, free from any right of redemption by Borrowers, which right is hereby waived and released. Each
Borrower covenants and agrees not to interfere with or impose any obstacle to Agent’s exercise of its rights and remedies
with respect to the Collateral. Agent shall have no obligation to prepare the Collateral for sale. Agent may comply with any applicable
state or federal law requirements in connection with a disposition of the Collateral and compliance will not be considered to adversely
affect the commercial reasonableness of any sale of the Collateral. Agent may sell the Collateral without giving any warranties
as to the Collateral. Agent may specifically disclaim any warranties of title or the like. This procedure will not be considered
to adversely affect the commercial reasonableness of any sale of the Collateral. In the event the purchaser fails to pay for the
Collateral, Agent may resell the Collateral and Borrowers shall be credited with the proceeds of the sale. Borrowers shall remain
liable for any deficiency if the proceeds of any sale or disposition of the Collateral are insufficient to pay all Obligations.


(c)               
Without restricting the generality of the foregoing and for the purposes aforesaid, each Borrower
hereby appoints and constitutes Agent its lawful attorney-in-fact with full power of substitution in the Collateral, upon the occurrence
and during the continuance of an Event of Default, to (i) use unadvanced funds remaining under this Agreement or which may be reserved,
escrowed or set aside for any purposes hereunder at any time, or to advance funds in excess of the face amount of the Notes, (ii)
pay, settle or compromise all existing bills and claims, which may be Liens or security interests, or to avoid such bills and claims
becoming Liens against the Collateral, (iii) execute all applications and certificates in the name of such Borrower and to prosecute
and defend all actions or proceedings in connection with the Collateral, and (iv) do any and every act which such Borrower might
do in its own behalf; it being understood and agreed that this power of attorney in this subsection (c) shall be a power coupled
with an interest and cannot be revoked.


(d)               
In connection with Agent’s exercise of its rights under this Article or any Financing
Document, Agent and each Lender is hereby granted a non-exclusive, royalty-free license or other right to use, without charge,
Borrowers’ labels, mask works, rights of use of any name, any other Intellectual Property and advertising matter, and any
similar property as it pertains to the Collateral, in completing production of, advertising for sale, and selling any Collateral
and, in connection with Agent’s exercise of its rights under this Article, Borrowers’ rights under all licenses (whether
as licensor or licensee) and all franchise agreements inure to Agent’s and each Lender’s benefit.






    	 	76	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    




Section
10.4            
Reserved.


Section 10.5        Default
Rate of Interest. At the election of Agent or Required Lenders, after the occurrence of an
Event of Default and for so long as it continues, the Loans and other Obligations shall bear interest at rates that are three percent
(3.0%) per annum in excess of the rates otherwise payable under this Agreement; provided, however, that in the case of any
Event of Default specified in Section 10.1(e) or 10.1(f) above, such default rates shall apply immediately and automatically
without the need for any election or action of any kind on the part of Agent or any Lender.


Section 10.6        Setoff
Rights. During the continuance of any Event of Default, each Lender is hereby authorized by
each Borrower at any time or from time to time, with reasonably prompt subsequent notice to such Borrower (any prior or contemporaneous
notice being hereby expressly waived) to set off and to appropriate and to apply any and all (a) balances held by such Lender
or any of such Lender’s Affiliates at any of its offices for the account of such Borrower or any of its Subsidiaries (regardless
of whether such balances are then due to such Borrower or its Subsidiaries), and (b) other property at any time held or owing
by such Lender to or for the credit or for the account of such Borrower or any of its Subsidiaries, against and on account of any
of the Obligations; except that no Lender shall exercise any such right without the prior written consent of Agent. Any Lender
exercising a right to set off shall purchase for cash (and the other Lenders shall sell) interests in each of such other Lender’s
Pro Rata Share of the Obligations as would be necessary to cause all Lenders to share the amount so set off with each other Lender
in accordance with their respective Pro Rata Share of the Obligations. Each Borrower agrees, to the fullest extent permitted by
law, that any Lender and any of such Lender’s Affiliates may exercise its right to set off with respect to the Obligations
as provided in this Section 10.6.


Section
10.7           
Application of Proceeds.


(a)               
Notwithstanding anything to the contrary contained in this Agreement, upon the occurrence
and during the continuance of an Event of Default, each Borrower irrevocably waives the right to direct the application of any
and all payments at any time or times thereafter received by Agent from or on behalf of such Borrower or any Guarantor of all or
any part of the Obligations, and, as between Borrowers on the one hand and Agent and Lenders on the other, Agent shall have the
continuing and exclusive right to apply and to reapply any and all payments received against the Obligations in such manner as
Agent may deem advisable notwithstanding any previous application by Agent.


(b)               
Following the occurrence and continuance of an Event of Default, but absent the occurrence
and continuance of an Acceleration Event, Agent shall apply any and all payments received by Agent in respect of the Obligations,
and any and all proceeds of Collateral received by Agent, in such order as Agent may from time to time elect.






    	 	77	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


(c)               
Notwithstanding anything to the contrary contained in this Agreement, if an Acceleration Event
shall have occurred, and so long as it continues, Agent shall promptly apply any and all payments received by Agent in respect
of the Obligations, and any and all proceeds of Collateral received by Agent, in the following order: first, to all fees,
costs, indemnities, liabilities, obligations and expenses incurred by or owing to Agent with respect to this Agreement, the other
Financing Documents or the Collateral; second, to all fees, costs, indemnities, liabilities, obligations and expenses incurred
by or owing to any Lender with respect to this Agreement, the other Financing Documents or the Collateral; third, to accrued
and unpaid interest on the Obligations (including any interest which, but for the provisions of the Bankruptcy Code, would have
accrued on such amounts); fourth, to the principal amount of the Obligations outstanding; and fifth to any other
indebtedness or obligations of Borrowers owing to Agent or any Lender under the Financing Documents. Any balance remaining shall
be delivered to Borrowers or to whomever may be lawfully entitled to receive such balance or as a court of competent jurisdiction
may direct. In carrying out the foregoing, (y) amounts received shall be applied in the numerical order provided until exhausted
prior to the application to the next succeeding category, and (z) each of the Persons entitled to receive a payment in any
particular category shall receive an amount equal to its Pro Rata Share of amounts available to be applied pursuant thereto for
such category.


Section
10.8           
Waivers.


(a)               
Except as otherwise provided for in this Agreement and to the fullest extent permitted by
applicable law, each Borrower waives: (i) presentment, demand and protest, and notice of presentment, dishonor, intent to
accelerate, acceleration, protest, default, nonpayment, maturity, release, compromise, settlement, extension or renewal of any
or all Financing Documents, the Notes or any other notes, commercial paper, accounts, contracts, documents, Instruments, Chattel
Paper and Guarantees at any time held by Lenders on which any Borrower may in any way be liable, and hereby ratifies and confirms
whatever Lenders may do in this regard; (ii) all rights to notice and a hearing prior to Agent’s or any Lender’s
taking possession or control of, or to Agent’s or any Lender’s replevy, attachment or levy upon, any Collateral or
any bond or security which might be required by any court prior to allowing Agent or any Lender to exercise any of its remedies;
and (iii) the benefit of all valuation, appraisal and exemption Laws. Each Borrower acknowledges that it has been advised
by counsel of its choices and decisions with respect to this Agreement, the other Financing Documents and the transactions evidenced
hereby and thereby.


(b)               
Each Borrower for itself and all its successors and assigns, (i) agrees that its liability
shall not be in any manner affected by any indulgence, extension of time, renewal, waiver, or modification granted or consented
to by Lender; (ii) consents to any indulgences and all extensions of time, renewals, waivers, or modifications that may be
granted by Agent or any Lender with respect to the payment or other provisions of the Financing Documents, and to any substitution,
exchange or release of the Collateral, or any part thereof, with or without substitution, and agrees to the addition or release
of any Borrower, endorsers, guarantors, or sureties, or whether primarily or secondarily liable, without notice to any other Borrower
and without affecting its liability hereunder; (iii) agrees that its liability shall be unconditional and without regard to
the liability of any other Borrower, Agent or any Lender for any tax on the indebtedness; and (iv) to the fullest extent permitted
by law, expressly waives the benefit of any statute or rule of law or equity now provided, or which may hereafter be provided,
which would produce a result contrary to or in conflict with the foregoing.






    	 	78	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


(c)               
To the extent that Agent or any Lender may have acquiesced in any noncompliance with any requirements
or conditions precedent to the closing of the Loans or to any subsequent disbursement of Loan proceeds, such acquiescence shall
not be deemed to constitute a waiver by Agent or any Lender of such requirements with respect to any future disbursements of Loan
proceeds and Agent may at any time after such acquiescence require Borrowers to comply with all such requirements. Any forbearance
by Agent or Lender in exercising any right or remedy under any of the Financing Documents, or otherwise afforded by applicable
law, including any failure to accelerate the maturity date of the Loans, shall not be a waiver of or preclude the exercise of any
right or remedy nor shall it serve as a novation of the Notes or as a reinstatement of the Loans or a waiver of such right of acceleration
or the right to insist upon strict compliance of the terms of the Financing Documents. Agent’s or any Lender’s acceptance
of payment of any sum secured by any of the Financing Documents after the due date of such payment shall not be a waiver of Agent’s
and such Lender’s right to either require prompt payment when due of all other sums so secured or to declare a default for
failure to make prompt payment. The procurement of insurance or the payment of taxes or other Liens or charges by Agent as the
result of an Event of Default shall not be a waiver of Agent’s right to accelerate the maturity of the Loans, nor shall Agent’s
receipt of any condemnation awards, insurance proceeds, or damages under this Agreement operate to cure or waive any Credit Party’s
default in payment of sums secured by any of the Financing Documents.


(d)               
Without limiting the generality of anything contained in this Agreement or the other Financing
Documents, each Borrower agrees that if an Event of Default is continuing (i) Agent and Lenders shall not be subject to any
“one action” or “election of remedies” law or rule, and (ii) all Liens and other rights, remedies
or privileges provided to Agent or Lenders shall remain in full force and effect until Agent or Lenders have exhausted all remedies
against the Collateral and any other properties owned by Borrowers and the Financing Documents and other security instruments or
agreements securing the Loans have been foreclosed, sold and/or otherwise realized upon in satisfaction of Borrowers’ obligations
under the Financing Documents.


(e)               
Nothing contained herein or in any other Financing Document shall be construed as requiring
Agent or any Lender to resort to any part of the Collateral for the satisfaction of any of Borrowers’ obligations under the
Financing Documents in preference or priority to any other Collateral, and Agent may seek satisfaction out of all of the Collateral
or any part thereof, in its absolute discretion in respect of Borrowers’ obligations under the Financing Documents. In addition,
Agent shall have the right from time to time to partially foreclose upon any Collateral in any manner and for any amounts secured
by the Financing Documents then due and payable as determined by Agent in its sole discretion, including, without limitation, the
following circumstances: (i) in the event any Borrower defaults beyond any applicable grace period in the payment of one or
more scheduled payments of principal and/or interest, Agent may foreclose upon all or any part of the Collateral to recover such
delinquent payments, or (ii) in the event Agent elects to accelerate less than the entire outstanding principal balance of
the Loans, Agent may foreclose all or any part of the Collateral to recover so much of the principal balance of the Loans as Lender
may accelerate and such other sums secured by one or more of the Financing Documents as Agent may elect. Notwithstanding one or
more partial foreclosures, any unforeclosed Collateral shall remain subject to the Financing Documents to secure payment of sums
secured by the Financing Documents and not previously recovered.


(f)                
To the fullest extent permitted by law, each Borrower, for itself and its successors and assigns,
waives in the event of foreclosure of any or all of the Collateral any equitable right otherwise available to any Credit Party
which would require the separate sale of any of the Collateral or require Agent or Lenders to exhaust their remedies against any
part of the Collateral before proceeding against any other part of the Collateral; and further in the event of such foreclosure
each Borrower does hereby expressly consent to and authorize, at the option of Agent, the foreclosure and sale either separately
or together of each part of the Collateral.






    	 	79	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


Section 10.9         Injunctive
Relief. The parties acknowledge and agree that, in the event of a breach or threatened breach
of any Credit Party’s obligations under any Financing Documents, Agent and Lenders may have no adequate remedy in money damages
and, accordingly, shall be entitled to seek an injunction (including, without limitation, a temporary restraining order, preliminary
injunction, writ of attachment, or order compelling an audit) against such breach or threatened breach, including, without limitation,
maintaining any cash management and collection procedure described herein. However, no specification in this Agreement of a specific
legal or equitable remedy shall be construed as a waiver or prohibition against any other legal or equitable remedies in the event
of a breach or threatened breach of any provision of this Agreement. Each Credit Party waives, to the fullest extent permitted
by law, the requirement of the posting of any bond in connection with such injunctive relief. By joining in the Financing Documents
as a Credit Party, each Credit Party specifically joins in this Section as if this Section were a part of each Financing
Document executed by such Credit Party.


Section 10.10       Marshalling;
Payments Set Aside. Neither Agent nor any Lender shall be under any obligation to marshal any
assets in payment of any or all of the Obligations. To the extent that Borrower makes any payment or Agent enforces its Liens or
Agent or any Lender exercises its right of set-off, and such payment or the proceeds of such enforcement or set-off is subsequently
invalidated, declared to be fraudulent or preferential, set aside, or required to be repaid by anyone, then to the extent of such
recovery, the Obligations or part thereof originally intended to be satisfied, and all Liens, rights and remedies therefor, shall
be revived and continued in full force and effect as if such payment had not been made or such enforcement or set-off had not occurred.


Article 11
- AGENT


Section 11.1         Appointment
and Authorization. Each Lender hereby irrevocably appoints and authorizes Agent to enter into
each of the Financing Documents to which it is a party (other than this Agreement) on its behalf and to take such actions as Agent
on its behalf and to exercise such powers under the Financing Documents as are delegated to Agent by the terms thereof, together
with all such powers as are reasonably incidental thereto. Subject to the terms of Section 11.16 and to the terms of the other
Financing Documents, Agent is authorized and empowered to amend, modify, or waive any provisions of this Agreement or the other
Financing Documents on behalf of Lenders. The provisions of this Article 11 are solely for the benefit of Agent and Lenders
and neither any Borrower nor any other Credit Party shall have any rights as a third party beneficiary of any of the provisions
hereof (other than as expressly provided herein). In performing its functions and duties under this Agreement, Agent shall act
solely as agent of Lenders and does not assume and shall not be deemed to have assumed any obligation toward or relationship of
agency or trust with or for any Borrower or any other Credit Party. Agent may perform any of its duties hereunder, or under the
Financing Documents, by or through its agents, servicers, trustees, investment managers or employees.


Section 11.2        Agent
and Affiliates. Agent shall have the same rights and powers under the Financing Documents as
any other Lender and may exercise or refrain from exercising the same as though it were not Agent, and Agent and its Affiliates
may lend money to, invest in and generally engage in any kind of business with each Credit Party or Affiliate of any Credit Party
as if it were not Agent hereunder.






    	 	80	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


Section 11.3        Action
by Agent. The duties of Agent shall be mechanical and administrative in nature. Agent shall
not have by reason of this Agreement a fiduciary relationship in respect of any Lender. Nothing in this Agreement or any of the
Financing Documents is intended to or shall be construed to impose upon Agent any obligations in respect of this Agreement or any
of the Financing Documents except as expressly set forth herein or therein.


Section 11.4         Consultation
with Experts. Agent may consult with legal counsel, independent public accountants and other
experts selected by it and shall not be liable for any action taken or omitted to be taken by it in good faith in accordance with
the advice of such counsel, accountants or experts.


Section 11.5         Liability
of Agent. Neither Agent nor any of its directors, officers, agents, trustees, investment managers,
servicers or employees shall be liable to any Lender for any action taken or not taken by it in connection with the Financing Documents,
except that Agent shall be liable with respect to its specific duties set forth hereunder but only to the extent of its own gross
negligence or willful misconduct in the discharge thereof as determined by a final non-appealable judgment of a court of competent
jurisdiction. Neither Agent nor any of its directors, officers, agents, trustees, investment managers, servicers or employees shall
be responsible for or have any duty to ascertain, inquire into or verify (a) any statement, warranty or representation made
in connection with any Financing Document or any borrowing hereunder; (b) the performance or observance of any of the covenants
or agreements specified in any Financing Document; (c) the satisfaction of any condition specified in any Financing Document;
(d) the validity, effectiveness, sufficiency or genuineness of any Financing Document, any Lien purported to be created or
perfected thereby or any other instrument or writing furnished in connection therewith; (e) the existence or non-existence
of any Default or Event of Default; or (f) the financial condition of any Credit Party. Agent shall not incur any liability
by acting in reliance upon any notice, consent, certificate, statement, or other writing (which may be a bank wire, facsimile or
electronic transmission or similar writing) believed by it to be genuine or to be signed by the proper party or parties. Agent
shall not be liable for any apportionment or distribution of payments made by it in good faith and if any such apportionment or
distribution is subsequently determined to have been made in error the sole recourse of any Lender to whom payment was due but
not made, shall be to recover from other Lenders any payment in excess of the amount to which they are determined to be entitled
(and such other Lenders hereby agree to return to such Lender any such erroneous payments received by them).


Section 11.6        Indemnification.
Each Lender shall, in accordance with its Pro Rata Share, indemnify Agent (to the extent not reimbursed by Borrowers) upon
demand against any cost, expense (including counsel fees and disbursements), claim, demand, action, loss or liability (except such
as result from Agent’s gross negligence or willful misconduct as determined by a final non-appealable judgment of a court
of competent jurisdiction) that Agent may suffer or incur in connection with the Financing Documents or any action taken or omitted
by Agent hereunder or thereunder. If any indemnity furnished to Agent for any purpose shall, in the opinion of Agent, be insufficient
or become impaired, Agent may call for additional indemnity and cease, or not commence, to do the acts indemnified against even
if so directed by Required Lenders until such additional indemnity is furnished.






    	 	81	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


Section 11.7        Right
to Request and Act on Instructions. Agent may at any time request instructions from Lenders
with respect to any actions or approvals which by the terms of this Agreement or of any of the Financing Documents Agent is permitted
or desires to take or to grant, and if such instructions are promptly requested, Agent shall be absolutely entitled to refrain
from taking any action or to withhold any approval and shall not be under any liability whatsoever to any Person for refraining
from any action or withholding any approval under any of the Financing Documents until it shall have received such instructions
from Required Lenders or all or such other portion of the Lenders as shall be prescribed by this Agreement. Without limiting the
foregoing, no Lender shall have any right of action whatsoever against Agent as a result of Agent acting or refraining from acting
under this Agreement or any of the other Financing Documents in accordance with the instructions of Required Lenders (or all or
such other portion of the Lenders as shall be prescribed by this Agreement) and, notwithstanding the instructions of Required Lenders
(or such other applicable portion of the Lenders), Agent shall have no obligation to take any action if it believes, in its commercially
reasonable discretion, that such action would violate applicable Law or exposes Agent to any liability for which it has not received
satisfactory indemnification in accordance with the provisions of Section 11.6.


Section 11.8         Credit
Decision. Each Lender acknowledges that it has, independently and without reliance upon Agent
or any other Lender, and based on such documents and information as it has deemed appropriate, made its own credit analysis and
decision to enter into this Agreement. Each Lender also acknowledges that it will, independently and without reliance upon Agent
or any other Lender, and based on such documents and information as it shall deem appropriate at the time, continue to make its
own credit decisions in taking or not taking any action under the Financing Documents.


Section 11.9        Collateral
Matters. Lenders irrevocably authorize Agent, at its option and in its discretion, to (a) release
any Lien granted to or held by Agent under any Security Document (i) upon termination of the Term Loan Commitment and payment
in full of all Obligations; or (ii) constituting property sold or disposed of as part of or in connection with any disposition
permitted under any Financing Document (it being understood and agreed that Agent may conclusively rely without further inquiry
on a certificate of a Responsible Officer as to the sale or other disposition of property being made in full compliance with the
provisions of the Financing Documents); and (b) subordinate any Lien granted to or held by Agent under any Security Document
to a Permitted Lien that is allowed to have priority over the Liens granted to or held by Agent pursuant to the definition of “Permitted
Liens”. Upon request by Agent at any time, Lenders will confirm Agent’s authority to release and/or subordinate particular
types or items of Collateral pursuant to this Section 11.9.


Section 11.10      Agency
for Perfection. Agent and each Lender hereby appoint each other Lender as agent for the purpose
of perfecting Agent’s security interest in assets which, in accordance with the Uniform Commercial Code in any applicable
jurisdiction, can be perfected by possession or control. Should any Lender (other than Agent) obtain possession or control of any
such assets, such Lender shall notify Agent thereof, and, promptly upon Agent’s request therefor, shall deliver such assets
to Agent or in accordance with Agent’s instructions or transfer control to Agent in accordance with Agent’s instructions.
Each Lender agrees that it will not have any right individually to enforce or seek to enforce any Security Document or to realize
upon any Collateral for the Loan unless instructed to do so by Agent (or consented to by Agent), it being understood and agreed
that such rights and remedies may be exercised only by Agent.






    	 	82	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


Section 11.11      Notice
of Default. Agent shall not be deemed to have knowledge or notice of the occurrence of any
Default or Event of Default except with respect to defaults in the payment of principal, interest and fees required to be paid
to Agent for the account of Lenders, unless Agent shall have received written notice from a Lender or a Borrower referring to this
Agreement, describing such Default or Event of Default and stating that such notice is a “notice of default”. Agent
will notify each Lender of its receipt of any such notice. Agent shall take such action with respect to such Default or Event of
Default as may be requested by Required Lenders (or all or such other portion of the Lenders as shall be prescribed by this Agreement)
in accordance with the terms hereof. Unless and until Agent has received any such request, Agent may (but shall not be obligated
to) take such action, or refrain from taking such action, with respect to such Default or Event of Default as it shall deem advisable
or in the best interests of Lenders.


Section
11.12           
Assignment by Agent; Resignation of Agent; Successor Agent.


(a)               
Agent may at any time assign its rights, powers, privileges and duties hereunder to (i) another
Lender or an Affiliate of Agent or any Approved Fund, or (ii) any Person to whom Agent, in its capacity as a Lender, has assigned
(or will assign, in conjunction with such assignment of agency rights hereunder) 50% or more of its Loan, in each case without
the consent of the Lenders or Borrowers. Following any such assignment, Agent shall endeavor to give notice to the Lenders and
Borrowers. Failure to give such notice shall not affect such assignment in any way or cause the assignment to be ineffective. An
assignment by Agent pursuant to this subsection (a) shall not be deemed a resignation by Agent for purposes of subsection (b)
below.


(b)               
Without limiting the rights of Agent to designate an assignee pursuant to subsection (a) above,
Agent may at any time give notice of its resignation to the Lenders and Borrowers. Upon receipt of any such notice of resignation,
Required Lenders shall have the right to appoint a successor Agent. If no such successor shall have been so appointed by Required
Lenders and shall have accepted such appointment within ten (10) Business Days after the retiring Agent gives notice of its resignation,
then the retiring Agent may on behalf of the Lenders, appoint a successor Agent; provided, however, that if Agent shall
notify Borrowers and the Lenders that no Person has accepted such appointment, then such resignation shall nonetheless become effective
in accordance with such notice from Agent that no Person has accepted such appointment and, from and following delivery of such
notice, (i) the retiring Agent shall be discharged from its duties and obligations hereunder and under the other Financing Documents,
and (ii) all payments, communications and determinations provided to be made by, to or through Agent shall instead be made by or
to each Lender directly, until such time as Required Lenders appoint a successor Agent as provided for above in this paragraph.



(c)               
Upon (i) an assignment permitted by subsection (a) above, or (ii) the acceptance of a successor’s
appointment as Agent pursuant to subsection (b) above, such successor shall succeed to and become vested with all of the rights,
powers, privileges and duties of the retiring (or retired) Agent, and the retiring Agent shall be discharged from all of its duties
and obligations hereunder and under the other Financing Documents (if not already discharged therefrom as provided above in this
paragraph). The fees payable by Borrowers to a successor Agent shall be the same as those payable to its predecessor unless otherwise
agreed between Borrowers and such successor. After the retiring Agent’s resignation hereunder and under the other Financing
Documents, the provisions of this Article and Section 11.12 shall continue in effect for the benefit of such retiring
Agent and its sub-agents in respect of any actions taken or omitted to be taken by any of them while the retiring Agent was acting
or was continuing to act as Agent.






    	 	83	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


Section
11.13           
Payment and Sharing of Payment.


(a)               
Term Loan Payments. Payments of principal, interest and fees in respect of the Term
Loans will be settled on the date of receipt if received by Agent on the last Business Day of a month or on the Business Day immediately
following the date of receipt if received on any day other than the last Business Day of a month; provided, however, that,
in the case such Lender is a Defaulted Lender, Agent shall be entitled to set off the funding short-fall against that Defaulted
Lender’s respective share of all payments received from any Borrower.


(b)               
Return of Payments.


(i)                
If Agent pays an amount to a Lender under this Agreement in the belief or expectation that
a related payment has been or will be received by Agent from a Borrower and such related payment is not received by Agent, then
Agent will be entitled to recover such amount from such Lender on demand without setoff, counterclaim or deduction of any kind,
together with interest accruing on a daily basis at the Federal Funds Rate.


(ii)              
If Agent determines at any time that any amount received by Agent under this Agreement must
be returned to any Borrower or paid to any other Person pursuant to any insolvency law or otherwise, then, notwithstanding any
other term or condition of this Agreement or any other Financing Document, Agent will not be required to distribute any portion
thereof to any Lender. In addition, each Lender will repay to Agent on demand any portion of such amount that Agent has distributed
to such Lender, together with interest at such rate, if any, as Agent is required to pay to any Borrower or such other Person,
without setoff, counterclaim or deduction of any kind.


(c)               
Defaulted Lenders. The failure of any Defaulted Lender to make any payment required
by it hereunder shall not relieve any other Lender of its obligations to make payment, but neither any other Lender nor Agent shall
be responsible for the failure of any Defaulted Lender to make any payment required hereunder. Notwithstanding anything set forth
herein to the contrary, a Defaulted Lender shall not have any voting or consent rights under or with respect to any Financing Document
or constitute a “Lender” (or be included in the calculation of “Required Lenders” hereunder) for any voting
or consent rights under or with respect to any Financing Document.


(d)               
Sharing of Payments. If any Lender shall obtain any payment or other recovery (whether
voluntary, involuntary, by application of setoff or otherwise) on account of any Loan (other than pursuant to the terms of Section 2.8(d))
in excess of its Pro Rata Share of payments entitled pursuant to the other provisions of this Section 11.13, such Lender shall
purchase from the other Lenders such participations in extensions of credit made by such other Lenders (without recourse, representation
or warranty) as shall be necessary to cause such purchasing Lender to share the excess payment or other recovery ratably with each
of them; provided, however, that if all or any portion of the excess payment or other recovery is thereafter required to
be returned or otherwise recovered from such purchasing Lender, such portion of such purchase shall be rescinded and each Lender
which has sold a participation to the purchasing Lender shall repay to the purchasing Lender the purchase price to the ratable
extent of such return or recovery, without interest. Each Borrower agrees that any Lender so purchasing a participation from another
Lender pursuant to this clause (d) may, to the fullest extent permitted by law, exercise all its rights of payment (including
pursuant to Section 10.6) with respect to such participation as fully as if such Lender were the direct creditor of Borrowers
in the amount of such participation). If under any applicable bankruptcy, insolvency or other similar law, any Lender receives
a secured claim in lieu of a setoff to which this clause (d) applies, such Lender shall, to the extent practicable, exercise
its rights in respect of such secured claim in a manner consistent with the rights of the Lenders entitled under this clause (d)
to share in the benefits of any recovery on such secured claim.






    	 	84	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


Section 11.14       Right
to Perform, Preserve and Protect. If any Credit Party fails to perform any obligation hereunder
or under any other Financing Document, Agent itself may, but shall not be obligated to, cause such obligation to be performed at
Borrowers’ expense. Agent is further authorized by Borrowers and the Lenders to make expenditures from time to time which
Agent, in its reasonable business judgment, deems necessary or desirable to (a) preserve or protect the business conducted
by Borrowers, the Collateral, or any portion thereof, and/or (b) enhance the likelihood of, or maximize the amount of, repayment
of the Loan and other Obligations. Each Borrower hereby agrees to reimburse Agent on demand for any and all costs, liabilities
and obligations incurred by Agent pursuant to this Section 11.14. Each Lender hereby agrees to indemnify Agent upon demand
for any and all costs, liabilities and obligations incurred by Agent pursuant to this Section 11.14, in accordance with the
provisions of Section 11.6.


Section 11.15      Additional
Titled Agents. Except for rights and powers, if any, expressly reserved under this Agreement
to any bookrunner, arranger or to any titled agent named on the cover page of this Agreement, other than Agent (collectively,
the “Additional Titled Agents”), and except for obligations, liabilities, duties and responsibilities, if any,
expressly assumed under this Agreement by any Additional Titled Agent, no Additional Titled Agent, in such capacity, has any rights,
powers, liabilities, duties or responsibilities hereunder or under any of the other Financing Documents. Without limiting the foregoing,
no Additional Titled Agent shall have nor be deemed to have a fiduciary relationship with any Lender. At any time that any Lender
serving as an Additional Titled Agent shall have transferred to any other Person (other than any Affiliates) all of its interests
in the Loan, such Lender shall be deemed to have concurrently resigned as such Additional Titled Agent.


Section
11.16           
Amendments and Waivers.


(a)               
No provision of this Agreement or any other Financing Document may be amended, waived or otherwise
modified unless such amendment, waiver or other modification is in writing and is signed or otherwise approved by Borrowers, the
Required Lenders and any other Lender to the extent required under Section 11.16(b); provided, however, the Fee Letter
may be amended, or rights or privileges thereunder waived, in a writing executed only by the parties thereto. 


(b)               
In addition to the required signatures under Section 11.16(a), no provision of this Agreement
or any other Financing Document may be amended, waived or otherwise modified unless such amendment, waiver or other modification
is in writing and is signed or otherwise approved by the following Persons:


(i)                
if any amendment, waiver or other modification would increase a Lender’s funding obligations
in respect of any Loan, by such Lender; and/or






    	 	85	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


(ii)              
if the rights or duties of Agent are affected thereby, by Agent;


provided, however, that, in each
of (i) and (ii) above, no such amendment, waiver or other modification shall, unless signed or otherwise approved in writing by
all the Lenders directly affected thereby, (A) reduce the principal of, rate of interest on or any fees with respect to any
Loan or forgive any principal, interest (other than default interest) or fees (other than late charges) with respect to any Loan;
(B) postpone the date fixed for, or waive, any payment (other than any mandatory prepayment pursuant to Section 2.1(b)(ii))
of principal of any Loan, or of interest on any Loan (other than default interest) or any fees provided for hereunder (other than
late charges) or postpone the date of termination of any commitment of any Lender hereunder; (C) change the definition of
the term Required Lenders or the percentage of Lenders which shall be required for Lenders to take any action hereunder; (D) release
all or substantially all of the Collateral, authorize any Borrower to sell or otherwise dispose of all or substantially all of
the Collateral, release any Guarantor of all or any portion of the Obligations or its Guarantee obligations with respect thereto,
or consent to a transfer of any of the Intellectual Property, except, in each case with respect to this clause (D), as otherwise
may be provided in this Agreement or the other Financing Documents (including in connection with any disposition permitted hereunder);
(E) amend, waive or otherwise modify this Section 11.16(b) or the definitions of the terms used in this Section 11.16(b)
insofar as the definitions affect the substance of this Section 11.16(b); (F) consent to the assignment, delegation or
other transfer by any Credit Party of any of its rights and obligations under any Financing Document or release any Borrower of
its payment obligations under any Financing Document, except, in each case with respect to this clause (F), pursuant to a
merger or consolidation permitted pursuant to this Agreement; or (G) amend any of the provisions of Section 10.7 or amend
any of the definitions Pro Rata Share, Term Loan Commitment, Term Loan Tranche 1 Commitments, Term Loan Tranche 2 Commitments,
Term Loan Tranche 3 Commitments, Term Loan Commitment Amount, Term Loan Tranche 1 Commitment Amount, Term Loan Tranche 2 Commitment
Amount, Term Loan Tranche 3 Commitment Amount, Term Loan Commitment Percentage, Term Loan Tranche 1 Commitment Percentage, Term
Loan Tranche 2 Commitment Percentage, Term Loan Tranche 3 Commitment Percentage or that provide for the Lenders to receive their
Pro Rata Shares of any fees, payments, setoffs or proceeds of Collateral hereunder. It is hereby understood and agreed that all
Lenders shall be deemed directly affected by an amendment, waiver or other modification of the type described in the preceding
clauses (C), (D), (E), (F) and (G) of the preceding sentence.


Section
11.17          
Assignments and Participations.


(a)               
Assignments.


(i)                
Any Lender may at any time assign to one or more Eligible Assignees all or any portion of
such Lender’s Loan together with all related obligations of such Lender hereunder. Except as Agent may otherwise agree, the
amount of any such assignment (determined as of the date of the applicable Assignment Agreement or, if a “Trade Date”
is specified in such Assignment Agreement, as of such Trade Date) shall be in a minimum aggregate amount equal to $1,000,000 or,
if less, the assignor’s entire interests in the outstanding Loan; provided, however, that, in connection with simultaneous
assignments to two or more related Approved Funds, such Approved Funds shall be treated as one assignee for purposes of determining
compliance with the minimum assignment size referred to above. Borrowers and Agent shall be entitled to continue to deal solely
and directly with such Lender in connection with the interests so assigned to an Eligible Assignee until Agent shall have received
and accepted an effective Assignment Agreement executed, delivered and fully completed by the applicable parties thereto and a
processing fee of $3,500 to be paid by the assigning Lender; provided, however, that only one processing fee shall be payable
in connection with simultaneous assignments to two or more related Approved Funds.






    	 	86	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


(ii)              
From and after the date on which the conditions described above have been met, (A) such
Eligible Assignee shall be deemed automatically to have become a party hereto and, to the extent of the interests assigned to such
Eligible Assignee pursuant to such Assignment Agreement, shall have the rights and obligations of a Lender hereunder, and (B) the
assigning Lender, to the extent that rights and obligations hereunder have been assigned by it pursuant to such Assignment Agreement,
shall be released from its rights and obligations hereunder (other than those that survive termination pursuant to Section 12.1).
Upon the request of the Eligible Assignee (and, as applicable, the assigning Lender) pursuant to an effective Assignment Agreement,
each Borrower shall execute and deliver to Agent for delivery to the Eligible Assignee (and, as applicable, the assigning Lender)
Notes in the aggregate principal amount of the Eligible Assignee’s Loan (and, as applicable, Notes in the principal amount
of that portion of the principal amount of the Loan retained by the assigning Lender). Upon receipt by the assigning Lender of
such Note, the assigning Lender shall return to Borrower Representative any prior Note held by it.


(iii)            
Agent, acting solely for this purpose as an agent of Borrower, shall maintain at the office
of its servicer located in Bethesda, Maryland a copy of each Assignment Agreement delivered to it and a register for the recordation
of the names and addresses of each Lender, and the commitments of, and principal amount of the Loan owing to, such Lender pursuant
to the terms hereof (the “Register”). The entries in such Register shall be conclusive, absent manifest effort,
and Borrower, Agent and Lenders may treat each Person whose name is recorded therein pursuant to the terms hereof as a Lender hereunder
for all purposes of this Agreement, notwithstanding notice to the contrary. Such Register shall be available for inspection by
Borrower and any Lender, at any reasonable time upon reasonable prior notice to Agent. Each Lender that sells a participation shall,
acting solely for this purpose as an agent of Borrower maintain a register on which it enters the name and address of each participant
and the principal amounts (and stated interest) of each participant’s interest in the Obligations (each, a “Participant
Register”). The entries in the Participant Registers shall be conclusive, absent manifest error. Each Participant Register
shall be available for inspection by Borrower and Agent at any reasonable time upon reasonable prior notice to the applicable Lender;
provided, that no Lender shall have any obligation to disclose all or any portion of the Participant Register (including the identity
of any Participant or any information relating to a Participant's interest in any commitments, loans, letters of credit or its
other obligations under any Financing Document) to any Person (including Borrower) except to the extent that such disclosure is
necessary to establish that such commitment, loan, letter of credit or other obligation is in registered form under Section 5f.103-1(c)
of the United States Treasury Regulations. For the avoidance of doubt, Agent (in its capacity as Agent) shall have no responsibility
for maintaining a participant register.


(iv)             
Notwithstanding the foregoing provisions of this Section 11.17(a) or any other provision
of this Agreement, any Lender may at any time pledge or assign a security interest in all or any portion of its rights under this
Agreement to secure obligations of such Lender, including any pledge or assignment to secure obligations to a Federal Reserve Bank;
provided, however, that no such pledge or assignment shall release such Lender from any of its obligations hereunder or
substitute any such pledgee or assignee for such Lender as a party hereto.


(v)               
Notwithstanding the foregoing provisions of this Section 11.17(a) or any other provision
of this Agreement, Agent has the right, but not the obligation, to effectuate assignments of Loan via an electronic settlement
system acceptable to Agent as designated in writing from time to time to the Lenders by Agent (the “Settlement Service”).
At any time when Agent elects, in its sole discretion, to implement such Settlement Service, each such assignment shall be effected
by the assigning Lender and proposed assignee pursuant to the procedures then in effect under the Settlement Service, which procedures
shall be consistent with the other provisions of this Section 11.17(a). Each assigning Lender and proposed Eligible Assignee
shall comply with the requirements of the Settlement Service in connection with effecting any assignment of Loan pursuant to the
Settlement Service. With the prior written approval of Agent, Agent’s approval of such Eligible Assignee shall be deemed
to have been automatically granted with respect to any transfer effected through the Settlement Service. Assignments and assumptions
of the Loan shall be effected by the provisions otherwise set forth herein until Agent notifies Lenders of the Settlement Service
as set forth herein.






    	 	87	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


(b)               
Participations. Any Lender may at any time, without the consent of, or notice to, any
Borrower or Agent, sell to one or more Persons (other than any Borrower or any Borrower’s Affiliates) participating interests
in its Loan, commitments or other interests hereunder (any such Person, a “Participant”). In the event of a
sale by a Lender of a participating interest to a Participant, (i) such Lender’s obligations hereunder shall remain
unchanged for all purposes, (ii) Borrowers and Agent shall continue to deal solely and directly with such Lender in connection
with such Lender’s rights and obligations hereunder, and (iii) all amounts payable by each Borrower shall be determined
as if such Lender had not sold such participation and shall be paid directly to such Lender. Each Borrower agrees that if amounts
outstanding under this Agreement are due and payable (as a result of acceleration or otherwise), each Participant shall be deemed
to have the right of set-off in respect of its participating interest in amounts owing under this Agreement to the same extent
as if the amount of its participating interest were owing directly to it as a Lender under this Agreement; provided, however,
that such right of set-off shall be subject to the obligation of each Participant to share with Lenders, and Lenders agree to share
with each Participant, as provided in Section 11.5.


(c)               
Replacement of Lenders. Within thirty (30) days after: (i) receipt by Agent
of notice and demand from any Lender for payment of additional costs as provided in Section 2.8(h), which demand shall not
have been revoked, (ii) any Borrower is required to pay any additional amount to any Lender or any Governmental Authority
for the account of any Lender pursuant to Section 2.8(a) through (h), (iii) any Lender is a Defaulted Lender, and the
circumstances causing such status shall not have been cured or waived; or (iv) any failure by any Lender to consent to a requested
amendment, waiver or modification to any Financing Document in which Required Lenders have already consented to such amendment,
waiver or modification but the consent of each Lender, or each Lender affected thereby, is required with respect thereto (each
relevant Lender in the foregoing clauses (i) through (iv) being an “Affected Lender”) each of Borrower
Representative and Agent may, at its option, notify such Affected Lender and, in the case of Borrowers’ election, Agent,
of such Person’s intention to obtain, at Borrowers’ expense, a replacement Lender (“Replacement Lender”)
for such Lender, which Replacement Lender shall be an Eligible Assignee and, in the event the Replacement Lender is to replace
an Affected Lender described in the preceding clause (iv), such Replacement Lender consents to the requested amendment, waiver
or modification making the replaced Lender an Affected Lender. In the event Borrowers or Agent, as applicable, obtains a Replacement
Lender within ninety (90) days following notice of its intention to do so, the Affected Lender shall sell, at par, and assign
all of its Loan and funding commitments hereunder to such Replacement Lender in accordance with the procedures set forth in Section 11.17(a);
provided, however, that (A) Borrowers shall have reimbursed such Lender for its increased costs and additional payments
for which it is entitled to reimbursement under Section 2.8(a) through (h), as applicable, of this Agreement through the date
of such sale and assignment, and (B) Borrowers shall pay to Agent the $3,500 processing fee in respect of such assignment.
In the event that a replaced Lender does not execute an Assignment Agreement pursuant to Section 11.17(a) within five (5) Business
Days after receipt by such replaced Lender of notice of replacement pursuant to this Section 11.17(c) and presentation to
such replaced Lender of an Assignment Agreement evidencing an assignment pursuant to this Section 11.17(c), such replaced
Lender shall be deemed to have consented to the terms of such Assignment Agreement, and any such Assignment Agreement executed
by Agent, the Replacement Lender and, to the extent required pursuant to Section 11.17(a), Borrowers, shall be effective for
purposes of this Section 11.17(c) and Section 11.17(a). Upon any such assignment and payment, such replaced Lender shall
no longer constitute a “Lender” for purposes hereof, other than with respect to such rights and obligations
that survive termination as set forth in Section 12.1.






    	 	88	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


(d)               
Credit Party Assignments. No Credit Party may assign, delegate or otherwise transfer
any of its rights or other obligations hereunder or under any other Financing Document without the prior written consent of Agent
and each Lender.


Section 11.18       Funding
and Settlement Provisions Applicable When Non-Funding Lenders Exist. So long as Agent has not
waived the conditions to the funding of Loans set forth in Section 7.2 or Section 2.1, any Lender may deliver a notice
to Agent stating that such Lender not fund the Term Loans due to the non-satisfaction of one or more conditions to funding Loans
set forth in Section 7.2 or Section 2.1, and specifying any such non-satisfied conditions. Any Lender delivering any
such notice shall become a non-funding Lender (a “Non-Funding Lender”) for purposes of this Agreement commencing
on the Business Day following receipt by Agent of such notice, and shall cease to be a Non-Funding Lender on the date on which
such Lender has either revoked the effectiveness of such notice or acknowledged in writing to each of Agent the satisfaction of
the condition(s) specified in such notice, or Required Lenders waive the conditions to the funding of such Loans giving rise to
such notice by Non-Funding Lender. Each Non-Funding Lender shall remain a Lender for purposes of this Agreement to the extent that
such Non-Funding Lender has Term Loans outstanding in excess of Zero Dollars ($0); provided, however, that during any period
of time that any Non-Funding Lender exists, and notwithstanding any provision to the contrary set forth herein, the following provisions
shall apply:


(a)               
For purposes of determining the Pro Rata Share of each Lender under clause (c) of the definition
of such term, each Non-Funding Lender shall be deemed to have a Term Loan Commitment Amount as in effect immediately before such
Lender became a Non-Funding Lender. 


(b)                
Except as provided in clause (a) above, the Term Loan Commitment Amount of each Non-Funding
Lender shall be deemed to be Zero Dollars ($0). 


(c)               
The Term Loan Commitment at any date of determination during such period shall be deemed to
be equal to the sum of (i) the aggregate Term Loan Commitment Amounts of all Lenders, other than the Non-Funding Lenders as of
such date plus (ii) the aggregate principal amount outstanding under the Term Loans of all Non-Funding Lenders as of such
date.


Article 12
- MISCELLANEOUS


Section 12.1         Survival.
All agreements, representations and warranties made herein and in every other Financing Document shall survive the execution
and delivery of this Agreement and the other Financing Documents. The provisions of section 2.1(a)(v)(B) and (C), Section 2.8,
Section 2.9, Article 11 (other than Sections 11.14 (other than the last sentence thereof) and Sections 11.16 and 11.17), and Section
12.8, Section 12.14 and Section 12.16 (and any other provision herein expressly stated to survive termination) shall survive the
payment of the Obligations (both with respect to any Lender and all Lenders collectively) and any termination of this Agreement
and any judgment with respect to any Obligations, including any final foreclosure judgment with respect to any Security Document,
and no unpaid or unperformed, current or future, Obligations will merge into any such judgment.






    	 	89	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


Section 12.2        No
Waivers. No failure or delay by Agent or any Lender in exercising any right, power or privilege
under any Financing Document shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other
or further exercise thereof or the exercise of any other right, power or privilege. The rights and remedies herein and therein
provided shall be cumulative and not exclusive of any rights or remedies provided by law. Any reference in any Financing Document
to the “continuing” nature of any Event of Default shall not be construed as establishing or otherwise indicating that
any Borrower or any other Credit Party has the independent right to cure any such Event of Default, but is rather presented merely
for convenience should such Event of Default be waived in accordance with the terms of the applicable Financing Documents.


Section
12.3            
Notices.


(a)            
All notices, requests and other communications to any party hereunder shall be in writing
(including prepaid overnight courier, facsimile transmission or similar writing) and shall be given to such party at its address,
facsimile number or e-mail address set forth on the signature pages hereof (or, in the case of any such Lender who becomes a Lender
after the date hereof, in an assignment agreement or in a notice delivered to Borrower Representative and Agent by the assignee
Lender forthwith upon such assignment) or at such other address, facsimile number or e-mail address as such party may hereafter
specify for the purpose by notice to Agent and Borrower Representative; provided, however, that notices, requests
or other communications shall be permitted by electronic means only in accordance with the provisions of Section 12.3(b) and
(c). Each such notice, request or other communication shall be effective (i) if given by facsimile, when such notice is transmitted
to the facsimile number specified by this Section and the sender receives a confirmation of transmission from the sending
facsimile machine, or (ii) if given by mail, prepaid overnight courier or any other means, when received or when receipt is
refused at the applicable address specified by this Section 12.3(a).


(b)               
Notices and other communications to the parties hereto may be delivered or furnished by electronic
communication (including e-mail and Internet or intranet websites) pursuant to procedures approved from time to time by Agent,
provided, however, that the foregoing shall not apply to notices sent directly to any Lender if such Lender has notified
Agent that it is incapable of receiving notices by electronic communication. Agent or Borrower Representative may, in their discretion,
agree to accept notices and other communications to them hereunder by electronic communications pursuant to procedures approved
by it, provided, however, that approval of such procedures may be limited to particular notices or communications.


(c)               
Unless Agent otherwise prescribes, (i) notices and other communications sent to an e-mail
address shall be deemed received upon the sender’s receipt of an acknowledgment from the intended recipient (such as by the
“return receipt requested” function, as available, return e-mail or other written acknowledgment), and (ii) notices
or communications posted to an Internet or intranet website shall be deemed received upon the deemed receipt by the intended recipient
at its e-mail address as described in the foregoing clause (i) of notification that such notice or communication is available and
identifying the website address therefor, provided, however, that if any such notice or other communication is not
sent or posted during normal business hours, such notice or communication shall be deemed to have been sent at the opening of business
on the next Business Day.






    	 	90	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


Section 12.4        Severability.
In case any provision of or obligation under this Agreement or any other Financing Document shall be invalid, illegal or
unenforceable in any jurisdiction, the validity, legality and enforceability of the remaining provisions or obligations, or of
such provision or obligation in any other jurisdiction, shall not in any way be affected or impaired thereby.


Section 12.5        Headings.
Headings and captions used in the Financing Documents (including the Exhibits, Schedules and Annexes hereto and thereto)
are included for convenience of reference only and shall not be given any substantive effect.


Section
12.6           
Confidentiality.


(a)               
Each Credit Party agrees (i) not to transmit or disclose provisions of any Financing Document
to any Person (other than to Borrowers’ advisors and officers on a need-to-know basis or as otherwise may be required by
Law) without Agent’s prior written consent, (ii) to inform all Persons of the confidential nature of the Financing Documents
and to direct them not to disclose the same to any other Person and to require each of them to be bound by these provisions.


(b)               
Agent and each Lender shall hold all non-public information regarding the Credit Parties and
their respective businesses identified as such by Borrowers and obtained by Agent or any Lender pursuant to the requirements hereof
in accordance with such Person’s customary procedures for handling information of such nature, except that disclosure of
such information may be made (i) to their respective agents, employees, Subsidiaries, Affiliates, attorneys, auditors, professional
consultants, rating agencies, insurance industry associations and portfolio management services, provided, however,
that any such Persons are bound by obligations of confidentiality, (ii) to prospective transferees or purchasers of any interest
in the Loans, Agent or a Lender, provided, however, that any such Persons are bound by obligations of confidentiality,
(iii) as required by Law, subpoena, judicial order or similar order and in connection with any litigation, (iv) as may
be required in connection with the examination, audit or similar investigation of such Person, and (v) to a Person that is
a trustee, investment advisor or investment manager, collateral manager, servicer, noteholder or secured party in a Securitization
(as hereinafter defined) in connection with the administration, servicing and reporting on the assets serving as collateral for
such Securitization provided, however, that any such Persons are bound by obligations of confidentiality. For the
purposes of this Section, “Securitization” means (A) the pledge of the Loans as collateral security for loans
to a Lender, or (B) a public or private offering by a Lender or any of its Affiliates or their respective successors and assigns,
of securities which represent an interest in, or which are collateralized, in whole or in part, by the Loans. Confidential information
shall include only such information identified as such at the time provided to Agent and shall not include information that either:
(y) is in the public domain, or becomes part of the public domain after disclosure to such Person through no fault of such
Person, or (z) is disclosed to such Person by a Person other than a Credit Party, provided, however, Agent does
not have actual knowledge that such Person is prohibited from disclosing such information. The obligations of Agent and Lenders
under this Section 12.6 shall supersede and replace the obligations of Agent and Lenders under any confidentiality agreement
in respect of this financing executed and delivered by Agent or any Lender prior to the date hereof.






    	 	91	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


Section 12.7        Waiver
of Consequential and Other Damages. To the fullest extent permitted by applicable law, no Borrower
shall assert, and each Borrower hereby waives, any claim against any Indemnitee (as defined below), on any theory of liability,
for special, indirect, consequential or punitive damages (as opposed to direct or actual damages) arising out of, in connection
with, or as a result of this Agreement, any other Financing Document or any agreement or instrument contemplated hereby or thereby,
the transactions contemplated hereby or thereby, any Loan or the use of the proceeds thereof. No Indemnitee shall be liable for
any damages arising from the use by unintended recipients of any information or other materials distributed by it through telecommunications,
electronic or other information transmission systems in connection with this Agreement or the other Financing Documents or the
transactions contemplated hereby or thereby.


Section
12.8           
GOVERNING LAW; SUBMISSION TO JURISDICTION.


(a)               
THIS AGREEMENT, EACH NOTE AND EACH OTHER FINANCING DOCUMENT, AND ALL DISPUTES AND OTHER MATTERS
RELATING HERETO OR THERETO OR ARISING THEREFROM (WHETHER SOUNDING IN CONTRACT LAW, TORT LAW OR OTHERWISE), SHALL BE GOVERNED BY,
AND SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO CONFLICTS OF LAWS
PRINCIPLES (OTHER THAN SECTION 5-1401 OF THE GENERAL OBLIGATIONS LAW).


(b)               
EACH PARTY HERETO HEREBY CONSENTS TO THE JURISDICTION OF ANY STATE OR FEDERAL COURT LOCATED
in the State of New York in the City of New York, Borough of Manhattan, AND IRREVOCABLY AGREES THAT ALL ACTIONS OR PROCEEDINGS
ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE OTHER FINANCING DOCUMENTS SHALL BE LITIGATED IN SUCH COURTS. EACH PARTY HERETO
EXPRESSLY SUBMITS AND CONSENTS TO THE JURISDICTION OF THE AFORESAID COURTS AND WAIVES ANY DEFENSE OF FORUM NON CONVENIENS. EACH
PARTY HERETO HEREBY WAIVES PERSONAL SERVICE OF ANY AND ALL PROCESS AND AGREES THAT ALL SUCH SERVICE OF PROCESS MAY BE MADE UPON
SUCH PARTY BY CERTIFIED OR REGISTERED MAIL, RETURN RECEIPT REQUESTED, ADDRESSED TO SUCH PARTY AT THE ADDRESS SET FORTH IN THIS
AGREEMENT AND SERVICE SO MADE SHALL BE COMPLETE TEN (10) DAYS AFTER THE SAME HAS BEEN POSTED. 


Section 12.9        WAIVER
OF JURY TRIAL.  EACH BORROWER, AGENT AND THE LENDERS HEREBY IRREVOCABLY WAIVES ANY AND
ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THE FINANCING DOCUMENTS OR THE TRANSACTIONS
CONTEMPLATED THEREBY AND AGREES THAT ANY SUCH ACTION OR PROCEEDING SHALL BE TRIED BEFORE A COURT AND NOT BEFORE A JURY. EACH BORROWER,
AGENT AND EACH LENDER ACKNOWLEDGES THAT THIS WAIVER IS A MATERIAL INDUCEMENT TO ENTER INTO A BUSINESS RELATIONSHIP, THAT EACH HAS
RELIED ON THE WAIVER IN ENTERING INTO THIS AGREEMENT AND THE OTHER FINANCING DOCUMENTS, AND THAT EACH WILL CONTINUE TO RELY ON
THIS WAIVER IN THEIR RELATED FUTURE DEALINGS. EACH BORROWER, AGENT AND EACH LENDER WARRANTS AND REPRESENTS THAT IT HAS HAD THE
OPPORTUNITY OF REVIEWING THIS JURY WAIVER WITH LEGAL COUNSEL, AND THAT IT KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS.






    	 	92	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


Section
12.10          
Publication; Advertisement.


(a)               
Publication. No Credit Party will directly or indirectly publish, disclose or otherwise
use in any public disclosure, advertising material, promotional material, press release or interview, any reference to the name,
logo or any trademark of MCF or any of its Affiliates or any reference to this Agreement or the financing evidenced hereby, in
any case except (i) as required by Law, subpoena or judicial or similar order, in which case the applicable Credit Party shall
give Agent prior written notice of such publication or other disclosure (provided that the applicable Credit Party is not required
to provide Agent with prior written notice in connection with any filings as may be required with the SEC to comply with disclosure
obligations), or (ii) with MCF’s prior written consent.


(b)               
Advertisement. Each Lender and each Credit Party hereby authorizes MCF to publish the
name of such Lender and Credit Party, the existence of the financing arrangements referenced under this Agreement, the primary
purpose and/or structure of those arrangements, the amount of credit extended under each facility, the title and role of each party
to this Agreement, and the total amount of the financing evidenced hereby in any “tombstone”, comparable advertisement
or press release which MCF elects to submit for publication. In addition, each Lender and each Credit Party agrees that MCF may
provide lending industry trade organizations with information necessary and customary for inclusion in league table measurements
after the Closing Date. With respect to any of the foregoing, MCF shall provide Borrowers with an opportunity to review and confer
with MCF regarding the contents of any such tombstone, advertisement or information, as applicable, prior to its submission for
publication and, following such review period, MCF may, from time to time, publish such information in any media form desired by
MCF, until such time that Borrowers shall have requested MCF cease any such further publication.


Section 12.11      Counterparts;
Integration. This Agreement and the other Financing Documents may be signed in any number of
counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same
instrument. Signatures by facsimile or by electronic mail delivery of an electronic version of any executed signature page shall
bind the parties hereto. This Agreement and the other Financing Documents constitute the entire agreement and understanding among
the parties hereto and supersede any and all prior agreements and understandings, oral or written, relating to the subject matter
hereof.


Section 12.12       No
Strict Construction. The parties hereto have participated jointly in the negotiation and drafting
of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed
as if drafted jointly by the parties hereto and no presumption or burden of proof shall arise favoring or disfavoring any party
by virtue of the authorship of any provisions of this Agreement.


Section 12.13      Lender
Approvals. Unless expressly provided herein to the contrary, any approval, consent, waiver
or satisfaction of Agent or Lenders with respect to any matter that is the subject of this Agreement, the other Financing Documents
may be granted or withheld by Agent and Lenders in their sole and absolute discretion and credit judgment.






    	 	93	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


Section
12.14         
Expenses; Indemnity.


(a)               
Borrowers hereby agree to promptly pay (i) all reasonable out-of-pocket costs and expenses
of Agent (including, without limitation, the fees, costs and expenses of counsel to, and independent appraisers and consultants
retained by Agent (which shall be limited to one firm of counsel, and, if necessary, one firm of local counsel in each appropriate
jurisdiction, and one specialist counsel for each appropriate specialty)) in connection with the examination, review, due diligence
investigation, documentation, negotiation, closing and syndication of the transactions contemplated by the Financing Documents,
in connection with the performance by Agent of its rights and remedies under the Financing Documents and in connection with the
continued administration of the Financing Documents including (A) any amendments, modifications, consents and waivers to and/or
under any and all Financing Documents, and (B) any periodic public record searches conducted by or at the request of Agent
(including, without limitation, title investigations, UCC searches, fixture filing searches, judgment, pending litigation and tax
lien searches and searches of applicable corporate, limited liability, partnership and related records concerning the continued
existence, organization and good standing of certain Persons); (ii) without limitation of the preceding clause (i), all reasonable
out-of-pocket costs and expenses of Agent in connection with the creation, perfection and maintenance of Liens pursuant to the
Financing Documents; (iii) without limitation of the preceding clause (i), all costs and expenses of Agent in connection with
(A) protecting, storing, insuring, handling, maintaining or selling any Collateral, (B) any litigation, dispute, suit
or proceeding relating to any Financing Document, and (C) any workout, collection, bankruptcy, insolvency and other enforcement
proceedings under any and all of the Financing Documents; (iv) without limitation of the preceding clause (i), all reasonable
out-of-pocket costs and expenses of Agent in connection with Agent’s reservation of funds in anticipation of the funding
of the initial Loans to be made hereunder; and (v) all costs and expenses incurred by Lenders in connection with any litigation,
dispute, suit or proceeding relating to any Financing Document and in connection with any workout, collection, bankruptcy, insolvency
and other enforcement proceedings under any and all Financing Documents, whether or not Agent or Lenders are a party thereto. This
Section 12.14(a) shall not apply to any Taxes except for Taxes arising from a non-Tax claim. 


(b)               
Each Borrower hereby agrees to indemnify, pay and hold harmless Agent and Lenders and the
officers, directors, employees, trustees, agents, investment advisors and investment managers, collateral managers, servicers,
and counsel of Agent and Lenders (collectively called the “Indemnitees”) from and against any and all liabilities,
obligations, losses, damages, penalties, actions, judgments, suits, claims, costs, expenses and disbursements of any kind or nature
whatsoever (including the reasonable out-of-pocket fees and disbursements of counsel for such Indemnitee, which shall be limited
to one firm of counsel for all similarly situated Indemnitees and if necessary, one firm of local counsel in each appropriate jurisdiction,
one specialist counsel for each appropriate specialty and, in the case of an actual conflict of interest, one additional firm of
counsel for such affected Indemnitees and one firm of local counsel in each appropriate jurisdiction) in connection with any investigative,
response, remedial, administrative or judicial matter or proceeding, whether or not such Indemnitee shall be designated a party
thereto and including any such proceeding initiated by or on behalf of a Credit Party, and the reasonable expenses of investigation
by engineers, environmental consultants and similar technical personnel and any commission, fee or compensation claimed by any
broker (other than any broker retained by Agent or Lenders) asserting any right to payment for the transactions contemplated hereby,
which may be imposed on, incurred by or asserted against such Indemnitee as a result of or in connection with the transactions
contemplated hereby or by the other Operative Documents (including (i)(A) as a direct or indirect result of the presence on
or under, or escape, seepage, leakage, spillage, discharge, emission or release from, any property now or previously owned, leased
or operated by Borrower, any Subsidiary or any other Person of any Hazardous Materials, (B) arising out of or relating to
the offsite disposal of any materials generated or present on any such property, or (C) arising out of or resulting from the
environmental condition of any such property or the applicability of any governmental requirements relating to Hazardous Materials,
whether or not occasioned wholly or in part by any condition, accident or event caused by any act or omission of Borrower or any
Subsidiary, and (ii) proposed and actual extensions of credit under this Agreement) and the use or intended use of the proceeds
of the Loans, except that Borrower shall have no obligation hereunder to any Indemnitee with respect to such liabilities, obligations,
losses, damages, penalties, actions, judgments, suits, claims, costs, expenses and disbursements of any kind or nature whatsoever
resulting from the gross negligence or willful misconduct of any Indemnitee, as determined by a final non-appealable judgment of
a court of competent jurisdiction. To the extent that the undertaking set forth in the immediately preceding sentence may be unenforceable,
Borrower shall contribute the maximum portion which it is permitted to pay and satisfy under applicable Law to the payment and
satisfaction of all such indemnified liabilities incurred by the Indemnitees or any of them.






    	 	94	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


(c)               
Notwithstanding any contrary provision in this Agreement, the obligations of Borrowers under
this Section 12.14 shall survive the payment in full of the Obligations and the termination of this Agreement. NO INDEMNITEE
OR CREDIT PARTY SHALL BE RESPONSIBLE OR LIABLE TO ANY PARTY TO ANY FINANCING DOCUMENT, ANY SUCCESSOR, ASSIGNEE OR THIRD PARTY BENEFICIARY
OR ANY OTHER PERSON ASSERTING CLAIMS DERIVATIVELY THROUGH SUCH PARTY, FOR INDIRECT, PUNITIVE, EXEMPLARY OR CONSEQUENTIAL DAMAGES
WHICH MAY BE ALLEGED UNDER THIS AGREEMENT OR ANY OTHER FINANCING DOCUMENT OR AS A RESULT OF ANY OTHER TRANSACTION CONTEMPLATED
HEREUNDER OR THEREUNDER.


Section 12.15       Reserved.



Section 12.16      Reinstatement.
This Agreement shall remain in full force and effect and continue to be effective should any petition or other proceeding
be filed by or against any Credit Party for liquidation or reorganization, should any Credit Party become insolvent or make an
assignment for the benefit of any creditor or creditors or should an interim receiver, receiver, receiver and manager or trustee
be appointed for all or any significant part of any Credit Party’s assets, and shall continue to be effective or to be reinstated,
as the case may be, if at any time payment and performance of the Obligations, or any part thereof, is, pursuant to applicable
law, rescinded or reduced in amount, or must otherwise be restored or returned by any obligee of the Obligations, whether as a
fraudulent preference reviewable transaction or otherwise, all as though such payment or performance had not been made. In the
event that any payment, or any part thereof, is rescinded, reduced, restored or returned, the Obligations shall be reinstated and
deemed reduced only by such amount paid and not so rescinded, reduced, restored or returned.


Section 12.17      Successors
and Assigns. This Agreement shall be binding upon and inure to the benefit of Borrowers and
Agent and each Lender and their respective successors and permitted assigns.






    	 	95	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


Section 12.18     USA
PATRIOT Act Notification. Agent (for itself and not on behalf of any Lender) and each Lender
hereby notifies Borrowers that pursuant to the requirements of the USA PATRIOT Act, it is required to obtain, verify and record
certain information and documentation that identifies Borrowers, which information includes the name and address of Borrower and
such other information that will allow Agent or such Lender, as applicable, to identify Borrowers in accordance with the USA PATRIOT
Act.


Section 12.19      Acknowledgement
and Consent to Bail-In of EEA Financial Institutions. Notwithstanding anything to the contrary
in any Financing Document or in any other agreement, arrangement or understanding among any such parties, each party hereto acknowledges
that any liability of any EEA Financial Institution arising under any Financing Document, to the extent such liability is unsecured,
may be subject to the write-down and conversion powers of an EEA Resolution Authority and agrees and consents to, and acknowledges
and agrees to be bound by:


(a)                
the application of any Write-Down and Conversion Powers by an EEA Resolution Authority to
any such liabilities arising hereunder which may be payable to it by any party hereto that is an EEA Financial Institution; and


(b)               
the effects of any Bail-In Action on any such liability, including, if applicable:


(i)                 
a reduction in full or in part or cancellation of any such liability;


(ii)               
a conversion of all, or a portion of, such liability into shares or other instruments of ownership
in such EEA Financial Institution, its parent undertaking, or a bridge institution that may be issued to it or otherwise conferred
on it, and that such shares or other instruments of ownership will be accepted by it in lieu of any rights with respect to any
such liability under this Agreement or any other Financing Document; or


(iii)             
the variation of the terms of such liability in connection with the exercise of the write-down
and conversion powers of any EEA Resolution Authority.


[SIGNATURES APPEAR ON FOLLOWING PAGE(S)]






    	 	96	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


IN WITNESS WHEREOF,
intending to be legally bound each of the parties have caused this Agreement to be executed the day and year first above mentioned.





	BORROWERS:	THERAPEUTICSMD, INC.
	 	 	 
	 	By:	/s/ Daniel Cartwright	 
	 	Name:	Daniel Cartwright
	 	Title:	Chief Financial Officer
	 	 	 
	 	 	 
	 	VITAMEDMD LLC
	 	 	 
	 	By:	/s/ Daniel Cartwright	 
	 	Name:	Daniel Cartwright
	 	Title:	Chief Financial Officer
	 	 	 
	 	 	 
	 	BOCAGREENMD, INC.
	 	 	 
	 	By:	/s/ Daniel Cartwright	 
	 	Name:	Daniel Cartwright
	 	Title:	Chief Financial Officer
	 	 	 
	 	 	 
	 	VITACARE PRESCRIPTION SERVICES, INC.
	 	 	 
	 	By:	/s/ Daniel Cartwright	 
	 	Name:	Daniel Cartwright
	 	Title:	Chief Financial Officer
	 	 	 
	 	Address:


6800 Broken Sound Parkway, NW, Third Floor 

Boca Raton, FL 33487

Attn: Daniel Cartwright, Chief Financial Officer

E-Mail: dcartwright@TherapeuticsMD.com


with a copy to:


 


Greenberg Traurig, P.A.


333 SE 2nd Avenue, Suite 4400


Miami, FL 33131


Attn: Joshua M. Samek, Esq.


E-Mail: samekj@gtlaw.com











 




    	 	 	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    


 


 




	AGENT:	MIDCAP FINANCIAL TRUST
	 	 	 
	 	By:	Apollo Capital Management, L.P.,

its investment manager
	 	 	 
	 	By:	Apollo Capital Management GP, LLC,

its general partner
	 	 	 
	 	By:	/s/ Maurice Amsellem	 
	 	Name:	Maurice Amsellem
	 	Title:	Authorized Signatory
	 	 	 
	 	Address:


 


c/o MidCap Financial Services, LLC, as servicer


7255 Woodmont Avenue, Suite 200

Bethesda, Maryland 20814

Attn: Account Manager for TherapeuticsMD transaction

Facsimile: 301-941-1450


E-mail: notices@midcapfinancial.com


 

with a copy to:


 


c/o MidCap Financial Services, LLC, as servicer


7255 Woodmont Avenue, Suite 200

Bethesda, Maryland 20814

Attn: General Counsel

Facsimile: 301-941-1450


E-mail: legalnotices@midcapfinancial.com

 

Payment Account Designation:

 

SunTrust Bank, N.A.
 ABA #: 061000104
 Account Name: MidCap Financial Trust – Collections
 Account #: 1000113400435
 Attention: TXMD Credit Facility




	 	 	 






 











 


 


 




    	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


	LENDER:	MIDCAP FINANCIAL TRUST
	 	 	 
	 	By:	Apollo Capital Management, L.P.,

its investment manager
	 	 	 
	 	By:	Apollo Capital Management GP, LLC,

its general partner
	 	 	 
	 	By:	/s/ Maurice Amsellem	 
	 	Name:	Maurice Amsellem
	 	Title:	Authorized Signatory
	 	 	 
	 	Address:


 


c/o MidCap Financial Services, LLC, as servicer


7255 Woodmont Avenue, Suite 200

Bethesda, Maryland 20814

Attn: Account Manager for TherapeuticsMD transaction

Facsimile: 301-941-1450


E-mail: notices@midcapfinancial.com


 

with a copy to:


 


c/o MidCap Financial Services, LLC, as servicer


7255 Woodmont Avenue, Suite 200

Bethesda, Maryland 20814

Attn: General Counsel

Facsimile: 301-941-1450


E-mail: legalnotices@midcapfinancial.com

 






	 	 	 



 




    	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


	LENDER:	MIDCAP FUNDING VI TRUST
	 	 	 
	 	By:	Apollo Capital Management, L.P.,

its investment manager
	 	 	 
	 	By:	Apollo Capital Management GP, LLC,

its general partner
	 	 	 
	 	By:	/s/ Maurice Amsellem	 
	 	Name:	Maurice Amsellem
	 	Title:	Authorized Signatory
	 	 	 
	 	Address:


 


c/o MidCap Financial Services, LLC, as servicer


7255 Woodmont Avenue, Suite 200

Bethesda, Maryland 20814

Attn: Account Manager for TherapeuticsMD transaction

Facsimile: 301-941-1450


E-mail: notices@midcapfinancial.com


 

with a copy to:


 


c/o MidCap Financial Services, LLC, as servicer


7255 Woodmont Avenue, Suite 200

Bethesda, Maryland 20814

Attn: General Counsel

Facsimile: 301-941-1450


E-mail: legalnotices@midcapfinancial.com

 






	 	 	 



 





    	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


	LENDER:	MIDCAP FUNDING XIII TRUST
	 	 	 
	 	By:	Apollo Capital Management, L.P.,

its investment manager
	 	 	 
	 	By:	Apollo Capital Management GP, LLC,

its general partner
	 	 	 
	 	By:	/s/ Maurice Amsellem	 
	 	Name:	Maurice Amsellem
	 	Title:	Authorized Signatory
	 	 	 
	 	Address:


 


c/o MidCap Financial Services, LLC, as servicer


7255 Woodmont Avenue, Suite 200

Bethesda, Maryland 20814

Attn: Account Manager for TherapeuticsMD transaction

Facsimile: 301-941-1450


E-mail: notices@midcapfinancial.com


 

with a copy to:


 


c/o MidCap Financial Services, LLC, as servicer


7255 Woodmont Avenue, Suite 200

Bethesda, Maryland 20814

Attn: General Counsel

Facsimile: 301-941-1450


E-mail: legalnotices@midcapfinancial.com

 






	 	 	 



 



 



    	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    




 


	LENDER:	APOLLO INVESTMENT CORPORATION
	 	 	 
	 	By:	Apollo Investment Management, L.P., as Advisor
	 	 	 
	 	By:	ACC Management, LLC, as its General
    Partner
	 	 	 
	 	By:	/s/ Tanner Powell	 
	 	Name:	Tanner Powell
	 	Title:	Authorized Signatory
	 	 	 
	 	Address:


 


Apollo Investment Corporation

9 West 57th Street, 37th Floor

New York, New York 10019

Attn: Howard Widra

E-mail: hwidra@apolloLP.com



 

with a copy to:


 


Apollo Investment Corporation

730 Fifth Avenue, 11th Floor

New York, New York 10019

Attn: Sheriff Ibrahim, Jonathan Krain

Facsimile: 602-680-4108

E-mail: RealEstateOps@apolloLP.com,

16026804108@tls.ldsprod.com

 






	 	 	 



 



 




    	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


	LENDER:	CION INVESTMENT CORPORATION
	 	 	 
	 	By:	/s/ Gregg Bresner	 
	 	Name:	Gregg Bresner
	 	Title:	Chief Investment Officer
	 	 	 
	 	Address:


 


__________________________

__________________________

__________________________

__________________________

Attn: ______________________

Facsimile: ___________________

E-mail: _____________________ 




 






	 	 	 




 


 




    	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


	LENDER:	FLEXPOINT MCLS HOLDINGS LLC
	 	 	 
	 	By:	/s/ Daniel Edelman	 
	 	Name:	Daniel Edelman
	 	Title:	Vice President
	 	 	 
	 	Address:


 

Flexpoint MCLS Holdings LLC

c/o MidCap Financial Services, LLC, as servicer

7255 Woodmont Avenue, Suite 200

Bethesda, Maryland 20814

Attn:  Account Manager for TherapeuticsMD transaction

Facsimile: 301-941-1450

E-mail:  notices@midcapfinancial.com




 

with a copy to:


 


Flexpoint MCLS Holdings LLC

c/o MidCap Financial Services, LLC, as servicer

7255 Woodmont Avenue, Suite 200

Bethesda, Maryland 20814

Attn:  General Counsel

Facsimile:  301-941-1450

E-mail:  legalnotices@midcapfinancial.com

 






	 	 	 



 



 




    	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


ANNEXES,
EXHIBITS AND SCHEDULES


ANNEXES


	Annex A	Commitment Annex







 


EXHIBITS


	Exhibit A	Form of Compliance Certificate
	Exhibit B	Form of Notice of Borrowing
	Exhibit C	Form of Payment Notification
	Exhibit D-1	Form of U.S. Tax Compliance Certificate
	Exhibit D-2	Form of U.S. Tax Compliance Certificate
	Exhibit D-3	Form of U.S. Tax Compliance Certificate
	Exhibit D-4	Form of U.S. Tax Compliance Certificate
	Exhibit E	Closing Checklist







SCHEDULES





	Schedule 2.1	Scheduled Principal Payments for Term Loan
	Schedule 3.1	Existence, Organizational ID Numbers, Foreign Qualification, Prior Names
	Schedule 3.4	Capitalization
	Schedule 3.6	Litigation
	Schedule 3.17	Material Contracts
	Schedule 3.18	Environmental Compliance
	Schedule 3.19	Intellectual Property
	Schedule 4.1(o)	Litigation, Governmental Proceedings and Other Notice Events
	Schedule 4.15	Products and Regulatory Required Permits
	Schedule 5.1	Debt; Contingent Obligations
	Schedule 5.2	Liens
	Schedule 5.7	Permitted Investments
	Schedule 5.8	Affiliate Transactions
	Schedule 5.11	Business Description
	Schedule 5.14	Deposit Accounts and Securities Accounts
	Schedule 6.1	Minimum Net Revenue 
	Schedule 7.2	Term Loan Tranche 2 Funding Conditions
	Schedule 7.4	Post-Closing Obligations
	Schedule 9.1	Collateral
	Schedule 9.2(b)	Location of Collateral
	Schedule 9.2(d)	Chattel Paper, Letter of Credit Rights, Commercial Tort Claims, Instruments, Documents, Investment Property




 







    	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

Annex A to Credit Agreement (Commitment
Annex)


	
        Lender
	
        Term
        Loan Tranche 1 Commitment Amount
	
        Term
        Loan Tranche 1 Commitment Percentage
	
        Term
        Loan Tranche 2 Commitment Amount
	
        Term
        Loan Tranche 2 Commitment Percentage
	
        Term
        Loan Tranche 3 Commitment Amount
	
        Term
        Loan Tranche 3 Commitment Percentage

	MidCap Financial Trust	$0.00	0.000000%	$36,562,500.00	48.750000%	$24,375,000.00	48.750000%
	MidCap Funding VI Trust	$21,562,500.00	28.750000%	$0.00	0.000000%	$0.00	0.000000%
	MidCap Funding XIII Trust	$15,000,000.00	20.000000%	$0.00	0.000000%	$0.00	0.000000%
	Apollo Investment Corporation	$22,500,000.00	30.000000%	$22,500,000.00	30.000000%	$15,000,000.00	30.000000%
	CION Investment Corporation	$15,000,000.00	20.000000%	$15,000,000.00	20.000000%	$10,000,000.00	20.000000%
	Flexpoint MCLS Holdings LLC	$937,500.00	1.250000%	$937,500.00	1.250000%	$625,000.00	1.250000%
	TOTALS	$75,000,000.00	100%	$75,000,000.00	100%	$50,000,000.00	100%


 


 




    	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


Exhibit A to Credit Agreement
(Form of Compliance Certificate)


 


COMPLIANCE
CERTIFICATE


This Compliance Certificate
is given by _____________________, a Responsible Officer of TherapeuticsMD, Inc. (the “Borrower Representative”),
pursuant to that certain Credit and Security Agreement dated as of May 1, 2018 among the Borrower Representative and any additional
Borrower that may hereafter be added thereto (collectively, “Borrowers”), MidCap Financial Trust, individually
as a Lender and as Agent, and the financial institutions or other entities from time to time parties hereto, each as a Lender (as
such agreement may have been amended, restated, supplemented or otherwise modified from time to time, the “Credit Agreement”).
Capitalized terms used herein without definition shall have the meanings set forth in the Credit Agreement.


The undersigned Responsible
Officer hereby certifies to Agent and Lenders that:


(a)    
[the financial statements delivered with this certificate in accordance with Section 4.1
of the Credit Agreement fairly present in all material respects the results of operations and financial condition of Borrowers
and their Consolidated Subsidiaries as of the dates and the accounting period covered by such financial statements;]1


(b)   
the representations and warranties of each Credit Party contained in the Financing Documents
are true, correct and complete in all material respects on and as of the date hereof, except to the extent that any such representation
or warranty relates to a specific date in which case such representation or warranty shall be true and correct in all material
respects as of such earlier date; provided, however, in each case, such materiality qualifier shall not be applicable to any representations
and warranties that already are qualified or modified by materiality in the text thereof;


(c)    
I have reviewed the terms of the Credit Agreement and have made, or caused to be made under
my supervision, a review in reasonable detail of the transactions and conditions of Borrowers and their Consolidated Subsidiaries
during the accounting period covered by such financial statements, and such review has not disclosed the existence during or at
the end of such accounting period, and I have no knowledge of the existence as of the date hereof, of any condition or event that
constitutes a Default or an Event of Default, except as set forth in Schedule 1 hereto, which includes a description
of the nature and period of existence of such Default or an Event of Default and what action Borrowers have taken, are undertaking
and propose to take with respect thereto;


(d)   
[except as noted on Schedule 2 attached hereto or as Borrowers have
previously reported to Agent on any Schedule 2 to any previous Compliance Certificate delivered by Borrower
to Agent, Schedule 3.19 of the Credit Agreement contains a complete and accurate list of all of Borrowers’ Registered
Intellectual Property and all in-bound license or sublicense agreement, exclusive out-bound license or sublicense agreement and
any other agreement with respect to rights in Intellectual Property;


(e)    
except as noted on Schedule 3 attached hereto or as Borrowers have previously
reported to Agent on any Schedule 3 to any previous Compliance Certificate delivered by Borrowers to Agent,
no Borrower has entered into any new Material Contract or any new material amendment, consent, waiver or other modification to
any Material Contract;


 


 






	1		Subsection
(a) only to be included in Compliance Certificates to be delivered for the last month of a fiscal quarter







    	Exhibit B – Page 1 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


(f)     
except as noted on Schedule 4 attached hereto or as Borrowers have previously
reported to Agent on any Schedule 4 to any previous Compliance Certificate delivered by Borrowers to Agent,
Schedule 4.15 of the Credit Agreement contains a complete and accurate list of all Borrowers’ material Products and
material Regulatory Required Permits;


(g)   
except as noted on Schedule 5 attached hereto or as Borrowers have previously
reported to Agent on any Schedule 5 to any previous Compliance Certificate delivered by Borrowers to Agent,
Schedule 5.14 to the Credit Agreement contains a complete and accurate statement of all deposit accounts or investment
accounts maintained by Borrowers;


(h)   
except as noted on Schedule 6 attached hereto or as Borrowers have previously
reported to Agent on any Schedule 6 to any previous Compliance Certificate delivered by Borrower to Agent, Schedule
9.2(b) to the Credit Agreement contains a complete and accurate list of all business locations of Borrowers and Guarantors;


(i)     
except as noted on Schedule 7 attached hereto or as Borrowers have previously
reported to Agent on any Schedule7 to any previous Compliance Certificate delivered by Borrowers to Agent, Schedule
9.2(d) of the Credit Agreement contains a complete and accurate list of all Chattel Paper, letter of credit rights, commercial
tort claims, Instruments, Documents or Investment Property of the Borrowers;]2


(j)     
The aggregate amount of cash and Cash Equivalents held by Borrowers
(on a consolidated basis) as of the date hereof is $[__________]; and


(k)   
Borrowers and Guarantor are in compliance with the covenants contained in Article 6 of
the Credit Agreement, and in any Guarantee constituting a part of the Financing Documents, as demonstrated by the calculation of
such covenants below, except as set forth below; in determining such compliance, the following calculations have been made: [See
attached worksheets]. Such calculations and the certifications contained therein are true, correct and complete.


The foregoing certifications
and computations are made as of ________________, 201__ (end of month) and as of _____________, 201__.





	 	Sincerely,
	 	 	 
	 	[BORROWER REPRESENTATIVE]
	 	 	 
	 	By:	 
	 	Name:	 
	 	Title:	 







 


 






	2		Subsections (d) through (i) only to be included in Compliance
Certificates to be delivered for the last month of a fiscal quarter



 




    	Exhibit B – Page 2 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


Exhibit B to Credit Agreement
(Form of Notice of Borrowing)


 


NOTICE
OF BORROWING


This Notice of Borrowing
is given by _____________________, a Responsible Officer of TherapeuticsMD, Inc. (the “Borrower Representative”),
pursuant to that certain Credit and Security Agreement dated as of May 1, 2018 among the Borrower Representative and any additional
Borrower that may hereafter be added thereto (collectively, “Borrowers”), MidCap Financial Trust, individually
as a Lender and as Agent, and the financial institutions or other entities from time to time parties hereto, each as a Lender (as
such agreement may have been amended, restated, supplemented or otherwise modified from time to time, the “Credit Agreement”).
Capitalized terms used herein without definition shall have the meanings set forth in the Credit Agreement.


The undersigned Responsible
Officer hereby gives notice to Agent of Borrower Representative’s request to borrow $____________________ of Term Loans on
_______________, 201__.


The undersigned officer
hereby certifies that, both before and after giving effect to the request above (a) each of the conditions precedent set forth
in Section 7.2 have been satisfied, (b) all of the representations and warranties contained in the Credit Agreement and
the other Financing Documents are true, correct and complete as of the date hereof, except to the extent such representation or
warranty relates to a specific date, in which case such representation or warranty is true, correct and complete as of such earlier
date, and (c) no Default or Event of Default has occurred and is continuing on the date hereof.


IN WITNESS WHEREOF,
the undersigned officer has executed and delivered this Notice of Borrowing this ____ day of ___________, 201__.


	 	Sincerely,
	 	 	 
	 	[BORROWER REPRESENTATIVE]
	 	 	 
	 	By:	 
	 	Name:	 
	 	Title:	 






 




    	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


Exhibit C to Credit Agreement
(Form of Payment Notification)


PAYMENT NOTIFICATION


This Payment Notification
is given by ____________________, a Responsible Officer of TherapeuticsMD, Inc. (the “Borrower Representative”),
pursuant to that certain Credit and Security Agreement dated as of May 1, 2018 among the Borrower Representative, and any additional
Borrower that may hereafter be added thereto (collectively, “Borrowers”), MidCap Financial Trust, individually
as a Lender and as Agent, and the financial institutions or other entities from time to time parties hereto, each as a Lender (as
such agreement may have been amended, restated, supplemented or otherwise modified from time to time, the “Credit Agreement”).
Capitalized terms used herein without definition shall have the meanings set forth in the Credit Agreement.


Please be advised
that funds in the amount of $_____________ will be wire transferred to Agent on _________, 201_. Such funds shall constitute [an
optional] [a mandatory] prepayment of the Term Loans, with such prepayments to be applied in the manner specified in Section 2.1(a)(iv).
[Such mandatory prepayment is being made pursuant to Section _____________ of the Credit Agreement.]


Fax to MCF Operations
301-941-1450 no later than noon Eastern time.


Note: Funds must
be received in the Payment Account by no later than noon Eastern time for same day application.


IN WITNESS WHEREOF,
the undersigned officer has executed and delivered this Payment Notification this ____ day of ___________, 201__.


	 	Sincerely,
	 	 	 
	 	[BORROWER REPRESENTATIVE]
	 	 	 
	 	By:	 
	 	Name:	 
	 	Title:	 








 




    	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


Exhibit D-1 to Credit Agreement
(Form of U.S. Tax Compliance Certificate)


U.S.
TAX COMPLIANCE CERTIFICATE


(For Foreign Lenders
That Are Not Partnerships For U.S. Federal Income Tax Purposes)


This
U.S. Tax Compliance Certificate is given to TherapeuticsMD, Inc. (the “Borrower Representative”), pursuant to
that certain Credit and Security Agreement dated as of May 1, 2018, among the Borrower Representative, and any additional Borrower
that may hereafter be added thereto (collectively, “Borrowers”), MidCap Financial Trust, individually as a Lender
and as Agent, and the financial institutions or other entities from time to time parties hereto, each as a Lender (as such agreement
may have been amended, restated, supplemented or otherwise modified from time to time, the “Credit Agreement”).
Capitalized terms used herein without definition shall have the meanings set forth in the Credit Agreement.


Pursuant to the provisions
of Section 2.8(c) of the Credit Agreement, the undersigned hereby certifies that (i) it is the sole record and beneficial owner
of the Loan(s) (as well as any Note(s) evidencing such Loan(s)) in respect of which it is providing this certificate, (ii) it is
not a bank within the meaning of Section 881(c)(3)(A) of the Code, (iii) it is not a ten percent shareholder of any Borrower within
the meaning of Section 871(h)(3)(B) of the Code and (iv) it is not a controlled foreign corporation related to any Borrower as
described in Section 881(c)(3)(C) of the Code.


The
undersigned has furnished Agent and the Borrower Representative with a certificate of its non-U.S. Person status on IRS Form W-8BEN
or IRS Form W-8BEN-E. By executing this certificate, the undersigned agrees that (1) if the information provided on this certificate
changes, the undersigned shall promptly so inform the Borrower Representative and Agent, and (2) the undersigned shall have at
all times furnished the Borrower Representative and Agent with a properly completed and currently effective certificate in either
the calendar year in which each payment is to be made to the undersigned, or in either of the two calendar years preceding such
payments.


 




	[NAME OF LENDER]	 
	 	 	 
	By:	 	 
	Name:	 	 
	Title:	 	 
	Date:	           , 20[  ]	 








 




    	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


Exhibit D-2 to Credit Agreement
(Form of U.S. Tax Compliance Certificate)


U.S.
TAX COMPLIANCE CERTIFICATE


(For Foreign Participants
That Are Not Partnerships For U.S. Federal Income Tax Purposes)


This
U.S. Tax Compliance Certificate is given to TherapeuticsMD, Inc. (the “Borrower Representative”), pursuant to
that certain Credit and Security Agreement dated as of May 1, 2018 among the Borrower Representative, and any additional Borrower
that may hereafter be added thereto (collectively, “Borrowers”), MidCap Financial Trust, individually as a Lender
and as Agent, and the financial institutions or other entities from time to time parties hereto, each as a Lender (as such agreement
may have been amended, restated, supplemented or otherwise modified from time to time, the “Credit Agreement”).
Capitalized terms used herein without definition shall have the meanings set forth in the Credit Agreement.


Pursuant to the provisions
of Section 2.8(c) of the Credit Agreement, the undersigned hereby certifies that (i) it is the sole record and beneficial owner
of the participation in respect of which it is providing this certificate, (ii) it is not a bank within the meaning of Section
881(c)(3)(A) of the Code, (iii) it is not a ten percent shareholder of any Borrower within the meaning of Section 871(h)(3)(B)
of the Code, and (iv) it is not a controlled foreign corporation related to any Borrower as described in Section 881(c)(3)(C) of
the Code.


The
undersigned has furnished its participating Lender with a certificate of its non-U.S. Person status on IRS Form -8BEN or IRS Form
W-8BEN-E. By executing this certificate, the undersigned agrees that (1) if the information provided on this certificate changes,
the undersigned shall promptly so inform such Lender in writing, and (2) the undersigned shall have at all times furnished such
Lender with a properly completed and currently effective certificate in either the calendar year in which each payment is to be
made to the undersigned, or in either of the two calendar years preceding such payments.


	[NAME OF PARTICIPANT]	 
	 	 	 
	By:	 	 
	Name:	 	 
	Title:	 	 
	Date:	           , 20[  ]	 







 


 




    	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


Exhibit D-3 to Credit Agreement
(Form of U.S. Tax Compliance Certificate)


U.S.
TAX COMPLIANCE CERTIFICATE


(For Foreign Participants
That Are Partnerships For U.S. Federal Income Tax Purposes)


This
U.S. Tax Compliance Certificate is given to TherapeuticsMD, Inc. (the “Borrower Representative”), pursuant to
that certain Credit and Security Agreement dated as of May 1, 2018 among the Borrower Representative, and any additional Borrower
that may hereafter be added thereto (collectively, “Borrowers”), MidCap Financial Trust, individually as a Lender
and as Agent, and the financial institutions or other entities from time to time parties hereto, each as a Lender (as such agreement
may have been amended, restated, supplemented or otherwise modified from time to time, the “Credit Agreement”).
Capitalized terms used herein without definition shall have the meanings set forth in the Credit Agreement.


Pursuant to the provisions
of Section 2.8(c) of the Credit Agreement, the undersigned hereby certifies that (i) it is the sole record owner of the participation
in respect of which it is providing this certificate, (ii) its direct or indirect partners/members are the sole beneficial owners
of such participation, (iii) with respect such participation, neither the undersigned nor any of its direct or indirect partners/members
is a bank extending credit pursuant to a loan agreement entered into in the ordinary course of its trade or business within the
meaning of Section 881(c)(3)(A) of the Code, (iv) none of its direct or indirect partners/members is a ten percent shareholder
of any Borrower within the meaning of Section 871(h)(3)(B) of the Code and (v) none of its direct or indirect partners/members
is a controlled foreign corporation related to any Borrower as described in Section 881(c)(3)(C) of the Code.


The
undersigned has furnished its participating Lender with IRS Form W-8IMY accompanied by one of the following forms from each of
its partners/members that is claiming the portfolio interest exemption: (i) an IRS Form W-8BEN or IRS Form W-8BEN-E or (ii) an
IRS Form W-8IMY accompanied by an IRS Form W-8BEN or IRS Form W-8BEN-E from each of such partner’s/member’s beneficial
owners that is claiming the portfolio interest exemption. By executing this certificate, the undersigned agrees that (1) if the
information provided on this certificate changes, the undersigned shall promptly so inform such Lender and (2) the undersigned
shall have at all times furnished such Lender with a properly completed and currently effective certificate in either the calendar
year in which each payment is to be made to the undersigned, or in either of the two calendar years preceding such payments.


	[NAME OF PARTICIPANT]	 
	 	 	 
	By:	 	 
	Name:	 	 
	Title:	 	 
	Date:	           , 20[  ]	 







 




    	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


Exhibit D-4 to Credit Agreement
(Form of U.S. Tax Compliance Certificate)





U.S.
TAX COMPLIANCE CERTIFICATE


(For Foreign Lenders
That Are Partnerships For U.S. Federal Income Tax Purposes)


 


This
U.S. Tax Compliance Certificate is given to TherapeuticsMD, Inc. (the “Borrower Representative”), pursuant to
that certain Credit and Security Agreement dated as of May 1, 2018 among the Borrower Representative, and any additional Borrower
that may hereafter be added thereto (collectively, “Borrowers”), MidCap Financial Trust, individually as a Lender
and as Agent, and the financial institutions or other entities from time to time parties hereto, each as a Lender (as such agreement
may have been amended, restated, supplemented or otherwise modified from time to time, the “Credit Agreement”).
Capitalized terms used herein without definition shall have the meanings set forth in the Credit Agreement.


Pursuant to the provisions
of Section 2.8(c) of the Credit Agreement, the undersigned hereby certifies that (i) it is the sole record owner of the Loan(s)
(as well as any Note(s) evidencing such Loan(s)) in respect of which it is providing this certificate, (ii) its direct or indirect
partners/members are the sole beneficial owners of such Loan(s) (as well as any Note(s) evidencing such Loan(s)), (iii) with respect
to the extension of credit pursuant to this Credit Agreement or any other Financing Document, neither the undersigned nor any of
its direct or indirect partners/members is a bank extending credit pursuant to a loan agreement entered into in the ordinary course
of its trade or business within the meaning of Section 881(c)(3)(A) of the Code, (iv) none of its direct or indirect partners/members
is a ten percent shareholder of any Borrower within the meaning of Section 871(h)(3)(B) of the Code and (v) none of its direct
or indirect partners/members is a controlled foreign corporation related to any Borrower as described in Section 881(c)(3)(C) of
the Code.


The
undersigned has furnished Agent and the Borrower Representative with IRS Form W-8IMY accompanied by one of the following forms
from each of its partners/members that is claiming the portfolio interest exemption: (i) an IRS Form W-8BEN or IRS Form W-8BEN-E
or (ii) an IRS Form W-8IMY accompanied by an IRS Form W-8BEN or IRS Form W-8BEN-E from each of such partner’s/member’s
beneficial owners that is claiming the portfolio interest exemption. By executing this certificate, the undersigned agrees that
(1) if the information provided on this certificate changes, the undersigned shall promptly so inform the Borrower Representative
and Agent, and (2) the undersigned shall have at all times furnished the Borrower Representative and Agent with a properly completed
and currently effective certificate in either the calendar year in which each payment is to be made to the undersigned, or in either
of the two calendar years preceding such payments.


	[NAME OF LENDER]	 
	 	 	 
	By:	 	 
	Name:	 	 
	Title:	 	 
	Date:	           , 20[  ]	 




 




    	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


Exhibit E to Credit Agreement


(Closing Checklist)




    	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


Schedule 2.1 - Amortization


Commencing on May
1, 2020 (the “Initial Amortization Start Date”) and continuing on the first day of each calendar month thereafter,
Borrower shall pay to Agent as a principal payment on the Term Loan(s) an amount equal to the total principal amount of the Term
Loan(s) made to Borrower divided by thirty-six (36), for a thirty-six (36) month straight-line amortization of equal monthly
principal payments; provided, however, Borrower Representative may, on any Business Day during the period beginning on February
15, 2020 and ending on the date that is fifteen (15) days prior to the Initial Amortization Start Date, request in writing that
Agent and the Lenders extend the Initial Amortization Start Date (an “IO Extension Request”) by twelve (12)
months, and if the IO Extension Conditions (as defined below) are satisfied to Agent’s and each Lender’s reasonable
satisfaction, then the Initial Amortization Start Date shall be extended to May 1, 2021 and the principal payments to be made in
respect of the Term Loan(s) shall be in an amount equal to the total principal amount of the Term Loan(s) made to Borrower divided
by twenty-four (24), for a twenty-four (24) month straight-line amortization of equal monthly principal payments.


For purposes hereof,
the “IO Extension Conditions” means the satisfaction of each of the following conditions: (i) the Agent has
received evidence reasonably satisfactory to it that the aggregate consolidated Net Revenue of Borrowers attributable solely to
the commercial sale of TX-001HR and TX-004HR by December 31, 2019 is equal to or greater than $95,000,000, and (ii) as of the date
of the IO Extension Request and the Initial Amortization Start Date (without giving effect to any extension thereof), no Default
or Event of Default has occurred and is continuing.


Notwithstanding anything
to the contrary contained in the foregoing, the entire remaining outstanding principal balance under the Term Loans shall mature
and be due and payable upon the Termination Date.




    	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


Schedule 3.1 – Existence,
Organizational ID Numbers, Foreign Qualification, Prior Names


 


 


	Borrower 	Prior Names	Type
    of Entity /

State of 

Formation	States Qualified	Federal Tax ID Number	
        Location of Borrower

(address)

	TherapeuticsMD, Inc.	None	Nevada	All other states	87-0233535	6800 Broken Sound Parkway NW, Suite 300, Boca Raton, FL 33487
	VitaMedMD LLC	None	Delaware	FL	26-2704476	6800 Broken Sound Parkway NW, Suite 300, Boca Raton, FL 33487
	BocaGreenMD, Inc.	None	Nevada	FL	45-4837581	6800 Broken Sound Parkway NW, Suite 300, Boca Raton, FL 33487
	VitaCare Prescription Services, Inc.	None	Florida	 	47-4220965	6800 Broken Sound Parkway NW, Suite 300, Boca Raton, FL 33487



 


 


 


 




    	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


Schedule 3.4 – Capitalization





	Issuer	Class of capital Stock Issued or Membership Interest	Holder	Capital Stock/Membership Interest Ownership
	VitaMedMD LLC	Membership Interest	TherapeuticsMD, Inc.	100%
	BocaGreenMD, Inc.	Common Stock	TherapeuticsMD, Inc.	100%
	VitaCare Prescription Services, Inc.	Common Stock	TherapeuticsMD, Inc.	100%



 


 


 




    	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


Schedule 3.6 – Litigation


None


 




    	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


Schedule 3.17 – Material Contracts


None




    	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


Schedule 3.18 – Environmental
Compliance


None


 






    	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    






Schedule 3.19 – Intellectual
Property


PATENTS


Issued/Allowed Patents:


	 	Patent Number	Title	Grant/

Allowed Date (mm/dd/yy)	Country
	1.                    	[***]	[***]	[***]	[***]
	2.                    	[***]	[***]	[***]	[***]
	3.                    	[***]	[***]	[***]	[***]
	4.                    	[***]	[***]	[***]	[***]
	5.                    	[***]	[***]	[***]	[***]
	6.                    	[***]	[***]	[***]	[***]
	7.                    	[***]	[***]	[***]	[***]
	8.                    	[***]	[***]	[***]	[***]
	9.                    	[***]	[***]	[***]	[***]
	10.                 	[***]	[***]	[***]	[***]
	11.                 	[***]	[***]	[***]	[***]
	12.                 	[***]	[***]	[***]	[***]
	13.                 	[***]	[***]	[***]	[***]
	14.                 	[***]	[***]	[***]	[***]
	15.                 	[***]	[***]	[***]	[***]
	16.                 	[***]	[***]	[***]	[***]
	17.                 	[***]	[***]	[***]	[***]
	18.                 	[***]	[***]	[***]	[***]
	19.                 	[***]	[***]	[***]	[***]
	20.                 	[***]	[***]	[***]	[***]
	21.                 	[***]	[***]	[***]	[***]
	22.                 	[***]	[***]	[***]	[***]
	23.                 	[***]	[***]	[***]	[***]
	24.                 	[***]	[***]	[***]	[***]



 






    	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


	 	Patent Number	Title	Grant/

Allowed Date (mm/dd/yy)	Country
	25.                 	[***]	[***]	[***]	[***]
	26.                 	[***]	[***]	[***]	[***]
	27.                 	[***]	[***]	[***]	[***]
	28.                 	[***]	[***]	[***]	[***]
	29.                 	[***]	[***]	[***]	[***]
	30.                 	[***]	[***]	[***]	[***]
	31.                 	[***]	[***]	[***]	[***]
	32.                 	[***]	[***]	[***]	[***]
	33.                 	[***]	[***]	[***]	[***]
	34.                 	[***]	[***]	[***]	[***]
	35.                 	[***]	[***]	[***]	[***]
	36.                 	[***]	[***]	[***]	[***]
	37.                 	[***]	[***]	[***]	[***]


 




    	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


Pending Patent Applications:





	 	Application Number	Title	Application Date	Country
	1.                    	[***]	[***]	[***]	[***]
	2.                    	[***]	[***]	[***]	[***]
	3.                    	[***]	[***]	[***]	[***]
	4.                    	[***]	[***]	[***]	[***]
	5.                    	[***]	[***]	[***]	[***]
	6.                    	[***]	[***]	[***]	[***]
	7.                    	[***]	[***]	[***]	[***]
	8.                    	[***]	[***]	[***]	[***]
	9.                    	[***]	[***]	[***]	[***]
	10.                 	[***]	[***]	[***]	[***]
	11.                 	[***]	[***]	[***]	[***]
	12.                 	[***]	[***]	[***]	[***]
	13.                 	[***]	[***]	[***]	[***]
	14.                 	[***]	[***]	[***]	[***]
	15.                 	[***]	[***]	[***]	[***]
	16.                 	[***]	[***]	[***]	[***]
	17.                 	[***]	[***]	[***]	[***]
	18.                 	[***]	[***]	[***]	[***]
	19.                 	[***]	[***]	[***]	[***]
	20.                 	[***]	[***]	[***]	[***]
	21.                 	[***]	[***]	[***]	[***]
	22.                 	[***]	[***]	[***]	[***]
	23.                 	[***]	[***]	[***]	[***]
	24.                 	[***]	[***]	[***]	[***]
	25.                 	[***]	[***]	[***]	[***]



 






    	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    




 


 


	 	Application Number	Title	Application Date	Country
	26.                 	[***]	[***]	[***]	[***]
	27.                 	[***]	[***]	[***]	[***]
	28.                 	[***]	[***]	[***]	[***]
	29.                 	[***]	[***]	[***]	[***]
	30.                 	[***]	[***]	[***]	[***]
	31.                 	[***]	[***]	[***]	[***]
	32.                 	[***]	[***]	[***]	[***]
	33.                 	[***]	[***]	[***]	[***]
	34.                 	[***]	[***]	[***]	[***]
	35.                 	[***]	[***]	[***]	[***]
	36.                 	[***]	[***]	[***]	[***]
	37.                 	[***]	[***]	[***]	[***]
	38.                 	[***]	[***]	[***]	[***]
	39.                 	[***]	[***]	[***]	[***]
	40.                 	[***]	[***]	[***]	[***]
	41.                 	[***]	[***]	[***]	[***]
	42.                 	[***]	[***]	[***]	[***]
	43.                 	[***]	[***]	[***]	[***]
	44.                 	[***]	[***]	[***]	[***]
	45.                 	[***]	[***]	[***]	[***]
	46.                 	[***]	[***]	[***]	[***]
	47.                 	[***]	[***]	[***]	[***]
	48.                 	[***]	[***]	[***]	[***]
	49.                 	[***]	[***]	[***]	[***]
	50.                 	[***]	[***]	[***]	[***]
	51.                 	[***]	[***]	[***]	[***]
	52.                 	[***]	[***]	[***]	[***]
	53.                 	[***]	[***]	[***]	[***]



 


 






    	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


 


	 	Application Number	Title	Application Date	Country
	54.                 	[***]	[***]	[***]	[***]
	55.                 	[***]	[***]	[***]	[***]
	56.                 	[***]	[***]	[***]	[***]
	57.                 	[***]	[***]	[***]	[***]
	58.                 	[***]	[***]	[***]	[***]
	59.                 	[***]	[***]	[***]	[***]
	60.                 	[***]	[***]	[***]	[***]
	61.                 	[***]	[***]	[***]	[***]
	62.                 	[***]	[***]	[***]	[***]
	63.                 	[***]	[***]	[***]	[***]
	64.                 	[***]	[***]	[***]	[***]
	65.                 	[***]	[***]	[***]	[***]
	66.                 	[***]	[***]	[***]	[***]
	67.                 	[***]	[***]	[***]	[***]
	68.                 	[***]	[***]	[***]	[***]
	69.                 	[***]	[***]	[***]	[***]
	70.                 	[***]	[***]	[***]	[***]
	71.                 	[***]	[***]	[***]	[***]
	72.                 	[***]	[***]	[***]	[***]
	73.                 	[***]	[***]	[***]	[***]
	74.                 	[***]	[***]	[***]	[***]
	75.                 	[***]	[***]	[***]	[***]
	76.                 	[***]	[***]	[***]	[***]
	77.                 	[***]	[***]	[***]	[***]
	78.                 	[***]	[***]	[***]	[***]
	79.                 	[***]	[***]	[***]	[***]
	80.                 	[***]	[***]	[***]	[***]
	81.                 	[***]	[***]	[***]	[***]



 


 


 



    	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    




 


	 	Application Number	Title	Application Date	Country
	82.                 	[***]	[***]	[***]	[***]
	83.                 	[***]	[***]	[***]	[***]
	84.                 	[***]	[***]	[***]	[***]
	85.                 	[***]	[***]	[***]	[***]
	86.                 	[***]	[***]	[***]	[***]
	87.                 	[***]	[***]	[***]	[***]
	88.                 	[***]	[***]	[***]	[***]
	89.                 	[***]	[***]	[***]	[***]
	90.                 	[***]	[***]	[***]	[***]
	91.                 	[***]	[***]	[***]	[***]
	92.                 	[***]	[***]	[***]	[***]
	93.                 	[***]	[***]	[***]	[***]
	94.                 	[***]	[***]	[***]	[***]
	95.                 	[***]	[***]	[***]	[***]
	96.                 	[***]	[***]	[***]	[***]
	97.                 	[***]	[***]	[***]	[***]
	98.                 	[***]	[***]	[***]	[***]
	99.                 	[***]	[***]	[***]	[***]
	100.              	[***]	[***]	[***]	[***]
	101.              	[***]	[***]	[***]	[***]
	102.              	[***]	[***]	[***]	[***]
	103.              	[***]	[***]	[***]	[***]
	104.              	[***]	[***]	[***]	[***]
	105.              	[***]	[***]	[***]	[***]
	106.              	[***]	[***]	[***]	[***]
	107.              	[***]	[***]	[***]	[***]
	108.              	[***]	[***]	[***]	[***]
	109.              	[***]	[***]	[***]	[***]



 


 


 



    	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    




 


	 	Application Number	Title	Application Date	Country
	110.              	[***]	[***]	[***]	[***]
	111.              	[***]	[***]	[***]	[***]
	112.              	[***]	[***]	[***]	[***]
	113.              	[***]	[***]	[***]	[***]
	114.              	[***]	[***]	[***]	[***]
	115.              	[***]	[***]	[***]	[***]
	116.              	[***]	[***]	[***]	[***]
	117.              	[***]	[***]	[***]	[***]
	118.              	[***]	[***]	[***]	[***]
	119.              	[***]	[***]	[***]	[***]
	120.              	[***]	[***]	[***]	[***]
	121.              	[***]	[***]	[***]	[***]
	122.              	[***]	[***]	[***]	[***]
	123.              	[***]	[***]	[***]	[***]
	124.              	[***]	[***]	[***]	[***]
	125.              	[***]	[***]	[***]	[***]
	126.              	[***]	[***]	[***]	[***]
	127.              	[***]	[***]	[***]	[***]
	128.              	[***]	[***]	[***]	[***]
	129.              	[***]	[***]	[***]	[***]
	130.              	[***]	[***]	[***]	[***]
	131.              	[***]	[***]	[***]	[***]


 


 



    	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    




TRADEMARKS


Registered Trademarks


	 	Registration
    Number	Trademark
    or Design	Registration
    Date 

    (mm/dd/yy)	Country
	1.                    	[***]	[***]	[***]	[***]
	2.                    	[***]	[***]	[***]	[***]
	3.                    	[***]	[***]	[***]	[***]
	4.                    	[***]	[***]	[***]	[***]
	5.                    	[***]	[***]	[***]	[***]
	6.                    	[***]	[***]	[***]	[***]
	7.                    	[***]	[***]	[***]	[***]
	8.                    	[***]	[***]	[***]	[***]
	9.                    	[***]	[***]	[***]	[***]
	10.                 	[***]	[***]	[***]	[***]
	11.                 	[***]	[***]	[***]	[***]
	12.                 	[***]	[***]	[***]	[***]
	13.                 	[***]	[***]	[***]	[***]
	14.                 	[***]	[***]	[***]	[***]


 


Pending Trademark Applications or Pending Designs


	 	Serial Number	Trademark or Design	Filing Date 

(mm/dd/yy)	Country
	1.                    	[***]	[***]	[***]	[***]
	2.                    	[***]	[***]	[***]	[***]
	3.                    	[***]	[***]	[***]	[***]
	4.                    	[***]	[***]	[***]	[***]
	5.                    	[***]	[***]	[***]	[***]



 


 






    	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


 


	 	Serial Number	Trademark or Design	Filing Date 

mm/dd/yy)	Country
	6.                    	[***]	[***]	[***]	[***]
	7.                    	[***]	[***]	[***]	[***]
	8.                    	[***]	[***]	[***]	[***]
	9.                    	[***]	[***]	[***]	[***]
	10.                 	[***]	[***]	[***]	[***]
	11.                 	[***]	[***]	[***]	[***]
	12.                 	[***]	[***]	[***]	[***]
	13.                 	[***]	[***]	[***]	[***]
	14.                 	[***]	[***]	[***]	[***]
	15.                 	[***]	[***]	[***]	[***]
	16.                 	[***]	[***]	[***]	[***]


 


SERVICE MARKS


Registered Service Marks or Designs


	 	Registration Number	Service Mark or Design	Registration Date 

(mm/dd/yy)	Country
	1.                    	[***]	[***]	[***]	[***]
	2.                    	[***]	[***]	[***]	[***]


 


Pending Service Mark Applications or Designs


	 	Serial Number	Service Mark or Design	Filing Date 

(mm/dd/yy)	Country
	1.                    	[***]	[***]	[***]	[***]


 


 


 




    	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


Schedule 4.1(o) – Litigation,
Governmental Proceedings and Other Notice Events


None




    	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


Schedule 4.15 – Products and
Regulatory Required Permits


 


Material Products:


vitaTrueTM


vitaPearlTM


vitaMedMD One Rx Prenatal Multivitamin


vitaMedMD RediChew® Rx Prenatal Multivitamin


BocaGreenMD Prena1 True


BocaGreenMD Prena1 Pearl


BocaGreenMD
Prena1 Chew


TX-001HR


TX-004HR
















Material Regulatory Required Permits:








Estradiol plus Progesterone Oral (TX-001HR) [***]


Estradiol Vaginal Insert (TX-004HR) [***]







 




    	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


 


Schedule 5.1 – Debt; Contingent
Obligations


Pharmaceutical Drug Facility Surety Bond issued by Great American
Insurance Company on behalf of TherapeuticsMD in favor of the State of Mississippi for the sum of $100,000.












    	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


Schedule 5.2 – Liens


None


 






    	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    






Schedule 5.7 – Permitted Investments


None






    	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    






Schedule 5.8 – Affiliate Transactions


None






    	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    






Schedule 5.11 –Business Description


Sale of prescription prenatal vitamins and future sale of
pharmaceutical products, if approved.




    	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


Schedule 5.14 – Deposit
Accounts and Securities Accounts


	Bank Name	Account Number	Account Type	Branch Address	Name of Company/Subsidiary holding Account
	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]



 


 


 




    	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


Schedule 6.1(a) – Minimum
Net Revenue Prior to Term Loan Tranche 2 Funding Date


	Defined
    Period Ending	Minimum
    Net Revenue
	September 30, 2018	[***]
	December 31, 2018	[***]
	March 31, 2019	[***]
	June 30, 2019	[***]
	September 30, 2019	[***]
	December 31, 2019	[***]
	March 31, 2020	[***]
	June 30, 2020	[***]
	September 30, 2020	[***]
	December 31, 2020	[***]
	March 31, 2021	[***]
	June 30, 2021	[***]
	September 30, 2021	[***]
	December 31, 2021	[***]
	March 31, 2022	[***]
	June 30, 2022	[***]
	September 30, 2022	[***]
	December 31, 2022	[***]
	March 31, 2023 and each Defined Period ending thereafter	[***]


 


 




    	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


Schedule 6.1(b) – Minimum
Net Revenue Following Term Loan Tranche 2 Funding Date (TX-001HR First Commercial Sale on or before 03/31/2019)


	Defined
    Period Ending	Minimum
    Net Revenue
	September 30, 2018	[***]
	December 31, 2018	[***]
	March 31, 2019	[***]
	June 30, 2019	[***]
	September 30, 2019	[***]
	December 31, 2019	[***]
	March 31, 2020	[***]
	June 30, 2020	[***]
	September 30, 2020	[***]
	December 31, 2020	[***]
	March 31, 2021	[***]
	June 30, 2021	[***]
	September 30, 2021	[***]
	December 31, 2021	[***]
	March 31, 2022	[***]
	June 30, 2022	[***]
	September 30, 2022	[***]
	December 31, 2022	[***]
	March 31, 2023 and each Defined Period ending thereafter	[***]


 




    	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


Schedule 6.1(c) – Minimum
Net Revenue Following Term Loan Tranche 2 Funding Date (TX-001HR First Commercial Sale after 03/31/2019)


	Defined
    Period Ending	Minimum
    Net Revenue
	September 30, 2018	[***]
	December 31, 2018	[***]
	March 31, 2019	[***]
	June 30, 2019	[***]
	September 30, 2019	[***]
	December 31, 2019	[***]
	March 31, 2020	[***]
	June 30, 2020	[***]
	September 30, 2020	[***]
	December 31, 2020	[***]
	March 31, 2021	[***]
	June 30, 2021	[***]
	September 30, 2021	[***]
	December 31, 2021	[***]
	March 31, 2022	[***]
	June 30, 2022	[***]
	September 30, 2022	[***]
	December 31, 2022	[***]
	March 31, 2023 and each Defined Period ending thereafter	[***]


 


 




    	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


Schedule 7.2 – Term Loan
Tranche 1 Funding Deliverables


		1.	[***]



		2.	[***]



		3.	[***]



		4.	[***]



		5.	[***]



		6.	[***]



 




    	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


 


Schedule 7.4 – Post-Closing
Requirements


Borrowers shall satisfy
and complete each of the following obligations, or provide Agent each of the items listed below, as applicable, on or before the
date indicated below, all to the satisfaction of Agent in its sole and absolute discretion:


 


1.       By
the date that is ninety (90) days after the Closing Date, Borrowers shall provide Agent with reasonably satisfactory evidence
of the recordation of valid assignments to Borrowers of the patents and patent applications listed in the below table.


 


	Patent Number	Title	Grant/

Allowed Date (mm/dd/yy)	Country
	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]


 


	ApplicatIon Number	Title	Filing date	Country
	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]


 


Borrower’s
failure to complete and satisfy any of the above obligations on or before the date indicated above, or Borrower’s failure
to deliver any of the above listed items on or before the date indicated above, shall constitute an immediate an automatic Event
of Default.




    	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


Schedule 9.1 – Collateral


The Collateral consists
of all of Borrower’s assets, other than Excluded Property, including without limitation, all of Borrower’s right, title
and interest in and to the following, whether now owned or hereafter created, acquired or arising:


		(a)	all goods, Accounts (including health-care insurance receivables),
equipment, inventory, contract rights or rights to payment of money, leases, license agreements, franchise agreements, General
Intangibles, commercial tort claims (including each such claim listed on Schedule 9.2(d)), documents, instruments (including any
promissory notes), chattel paper (whether tangible or electronic), cash, deposit accounts, securities accounts, fixtures, letter
of credit rights (whether or not the letter of credit is evidenced by a writing), securities, and all other investment property,
supporting obligations, and financial assets, whether now owned or hereafter acquired, wherever located; 



		(b)	all of Borrowers’ books and records relating to any of the
foregoing; and 



		(c)	any and all claims, rights and interests in any of the above and
all substitutions for, additions, attachments, accessories, accessions and improvements to and replacements, products, proceeds
and insurance proceeds of any or all of the foregoing.



 


 


 


 




    	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


Schedule 9.2(b) – Collateral
Information


The
following are all the locations where the Borrowers own, lease, or occupy any real property:


	Complete Street and Mailing Address, including County and Zip Code	Borrower
	[***]	[***]
	[***]	[***]
	[***]	[***]
	[***]	[***]


 


The
following are all of the locations where the indicated Borrowers maintain inventory, equipment, or other property:


	Complete Address	Borrower
	[***]	[***]
	[***]	[***]


 


The
following are the names and addresses of all warehousemen, bailees, or other third parties who have possession of any of the Company’s
inventory or equipment or any of the inventory or equipment of its subsidiaries:


	Name	Complete Street and Mailing Address, including County and Zip Code	Company/Subsidiary
	[***]	[***]	[***]
	[***]	[***]	[***]


 


 




    	 



    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR
PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED
AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.




    

 


Schedule 9.2(d) – Chattel
Paper, Letter of Credit Rights, Commercial Tort Claims, Instruments, Documents, Investment Property


Securities Account list in Schedule 5.14